tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['Phase', 'II', 'Clinical', 'Trial', ',', 'Use', 'of', 'KL16', '-', '012', 'in', 'Women', 'With', 'Fibromyalgia', 'Refractary', 'to', 'Conventional', 'Treatment', '.', '|', 'A', 'double', 'blind', 'randomized', 'placebo', 'controlled', 'trial', 'in', '44', 'women', 'with', 'fibromyalgia', 'and', 'persistent', 'symptoms', 'in', 'spite', 'of', 'use', 'of', 'conventional', 'pharmacotherapy', ',', 'will', 'be', 'performed', 'in', 'the', 'city', 'of', 'Valparaiso', '.', 'Patients', 'will', 'be', 'randomized', 'to', 'either', 'placebo', 'or', 'active', 'principle', 'and', 'be', 'followed', 'for', '3', 'months', '.', 'Assesment', 'of', 'efficacy', 'and', 'safety', 'will', 'be', 'done', 'by', 'measurement', 'of', 'changes', 'in', 'their', 'Fibromyalgia', 'Impact', 'Questionnaire', '(', 'FIQ', ')', 'score', ',', 'Insomnia', 'Severity', 'Index', '(', 'ISI', ')', 'score', ',', 'pain', 'Visual', 'Analogue', 'Scale', '(', 'VAS', ')', 'score', ',', 'plasma', 'cytokine', 'levels', 'and', 'detection', 'of', 'adverse', 'effects', '.', '\n\n', 'The', 'active', 'principle', 'will', 'be', 'a', 'standardized', 'extract', 'of', 'cannabis', 'sativa', 'containing', '1', 'milligram', 'of', 'tetrahydrocannabinol', '(', 'THC', ')', 'and', '0.45', 'milligrams', 'cannabidiol', '(', 'CBD', ')', 'per', 'drop', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT04239469,NCT04239469,"Phase II Clinical Trial, Use of KL16-012 in Women With Fibromyalgia Refractary to Conventional Treatment. | A double blind randomized placebo controlled trial in 44 women with fibromyalgia and persistent symptoms in spite of use of conventional pharmacotherapy, will be performed in the city of Valparaiso. Patients will be randomized to either placebo or active principle and be followed for 3 months. Assesment of efficacy and safety will be done by measurement of changes in their Fibromyalgia Impact Questionnaire (FIQ) score, Insomnia Severity Index (ISI) score, pain Visual Analogue Scale (VAS) score, plasma cytokine levels and detection of adverse effects.

The active principle will be a standardized extract of cannabis sativa containing 1 milligram of tetrahydrocannabinol (THC) and 0.45 milligrams cannabidiol (CBD) per drop.","[(32, 40, 'DRUG', 'KL16-012'), (55, 104, 'CONDITION', 'Fibromyalgia Refractary to Conventional Treatment'), (176, 188, 'CONDITION', 'fibromyalgia'), (345, 352, 'CONTROL', 'placebo'), (484, 496, 'CONDITION', 'Fibromyalgia'), (710, 736, 'OTHER', 'extract of cannabis sativa'), (763, 783, 'DRUG', 'tetrahydrocannabinol'), (785, 788, 'DRUG', 'THC'), (810, 821, 'DRUG', 'cannabidiol'), (823, 826, 'DRUG', 'CBD')]"
"['Effects', 'of', 'a', 'Home', 'Based', 'Walking', 'Program', 'Using', 'Rhythmic', 'Auditory', 'Stimulation', 'on', 'Walking', 'and', 'Cortical', 'Activation', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '.', '|', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'is', 'a', 'music', 'therapy', 'technique', 'that', 'provides', 'rhythmic', 'auditory', 'cues', '(', 'like', 'a', 'beat', ')', 'to', 'help', 'improve', 'patients', ""'"", 'movements', ',', 'especially', 'when', 'walking', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effect', 'on', 'walking', 'performance', 'of', 'a', 'home', 'based', 'walking', 'program', '(', 'HBWP', ')', 'with', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', ',', 'to', 'that', 'of', 'a', 'HBWP', 'without', 'RAS', ',', 'or', 'to', 'RAS', 'without', 'walking', 'exercise', '.', '\n\n', 'A', 'second', 'part', 'of', 'this', 'study', 'will', 'assess', 'the', 'effects', 'of', 'Rhythmic', 'Auditory', 'Stimulation', '(', 'RAS', ')', 'on', 'brain', 'activity', 'in', 'patients', 'with', 'Multiple', 'Sclerosis', 'while', 'performing', 'mental', 'imagery', 'of', 'walking', '.']","['O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O']",NCT02065284,NCT02065284,"Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis. | Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.

The purpose of this study is to compare the effect on walking performance of a home based walking program (HBWP) with Rhythmic Auditory Stimulation (RAS), to that of a HBWP without RAS, or to RAS without walking exercise.

A second part of this study will assess the effects of Rhythmic Auditory Stimulation (RAS) on brain activity in patients with Multiple Sclerosis while performing mental imagery of walking.","[(13, 39, 'PHYSICAL', 'Home Based Walking Program'), (46, 75, 'OTHER', 'Rhythmic Auditory Stimulation'), (128, 146, 'CONDITION', 'Multiple Sclerosis'), (150, 179, 'OTHER', 'Rhythmic Auditory Stimulation'), (181, 184, 'OTHER', 'RAS'), (408, 434, 'PHYSICAL', 'home based walking program'), (436, 440, 'PHYSICAL', 'HBWP'), (447, 476, 'OTHER', 'Rhythmic Auditory Stimulation'), (478, 481, 'OTHER', 'RAS'), (497, 513, 'CONTROL', 'HBWP without RAS'), (521, 549, 'CONTROL', 'RAS without walking exercise'), (607, 636, 'OTHER', 'Rhythmic Auditory Stimulation'), (638, 641, 'OTHER', 'RAS'), (678, 696, 'CONDITION', 'Multiple Sclerosis'), (714, 739, 'BEHAVIOURAL', 'mental imagery of walking')]"
"['Comparison', 'of', 'the', 'Effects', 'of', 'Ultrasound', '-', 'guided', 'Suprascapular', 'Nerve', 'Block', 'and', 'Subacromial', 'Injection', 'in', 'Hemiplegic', 'Shoulder', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Trial', '|', 'Hemiplegic', 'shoulder', 'pain', 'is', 'the', 'most', 'common', 'poststroke', 'painful', 'condition', '.', 'Hemiplegic', 'shoulder', 'pain', 'reduces', 'range', 'of', 'motion', '(', 'ROM', ')', 'and', 'hand', 'function', ',', 'resulting', 'in', 'limited', 'daily', 'life', 'activity', 'and', 'decreased', 'quality', 'of', 'life', '.', '\n\n', 'In', 'the', 'literature', ',', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', 'has', 'been', 'previously', 'evaluated', ',', 'but', 'these', 'injection', 'treatments', 'have', 'not', 'been', 'compared', '.', '\n\n', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'compare', 'the', 'effectiveness', 'of', 'suprascapular', 'nerve', 'block', 'and', 'subacromial', 'injection', 'on', 'pain', ',', 'shoulder', '(', 'ROM', ')', ',', 'function', 'and', 'quality', 'of', 'life', 'in', 'hemiplegia', 'patients', 'with', 'shoulder', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04433377,NCT04433377,"Comparison of the Effects of Ultrasound-guided Suprascapular Nerve Block and Subacromial Injection in Hemiplegic Shoulder Pain: a Randomized Controlled Trial | Hemiplegic shoulder pain is the most common poststroke painful condition. Hemiplegic shoulder pain reduces range of motion (ROM) and hand function, resulting in limited daily life activity and decreased quality of life.

In the literature, the effectiveness of suprascapular nerve block and subacromial injection in hemiplegia patients with shoulder pain has been previously evaluated, but these injection treatments have not been compared.

Therefore, the aim of this study is to compare the effectiveness of suprascapular nerve block and subacromial injection on pain, shoulder (ROM), function and quality of life in hemiplegia patients with shoulder pain.","[(29, 72, 'OTHER', 'Ultrasound-guided Suprascapular Nerve Block'), (77, 98, 'OTHER', 'Subacromial Injection'), (102, 112, 'CONDITION', 'Hemiplegic'), (113, 126, 'CONDITION', 'Shoulder Pain'), (160, 170, 'CONDITION', 'Hemiplegic'), (171, 184, 'CONDITION', 'shoulder pain'), (204, 214, 'CONDITION', 'poststroke'), (234, 244, 'CONDITION', 'Hemiplegic'), (245, 258, 'CONDITION', 'shoulder pain'), (421, 446, 'OTHER', 'suprascapular nerve block'), (451, 472, 'OTHER', 'subacromial injection'), (476, 486, 'CONDITION', 'hemiplegia'), (501, 514, 'CONDITION', 'shoulder pain'), (670, 695, 'OTHER', 'suprascapular nerve block'), (700, 721, 'OTHER', 'subacromial injection'), (725, 729, 'CONDITION', 'pain'), (779, 789, 'CONDITION', 'hemiplegia'), (804, 817, 'CONDITION', 'shoulder pain')]"
"['A', 'Pilot', 'Trial', 'of', 'Lithium', 'in', 'Progressive', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'lithium', 'carbonate', 'is', 'safe', ',', 'well', '-', 'tolerated', ',', 'and', 'effective', 'at', 'treating', 'progressive', 'forms', 'of', 'multiple', 'sclerosis', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01259388,NCT01259388,"A Pilot Trial of Lithium in Progressive Multiple Sclerosis | The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.","[(17, 24, 'DRUG', 'Lithium'), (28, 58, 'CONDITION', 'Progressive Multiple Sclerosis'), (111, 128, 'DRUG', 'lithium carbonate'), (180, 219, 'CONDITION', 'progressive forms of multiple sclerosis')]"
"['Pharmacokinetics', 'and', 'Nitrative', '-', 'Oxidative', 'Stress', 'Pharmacodynamics', 'in', 'Amyotrophic', 'Lateral', 'Sclerosis', 'Subjects', 'Taking', 'Daily', 'High', '-', 'Dose', 'R(+', ')', 'Pramipexole', 'Dihydrochloride', 'for', 'Six', 'Months', '|', 'R(+)pramipexole', 'is', 'administered', 'in', 'escalating', 'doses', 'to', 'patients', 'with', 'early', 'ALS', '.', 'Plasma', 'and', 'spinal', 'fluid', 'levels', 'of', 'R(+)PPX', 'are', 'monitored', ',', 'in', 'addition', 'to', 'biochemical', 'markers', 'of', 'oxidative', 'stress', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00600873,NCT00600873,"Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months | R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.","[(68, 97, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (130, 162, 'DRUG', 'R(+) Pramipexole Dihydrochloride'), (180, 195, 'DRUG', 'R(+)pramipexole'), (249, 258, 'CONDITION', 'early ALS'), (294, 301, 'DRUG', 'R(+)PPX')]"
"['Exercise', 'Training', 'as', 'an', 'Intervention', 'to', 'Improve', 'Muscle', 'Function', 'and', 'Recovery', 'Following', 'Bed', 'Rest', 'in', 'Older', 'Adults', 'With', 'Type', '2', 'Diabetes', '|', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'gather', 'data', 'on', 'how', 'exercise', 'can', 'help', 'recovery', 'of', 'muscle', 'mass', ',', 'strength', ',', 'and', 'physical', 'function', 'after', 'bedrest', 'in', 'older', 'adults', 'with', 'pre', '-', 'diabetes', 'and', 'type', '2', 'diabetes', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04057677,NCT04057677,"Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes | The purpose of this research is to gather data on how exercise can help recovery of muscle mass, strength, and physical function after bedrest in older adults with pre-diabetes and type 2 diabetes.","[(0, 17, 'PHYSICAL', 'Exercise Training'), (117, 132, 'CONDITION', 'Type 2 Diabetes'), (189, 197, 'PHYSICAL', 'exercise'), (299, 311, 'CONDITION', 'pre-diabetes'), (316, 331, 'CONDITION', 'type 2 diabetes')]"
"['A', 'Phase', '2a', 'Safety', ',', 'Tolerability', ',', 'Pharmacokinetic', '(', 'PK', ')', ',', 'and', 'Pharmacodynamic', '(', 'PD', ')', 'Study', 'of', 'Intravenous', 'ANX005', 'in', 'Subjects', 'With', 'Amyotrophic', 'Lateral', 'Sclerosis', '(', 'ALS', ')', '|', 'This', 'study', 'is', 'a', 'multi', '-', 'center', ',', 'open', '-', 'label', 'study', 'of', 'intravenous', '(', 'IV', ')', 'ANX005', 'in', 'participants', 'with', 'ALS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O']",NCT04569435,NCT04569435,"A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.","[(101, 107, 'DRUG', 'ANX005'), (125, 154, 'CONDITION', 'Amyotrophic Lateral Sclerosis'), (156, 159, 'CONDITION', 'ALS'), (230, 236, 'DRUG', 'ANX005'), (258, 261, 'CONDITION', 'ALS')]"
"['Preparation', 'for', 'End', '-', 'of', '-', 'Life', 'Decision', 'Making', 'in', 'Mild', 'Dementia', '|', 'The', 'proposed', 'study', 'will', 'adapt', 'and', 'pilot', 'test', 'an', 'efficacious', 'advance', 'care', 'planning', 'interventions', ',', 'Sharing', 'Patient', ""'s"", 'Illness', 'Representations', 'to', 'Increase', 'Trust', '(', 'SPIRIT', ')', ',', 'with', 'patients', 'with', 'mild', 'dementia', 'and', 'their', 'surrogates', 'to', 'promote', 'open', ',', 'honest', 'discussions', 'while', 'such', 'discussions', 'about', 'end', '-', 'of', '-', 'life', 'care', 'are', 'possible', '.', 'Patient', 'and', 'surrogate', 'decision', 'maker', 'dyads', 'will', 'participate', 'in', 'a', 'single', 'SPIRIT', 'session', 'and', 'will', 'then', 'have', 'a', 'follow', 'up', 'phone', 'call', '2', '-', '3', 'days', 'later', '.', 'One', 'year', 'after', 'the', 'SPIRIT', 'session', 'some', 'surrogates', 'will', 'be', 'contacted', 'to', 'provide', 'additional', 'feedback', 'about', 'the', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03311711,NCT03311711,"Preparation for End-of-Life Decision Making in Mild Dementia | The proposed study will adapt and pilot test an efficacious advance care planning interventions, Sharing Patient's Illness Representations to Increase Trust (SPIRIT), with patients with mild dementia and their surrogates to promote open, honest discussions while such discussions about end-of-life care are possible. Patient and surrogate decision maker dyads will participate in a single SPIRIT session and will then have a follow up phone call 2-3 days later. One year after the SPIRIT session some surrogates will be contacted to provide additional feedback about the intervention.","[(47, 60, 'CONDITION', 'Mild Dementia'), (160, 219, 'BEHAVIOURAL', ""Sharing Patient's Illness Representations to Increase Trust""), (221, 227, 'BEHAVIOURAL', 'SPIRIT'), (249, 262, 'CONDITION', 'mild dementia'), (452, 458, 'BEHAVIOURAL', 'SPIRIT'), (544, 550, 'BEHAVIOURAL', 'SPIRIT')]"
"['Action', 'Observation', 'and', 'Motor', 'Imagery', 'Induced', 'Hypoalgesia', 'in', 'Asymptomatic', 'Subjects', '|', 'This', 'study', 'evaluates', 'the', 'influence', 'of', 'motor', 'imagery', 'and', 'the', 'observation', 'of', 'actions', 'on', 'pain', 'perception', '.', 'Participants', 'in', 'this', 'study', 'are', 'asymptomatic', 'subjects', 'who', 'will', 'perform', 'an', 'IM', 'and', 'AO', 'protocol', 'of', 'an', 'aerobic', 'exercise', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03959449,NCT03959449,Action Observation and Motor Imagery Induced Hypoalgesia in Asymptomatic Subjects | This study evaluates the influence of motor imagery and the observation of actions on pain perception. Participants in this study are asymptomatic subjects who will perform an IM and AO protocol of an aerobic exercise.,"[(0, 18, 'OTHER', 'Action Observation'), (23, 36, 'OTHER', 'Motor Imagery'), (122, 135, 'OTHER', 'motor imagery'), (144, 166, 'OTHER', 'observation of actions'), (170, 174, 'CONDITION', 'pain'), (260, 262, 'OTHER', 'IM'), (267, 269, 'OTHER', 'AO')]"
"['Lactobacillus', 'Plantarum', 'PS128', 'May', 'Improve', 'Off', 'Duration', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'a', 'Pilot', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'short', 'term', 'effects', '(', '12', 'Weeks', ')', 'of', 'Lactobacillus', 'plantarum', 'PS128', '(', 'PS128', ')', 'on', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'symptoms', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT04389762,NCT04389762,Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study | The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.,"[(0, 29, 'OTHER', 'Lactobacillus Plantarum PS128'), (58, 77, 'CONDITION', ""Parkinson's Disease""), (176, 205, 'OTHER', 'Lactobacillus plantarum PS128'), (207, 212, 'OTHER', 'PS128'), (217, 236, 'CONDITION', ""Parkinson's disease""), (238, 240, 'CONDITION', 'PD')]"
"['Stereotactic', 'Body', 'Radiotherapy', '(', 'SBRT', ')', 'Boost', 'Following', 'Urgent', '3D', 'Conformal', 'Radiotherapy', 'in', 'the', 'Treatment', 'of', 'Metastatic', 'Epidural', 'Spinal', 'Cord', 'Compression', '(', 'SCC', '):', 'A', 'Phase', 'I', 'Feasibility', 'Trial', '|', 'Spinal', 'cord', 'compression', '(', 'SCC', ')', 'is', 'a', 'devastating', 'complication', 'of', 'advanced', 'malignancy', ',', 'and', 'can', 'cause', 'significant', 'deterioration', 'in', 'function', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', '.', 'The', 'goal', 'of', 'treatment', 'is', 'to', 'improve', 'functional', 'status', 'and', 'symptoms', ',', 'but', 'the', 'optimal', 'treatment', 'regimen', 'for', 'these', 'patients', 'has', 'not', 'been', 'thoroughly', 'established', '.', 'Many', 'patients', 'with', 'SCC', 'present', 'with', 'uncontrolled', 'systemic', 'disease', 'and', 'poor', 'performance', 'status', ',', 'and', 'are', 'not', 'eligible', 'for', 'standard', 'surgical', 'resection', '.', 'They', 'are', 'generally', 'treated', 'with', '3D', 'conformal', 'palliative', 'RT', '(', '3DCRT', ')', 'alone', ',', 'however', 'recent', 'trials', 'suggest', 'that', 'less', 'than', '70', '%', 'of', 'patients', 'are', 'ambulatory', ',', 'that', 'the', 're', '-', 'establishment', 'of', 'ambulation', 'in', 'non', '-', 'ambulatory', 'patients', 'is', 'poor', ',', 'and', 'the', 'duration', 'of', 'improvement', 'is', 'guarded', 'with', 'radiotherapy', 'alone', '.', '\n\n', 'Recently', ',', 'stereotactic', 'body', 'radiotherapy', '(', 'SBRT', ')', 'used', 'alone', 'or', 'after', 'previous', 'radiotherapy', 'to', 'treat', 'spinal', 'metastasis', 'has', 'demonstrated', 'superior', 'results', 'in', 'pain', 'control', ',', 'tumour', 'response', 'and', 'durability', '.', 'SBRT', 'requires', 'time', 'for', 'careful', 'planning', ',', 'and', 'many', 'patients', 'with', 'neurologic', 'symptoms', 'must', 'be', 'treated', 'immediately', 'to', 'prevent', 'progression', '.', 'Therefore', 'the', 'role', 'of', 'SBRT', 'is', 'still', 'unclear', 'in', 'this', 'patient', 'population', ',', 'although', 'it', 'seems', 'to', 'be', 'a', 'potential', 'alternative', 'to', 'surgical', 'decompression', 'in', 'patient', 'not', 'suitable', 'for', 'surgery', '.', 'The', 'investigators', 'propose', 'a', 'feasibility', 'study', 'to', 'investigate', 'the', 'potential', 'benefits', 'of', 'dose', 'escalation', 'with', 'a', 'sequential', 'SBRT', 'boost', 'to', 'urgent', '3D', 'CRT', 'in', 'the', 'setting', 'of', 'SCC', '.', 'This', 'regimen', 'will', 'allow', 'inoperable', 'patients', 'to', 'receive', 'urgent', '3DCRT', 'while', 'simultaneously', 'creating', 'the', 'opportunity', 'for', 'superior', 'outcomes', 'with', 'SBRT', '.', 'The', 'investigators', 'also', 'aim', 'to', 'characterize', 'the', 'effect', 'on', 'motor', 'function', 'and', 'ambulation', ',', 'pain', 'and', 'QoL.', 'This', 'study', 'could', 'stimulate', 'further', 'multi', '-', 'center', 'randomized', 'trials', 'in', 'this', 'area', ',', 'improve', 'motor', 'function', 'and', 'patient', '-', 'reported', 'QoL', ',', 'and', 'contribute', 'to', 'improving', 'oncology', 'care', 'in', 'Canada', 'in', 'a', 'meaningful', 'way', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03529708,NCT03529708,"Stereotactic Body Radiotherapy (SBRT) Boost Following Urgent 3D Conformal Radiotherapy in the Treatment of Metastatic Epidural Spinal Cord Compression (SCC): A Phase I Feasibility Trial | Spinal cord compression (SCC) is a devastating complication of advanced malignancy, and can cause significant deterioration in function and quality of life (QoL). The goal of treatment is to improve functional status and symptoms, but the optimal treatment regimen for these patients has not been thoroughly established. Many patients with SCC present with uncontrolled systemic disease and poor performance status, and are not eligible for standard surgical resection. They are generally treated with 3D conformal palliative RT (3DCRT) alone, however recent trials suggest that less than 70% of patients are ambulatory, that the re-establishment of ambulation in non-ambulatory patients is poor, and the duration of improvement is guarded with radiotherapy alone.

Recently, stereotactic body radiotherapy (SBRT) used alone or after previous radiotherapy to treat spinal metastasis has demonstrated superior results in pain control, tumour response and durability. SBRT requires time for careful planning, and many patients with neurologic symptoms must be treated immediately to prevent progression. Therefore the role of SBRT is still unclear in this patient population, although it seems to be a potential alternative to surgical decompression in patient not suitable for surgery. The investigators propose a feasibility study to investigate the potential benefits of dose escalation with a sequential SBRT boost to urgent 3D CRT in the setting of SCC. This regimen will allow inoperable patients to receive urgent 3DCRT while simultaneously creating the opportunity for superior outcomes with SBRT. The investigators also aim to characterize the effect on motor function and ambulation, pain and QoL. This study could stimulate further multi-center randomized trials in this area, improve motor function and patient-reported QoL, and contribute to improving oncology care in Canada in a meaningful way.","[(0, 30, 'RADIOTHERAPY', 'Stereotactic Body Radiotherapy'), (32, 36, 'RADIOTHERAPY', 'SBRT'), (61, 86, 'RADIOTHERAPY', '3D Conformal Radiotherapy'), (107, 150, 'CONDITION', 'Metastatic Epidural Spinal Cord Compression'), (152, 155, 'CONDITION', 'SCC'), (188, 211, 'CONDITION', 'Spinal cord compression'), (213, 216, 'CONDITION', 'SCC'), (528, 531, 'CONDITION', 'SCC'), (690, 716, 'RADIOTHERAPY', '3D conformal palliative RT'), (718, 723, 'RADIOTHERAPY', '3DCRT'), (933, 945, 'RADIOTHERAPY', 'radiotherapy'), (964, 994, 'RADIOTHERAPY', 'stereotactic body radiotherapy'), (996, 1000, 'RADIOTHERAPY', 'SBRT'), (1031, 1043, 'RADIOTHERAPY', 'radiotherapy'), (1053, 1070, 'CONDITION', 'spinal metastasis'), (1108, 1112, 'CONDITION', 'pain'), (1122, 1128, 'CONDITION', 'tumour'), (1154, 1158, 'RADIOTHERAPY', 'SBRT'), (1312, 1316, 'RADIOTHERAPY', 'SBRT'), (1594, 1598, 'RADIOTHERAPY', 'SBRT'), (1615, 1621, 'RADIOTHERAPY', '3D CRT'), (1640, 1643, 'CONDITION', 'SCC'), (1707, 1712, 'RADIOTHERAPY', '3DCRT'), (1786, 1790, 'RADIOTHERAPY', 'SBRT'), (1880, 1884, 'CONDITION', 'pain')]"
"['Using', 'Advanced', 'Driver', 'Assistance', 'Systems', '(', 'ADAS', ')', 'as', 'an', 'Intervention', 'Strategy', 'for', 'Drivers', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'impacts', 'an', 'individual', ""'s"", 'fitness', 'to', 'drive', 'in', 'a', 'number', 'of', 'ways', 'that', 'increase', 'the', 'crash', 'risk', 'in', 'this', 'population', '.', 'Current', 'vehicle', 'automation', 'technologies', 'are', 'available', ',', 'that', 'although', 'designed', 'for', 'the', 'general', 'public', ',', 'may', 'help', 'drivers', 'with', 'PD', 'stay', 'on', 'the', 'roads', 'longer', 'and', 'safer', 'than', 'currently', 'possible', '.', 'Using', 'a', 'driving', 'simulator', '(', 'a', 'safe', 'and', 'cost', '-', 'effective', 'alternative', 'with', 'no', 'impact', 'on', 'licensing', 'for', 'participants', ')', ',', 'this', 'study', 'will', 'investigate', 'the', 'feasibility', 'and', 'preliminary', 'efficacy', 'of', 'utilizing', 'in', '-', 'vehicle', 'technology', '(', 'i.e.', ',', 'a', 'simulated', 'lane', 'change', 'assistance', 'system', ')', 'to', 'address', 'critical', 'driving', 'errors', 'in', 'individuals', 'with', 'mild', 'to', 'moderate', 'Parkinson', ""'s"", 'disease', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT03195608,NCT03195608,"Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease | Parkinson's disease (PD) impacts an individual's fitness to drive in a number of ways that increase the crash risk in this population. Current vehicle automation technologies are available, that although designed for the general public, may help drivers with PD stay on the roads longer and safer than currently possible. Using a driving simulator (a safe and cost-effective alternative with no impact on licensing for participants), this study will investigate the feasibility and preliminary efficacy of utilizing in-vehicle technology (i.e., a simulated lane change assistance system) to address critical driving errors in individuals with mild to moderate Parkinson's disease.","[(6, 40, 'OTHER', 'Advanced Driver Assistance Systems'), (42, 46, 'OTHER', 'ADAS'), (93, 112, 'CONDITION', ""Parkinson's Disease""), (115, 134, 'CONDITION', ""Parkinson's disease""), (136, 138, 'CONDITION', 'PD'), (374, 376, 'CONDITION', 'PD'), (631, 652, 'OTHER', 'in-vehicle technology'), (662, 701, 'OTHER', 'simulated lane change assistance system'), (758, 794, 'CONDITION', ""mild to moderate Parkinson's disease"")]"
"['Context', '-', 'Aware', 'Mobile', 'Intervention', 'for', 'Social', 'Recovery', 'in', 'Serious', 'Mental', 'Illness', '|', 'This', 'open', 'trial', 'will', 'test', 'a', 'new', 'technology', '-', 'supported', 'blended', 'intervention', ',', 'mobile', 'Social', 'Interaction', 'Therapy', 'by', 'Exposure', '(', 'mSITE', ')', ',', 'that', 'targets', 'social', 'engagement', 'in', 'consumers', 'with', 'serious', 'mental', 'illness', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05660070,NCT05660070,"Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness | This open trial will test a new technology-supported blended intervention, mobile Social Interaction Therapy by Exposure (mSITE), that targets social engagement in consumers with serious mental illness.","[(0, 33, 'BEHAVIOURAL', 'Context-Aware Mobile Intervention'), (57, 79, 'CONDITION', 'Serious Mental Illness'), (114, 155, 'BEHAVIOURAL', 'technology-supported blended intervention'), (157, 202, 'BEHAVIOURAL', 'mobile Social Interaction Therapy by Exposure'), (204, 209, 'BEHAVIOURAL', 'mSITE'), (261, 283, 'CONDITION', 'serious mental illness')]"
"['""', 'Brain', 'Changes', 'After', 'Repetitive', 'Head', 'Impacts', 'in', 'Soccer', 'and', 'the', 'Effects', 'of', 'a', 'Protective', 'Device', ':', 'Biomechanical', ',', 'Cognitive', ',', 'Electrophysiological', 'and', 'Multimodal', 'Neuroimaging', 'Study', '""', '|', 'Soccer', ',', 'the', 'most', 'popular', 'sport', 'in', 'the', 'world', ',', 'exposes', 'players', 'to', 'repeated', 'head', 'impacts', 'and', 'concussions', ',', 'due', 'to', 'contact', 'with', 'another', 'player', 'or', 'with', 'the', 'ground', '.', 'Moreover', ',', 'routine', 'game', '-', 'play', 'in', 'soccer', 'involves', 'intentional', 'and', 'repeated', 'head', 'impacts', 'through', 'ball', '""', 'heading', '""', ',', 'with', 'frequent', 'high', 'velocities', ',', 'which', 'might', 'cause', 'a', 'transient', 'brain', 'dysfunction', '.', 'In', 'this', 'pre', '-', 'post', 'prospective', 'interventional', 'study', ',', '22', 'soccer', 'players', 'will', 'perform', '10', 'headers', 'from', 'machine', '-', 'projected', 'soccer', 'balls', 'at', 'standardized', 'speeds', ',', 'modelling', 'routine', 'soccer', 'practice', '.', 'They', 'will', 'perform', 'heading', 'series', 'in', '2', 'different', 'oral', 'conditions', ',', 'on', 'different', 'days', 'at', 'least', '1', 'week', 'apart', ':', '1', ')', 'Without', 'mouthguard', 'and', 'tight', 'jaws', ';', '2', ')', 'With', 'mouthguard', 'and', 'tight', 'jaws', '.', 'The', 'strength', 'of', 'the', 'neck', 'muscles', 'will', 'be', 'measured', 'before', 'the', 'heading', 'series', '.', 'The', 'kinematic', 'of', 'the', 'movement', 'will', 'be', 'recorded', 'during', 'each', 'impact', 'during', 'the', '2', 'heading', 'series', ',', 'as', 'well', 'as', 'the', 'activity', 'of', 'the', 'jaw', 'muscles', 'which', 'will', 'be', 'recorded', 'by', 'electromyogram', '.', 'Before', 'and', 'after', 'each', 'heading', 'series', ',', 'electrophysiological', 'data', ',', 'multimodal', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', ',', 'and', 'cognitive', 'computerized', 'assessment', 'will', 'be', 'acquired']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04426188,NCT04426188,""" Brain Changes After Repetitive Head Impacts in Soccer and the Effects of a Protective Device: Biomechanical, Cognitive, Electrophysiological and Multimodal Neuroimaging Study "" | Soccer, the most popular sport in the world, exposes players to repeated head impacts and concussions, due to contact with another player or with the ground. Moreover, routine game-play in soccer involves intentional and repeated head impacts through ball ""heading"", with frequent high velocities, which might cause a transient brain dysfunction. In this pre-post prospective interventional study, 22 soccer players will perform 10 headers from machine-projected soccer balls at standardized speeds, modelling routine soccer practice. They will perform heading series in 2 different oral conditions, on different days at least 1 week apart: 1) Without mouthguard and tight jaws ; 2) With mouthguard and tight jaws. The strength of the neck muscles will be measured before the heading series. The kinematic of the movement will be recorded during each impact during the 2 heading series, as well as the activity of the jaw muscles which will be recorded by electromyogram. Before and after each heading series, electrophysiological data, multimodal magnetic resonance imaging (MRI), and cognitive computerized assessment will be acquired","[(22, 45, 'CONDITION', 'Repetitive Head Impacts'), (77, 94, 'OTHER', 'Protective Device'), (245, 266, 'CONDITION', 'repeated head impacts'), (271, 282, 'CONDITION', 'concussions'), (402, 423, 'CONDITION', 'repeated head impacts'), (825, 858, 'CONTROL', 'Without mouthguard and tight jaws'), (869, 879, 'OTHER', 'mouthguard'), (884, 894, 'OTHER', 'tight jaws')]"
"['Phase', 'I', '/', 'II', 'Trial', 'of', 'Dasatinib', '(', 'Sprycel', ')', 'With', 'Radiation', 'Therapy', 'and', 'Concomitant', 'and', 'Adjuvant', 'Temozolomide', 'in', 'Patients', 'With', 'Newly', '-', 'Diagnosed', 'Glioblastoma', '|', 'Phase', 'I', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'define', 'the', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'radiotherapy', '(', 'RT', ')', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'glioblastoma', 'after', 'RT', '.', '\n\n', 'STUDY', 'DID', 'NOT', 'PROGRESS', 'TO', 'PHASE', 'II', 'PORTION', '.', '\n\n', 'Phase', 'II', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'determine', 'the', 'effectiveness', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'followed', 'by', 'adjuvant', 'temozolomide', 'with', 'concurrent', 'dasatinib', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', 'as', 'measured', 'by', 'overall', 'survival', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'determine', 'the', 'efficacy', 'of', 'this', 'treatment', 'as', 'measured', 'by', 'radiographic', 'response', '(', 'RR', ')', ',', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', 'and', 'time', 'to', 'progression', '(', 'TTP', ')', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'RT', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'GBM', 'after', 'RT', '.', '\n\n', 'Exploratory', 'Objectives', ':', '\n\n', '-To', 'correlate', 'tumor', 'genotype', ',', 'tumor', 'expression', 'of', 'dasatinib', 'target', 'proteins', '(', 'e.g.', 'Src', ',', 'EphA2', ',', 'c', '-', 'kit', 'and', 'PDGFR', ')', ',', 'and', 'PTEN', 'levels', 'with', 'response', 'to', 'therapy', 'with', 'dasatinib', 'and', 'temozolomide', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT00895960,NCT00895960,"Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma | Phase I:

Primary Objectives:

-To define the maximum tolerated dose (MTD) of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly-diagnosed glioblastoma (GBM).

Secondary Objectives:

To characterize the safety profile of dasatinib (Sprycel) in combination with radiotherapy (RT) and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with glioblastoma after RT.

STUDY DID NOT PROGRESS TO PHASE II PORTION.

Phase II:

Primary Objectives:

-To determine the effectiveness of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day followed by adjuvant temozolomide with concurrent dasatinib in patients with newly-diagnosed glioblastoma (GBM) as measured by overall survival.

Secondary Objectives:

To determine the efficacy of this treatment as measured by radiographic response (RR), progression-free survival (PFS) and time to progression (TTP).
To characterize the safety profile of dasatinib (Sprycel) in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with GBM after RT.

Exploratory Objectives:

-To correlate tumor genotype, tumor expression of dasatinib target proteins (e.g. Src, EphA2, c-kit and PDGFR), and PTEN levels with response to therapy with dasatinib and temozolomide.","[(20, 29, 'DRUG', 'Dasatinib'), (31, 38, 'DRUG', 'Sprycel'), (45, 62, 'RADIOTHERAPY', 'Radiation Therapy'), (92, 104, 'DRUG', 'Temozolomide'), (122, 150, 'CONDITION', 'Newly-Diagnosed Glioblastoma'), (231, 240, 'DRUG', 'dasatinib'), (242, 249, 'DRUG', 'Sprycel'), (256, 268, 'RADIOTHERAPY', 'radiotherapy'), (270, 272, 'RADIOTHERAPY', 'RT'), (301, 313, 'DRUG', 'temozolomide'), (315, 318, 'DRUG', 'TMZ'), (367, 395, 'CONDITION', 'newly-diagnosed glioblastoma'), (397, 400, 'CONDITION', 'GBM'), (465, 474, 'DRUG', 'dasatinib'), (476, 483, 'DRUG', 'Sprycel'), (505, 517, 'RADIOTHERAPY', 'radiotherapy'), (519, 521, 'RADIOTHERAPY', 'RT'), (539, 542, 'DRUG', 'TMZ'), (560, 579, 'CONDITION', 'newly-diagnosed GBM'), (619, 628, 'DRUG', 'dasatinib'), (630, 637, 'DRUG', 'Sprycel'), (668, 671, 'DRUG', 'TMZ'), (689, 701, 'CONDITION', 'glioblastoma'), (708, 710, 'RADIOTHERAPY', 'RT'), (825, 834, 'DRUG', 'dasatinib'), (836, 843, 'DRUG', 'Sprycel'), (850, 862, 'RADIOTHERAPY', 'radiotherapy'), (864, 866, 'RADIOTHERAPY', 'RT'), (895, 907, 'DRUG', 'temozolomide'), (909, 912, 'DRUG', 'TMZ'), (965, 977, 'DRUG', 'temozolomide'), (994, 1003, 'DRUG', 'dasatinib'), (1021, 1049, 'CONDITION', 'newly-diagnosed glioblastoma'), (1051, 1054, 'CONDITION', 'GBM'), (1301, 1310, 'DRUG', 'dasatinib'), (1312, 1319, 'DRUG', 'Sprycel'), (1341, 1343, 'RADIOTHERAPY', 'RT'), (1360, 1363, 'DRUG', 'TMZ'), (1381, 1400, 'CONDITION', 'newly-diagnosed GBM'), (1440, 1449, 'DRUG', 'dasatinib'), (1451, 1458, 'DRUG', 'Sprycel'), (1489, 1492, 'DRUG', 'TMZ'), (1510, 1513, 'CONDITION', 'GBM'), (1520, 1522, 'RADIOTHERAPY', 'RT'), (1564, 1569, 'CONDITION', 'tumor'), (1580, 1585, 'CONDITION', 'tumor'), (1600, 1609, 'DRUG', 'dasatinib'), (1708, 1717, 'DRUG', 'dasatinib'), (1722, 1734, 'DRUG', 'temozolomide')]"
"['12', 'Month', 'Open', '-', 'Label', 'Extension', 'Study', 'of', 'the', 'Effect', 'of', 'Alendronate', 'on', 'Bone', 'in', 'People', 'With', 'Chronic', 'SCI', 'Previously', 'Treated', 'With', 'Teriparatide', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'a', 'year', 'of', 'alendronate', 'treatment', 'will', 'maintain', 'or', 'increase', 'bone', 'mass', 'density', '(', 'BMD', ')', 'compared', 'to', 'baseline', 'BMD', 'values', 'in', 'people', 'with', 'chronic', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', '\n\n', 'This', 'study', 'will', 'also', 'investigate', '1', ')', 'if', 'alendronate', 'therapy', 'will', 'increase', 'bone', 'strength', 'in', 'people', 'with', 'chronic', 'SCI', ',', '2', ')', 'the', 'number', 'of', 'participants', 'with', 'adverse', 'events', 'from', 'alendronate', ',', 'and', '3', ')', 'the', 'effects', 'of', 'alendronate', 'on', 'serum', 'markers', 'of', 'bone', 'metabolism', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02195895,NCT02195895,"12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide | The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).

This study will also investigate 1) if alendronate therapy will increase bone strength in people with chronic SCI, 2) the number of participants with adverse events from alendronate, and 3) the effects of alendronate on serum markers of bone metabolism.","[(53, 64, 'DRUG', 'Alendronate'), (88, 99, 'CONDITION', 'Chronic SCI'), (124, 136, 'DRUG', 'Teriparatide'), (194, 205, 'DRUG', 'alendronate'), (313, 339, 'CONDITION', 'chronic spinal cord injury'), (341, 344, 'CONDITION', 'SCI'), (387, 398, 'DRUG', 'alendronate'), (450, 461, 'CONDITION', 'chronic SCI'), (518, 529, 'DRUG', 'alendronate'), (553, 564, 'DRUG', 'alendronate')]"
"['Non', '-', 'invasive', 'Brain', '-', 'computer', 'Interfaces', 'for', 'Control', 'of', 'Assistive', 'Devices', '|', 'A', 'brain', '-', 'computer', 'interface', '(', 'BCI', ')', 'decodes', 'users', ""'"", 'behavioral', 'intentions', 'or', 'mental', 'states', 'directly', 'from', 'their', 'brain', 'activity', ',', 'thus', 'allowing', 'operation', 'of', 'devices', 'without', 'requiring', 'any', 'overt', 'motor', 'action', '.', 'One', 'major', 'modality', 'for', 'BCI', 'control', 'is', 'based', 'on', 'motor', 'imagery', '(', 'MI', ')', ',', 'which', 'is', 'the', 'mental', 'rehearsal', 'of', 'the', 'kinesthetics', 'of', 'a', 'movement', 'without', 'actually', 'performing', 'it', '.', 'MI', '-', 'based', 'BCIs', 'translate', 'motor', 'intents', 'into', 'control', 'commands', 'for', 'external', 'devices', '.', 'A', 'major', 'challenge', 'in', 'such', 'BCIs', 'is', 'differentiating', 'MI', 'patterns', 'corresponding', 'to', 'fine', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'from', 'non', '-', 'invasive', 'EEG', 'recordings', 'with', 'low', 'spatial', 'resolution', 'since', 'the', 'cortical', 'sources', 'responsible', 'for', 'these', 'movements', 'are', 'overlapping', '.', 'In', 'this', 'study', ',', 'the', 'investigators', 'hypothesize', 'that', 'neuromuscular', 'electrical', 'stimulation', '(', 'NMES', ')', 'applied', 'contingent', 'to', 'the', 'voluntary', 'activation', 'of', 'the', 'primary', 'motor', 'cortex', 'through', 'MI', 'can', 'help', 'differentiate', 'patterns', 'of', 'activity', 'associated', 'with', 'different', 'hand', 'movements', 'of', 'the', 'same', 'limb', 'by', 'consistently', 'recruiting', 'the', 'separate', 'neural', 'pathways', 'associated', 'with', 'each', 'of', 'the', 'movements', 'within', 'a', 'closed', '-', 'loop', 'BCI', 'setup', '.', 'This', 'is', 'expected', 'to', 'be', 'associated', 'with', 'neuroplastic', 'changes', 'at', 'the', 'cortical', 'or', 'corticospinal', 'levels', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05183152,NCT05183152,"Non-invasive Brain-computer Interfaces for Control of Assistive Devices | A brain-computer interface (BCI) decodes users' behavioral intentions or mental states directly from their brain activity, thus allowing operation of devices without requiring any overt motor action. One major modality for BCI control is based on motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. MI-based BCIs translate motor intents into control commands for external devices. A major challenge in such BCIs is differentiating MI patterns corresponding to fine hand movements of the same limb from non-invasive EEG recordings with low spatial resolution since the cortical sources responsible for these movements are overlapping. In this study, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. This is expected to be associated with neuroplastic changes at the cortical or corticospinal levels.","[(13, 38, 'OTHER', 'Brain-computer Interfaces'), (54, 71, 'OTHER', 'Assistive Devices'), (76, 100, 'OTHER', 'brain-computer interface'), (102, 105, 'OTHER', 'BCI'), (297, 300, 'OTHER', 'BCI'), (321, 334, 'OTHER', 'motor imagery'), (336, 338, 'OTHER', 'MI'), (437, 450, 'OTHER', 'MI-based BCIs'), (545, 549, 'OTHER', 'BCIs'), (569, 571, 'OTHER', 'MI'), (822, 858, 'OTHER', 'neuromuscular electrical stimulation'), (860, 864, 'OTHER', 'NMES'), (949, 951, 'OTHER', 'MI'), (1157, 1172, 'OTHER', 'closed-loop BCI')]"
"['An', 'Open', '-', 'label', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Perampanel', '(', 'E2007', ')', 'Administered', 'as', 'an', 'Adjunctive', 'Therapy', 'in', 'Epilepsy', 'Subjects', '|', 'To', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'perampanel', 'given', 'as', 'an', 'adjunctive', 'therapy', 'in', 'participants', 'with', 'epilepsy', '.', 'This', 'study', 'will', 'be', 'continued', 'until', 'perampanel', 'is', 'commercially', 'available', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT02427607,NCT02427607,An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects | To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.,"[(73, 83, 'DRUG', 'Perampanel'), (85, 90, 'DRUG', 'E2007'), (133, 141, 'CONDITION', 'Epilepsy'), (196, 206, 'DRUG', 'perampanel'), (259, 267, 'CONDITION', 'epilepsy'), (304, 314, 'DRUG', 'perampanel')]"
"['Chronic', 'Treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'With', 'Gamma', 'Frequency', 'Stimulation', '|', 'In', 'this', 'trial', ',', 'the', 'safety', 'and', 'effect', 'of', 'daily', 'exposure', 'to', 'light', 'and', 'sound', 'stimulation', 'on', 'people', 'with', 'mild', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'will', 'be', 'studied', '.', '\n\n', 'COVID-19', 'Amendment', ':', 'Due', 'to', 'the', 'ongoing', 'suspension', 'of', 'all', 'in', '-', 'person', 'humans', 'subject', 'research', 'across', 'MIT', 'in', 'response', 'to', 'the', 'COVID-19', 'pandemic', ',', 'all', 'enrolled', 'participants', 'who', 'have', 'not', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'have', 'their', 'visit', 'postponed', 'to', '9', 'months', 'with', 'a', 'follow', 'up', 'at', '18', 'months', '.', 'Subjects', 'who', 'have', 'completed', 'their', '6', '-', 'month', 'visit', 'will', 'still', 'be', 'instructed', 'to', 'continue', 'and', 'return', 'at', 'Month', '12', 'for', 'an', 'evaluation', '.', '\n\n', 'OPTIONAL', ':', 'If', 'the', 'subject', 'would', 'like', 'to', 'come', 'in', 'for', 'an', 'evaluation', 'between', 'Month', '9', 'and', '18', ',', 'we', 'will', 'invite', 'participants', 'to', 'come', 'on', 'Month', '12', 'to', 'complete', 'cognitive', 'testing', 'and', 'EEG', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04055376,NCT04055376,"Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation | In this trial, the safety and effect of daily exposure to light and sound stimulation on people with mild Alzheimer's Disease (AD) will be studied.

COVID-19 Amendment: Due to the ongoing suspension of all in-person humans subject research across MIT in response to the COVID-19 pandemic, all enrolled participants who have not completed their 6-month visit will have their visit postponed to 9 months with a follow up at 18 months. Subjects who have completed their 6-month visit will still be instructed to continue and return at Month 12 for an evaluation.

OPTIONAL: If the subject would like to come in for an evaluation between Month 9 and 18, we will invite participants to come on Month 12 to complete cognitive testing and EEG.","[(21, 40, 'CONDITION', ""Alzheimer's Disease""), (46, 73, 'OTHER', 'Gamma Frequency Stimulation'), (116, 161, 'OTHER', 'daily exposure to light and sound stimulation'), (177, 201, 'CONDITION', ""mild Alzheimer's Disease""), (203, 205, 'CONDITION', 'AD')]"
"['Detection', 'of', 'Silent', 'Atrial', 'Fibrillation', 'aFter', 'Ischemic', 'StrOke', '(', 'SAFFO', ')', 'Guided', 'by', 'Implantable', 'Loop', 'Recorder', '.', 'Multicentre', 'Italian', 'Trial', 'Based', 'on', 'Stroke', 'Unit', 'Network', 'With', 'Paired', 'Cardio', '-', 'Arrhythmology', 'Units', '(', 'Italian', 'Neurocardiology', 'Unit', 'Network', ')', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', ',', 'in', 'patients', 'with', 'first', '-', 'ever', 'atherothrombotic', 'or', 'lacunar', 'stroke', 'without', 'any', 'previous', 'history', 'of', 'atrial', 'fibrillation', '(', 'AF)/atrial', 'flutter', '(', 'AFL)/atrial', 'tachycardia', '(', 'AT', ')', ',', 'the', 'detection', 'of', 'AF', '/', 'AFL', '/', 'AT', '(', 'silent', 'or', 'symptomatic', ')', 'by', 'using', 'a', 'continuous', 'cardiac', 'rhythm', 'monitoring', 'with', 'implantable', 'loop', 'recorder', '(', 'ILR', ')', 'during', 'the', 'first', '12', 'months', 'of', 'observation', 'is', 'higher', 'than', 'the', 'detection', 'by', 'using', 'a', 'standard', 'cardiac', 'monitoring', '(', 'physical', 'exam', ',', '12', '-', 'lead', 'electrocardiogram', '[', 'ECG', ']', 'at', 'baseline', ',', '3', ',', '6', ',', 'and', '12', 'months', 'and', 'Holter', 'ECG', 'at', '3', 'months', ')', 'in', 'the', 'same', 'period', 'of', 'time', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02684825,NCT02684825,"Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) | The primary objective of this study is to evaluate whether, in patients with first-ever atherothrombotic or lacunar stroke without any previous history of atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT), the detection of AF/AFL/AT (silent or symptomatic) by using a continuous cardiac rhythm monitoring with implantable loop recorder (ILR) during the first 12 months of observation is higher than the detection by using a standard cardiac monitoring (physical exam, 12-lead electrocardiogram [ECG] at baseline, 3, 6, and 12 months and Holter ECG at 3 months) in the same period of time.","[(13, 39, 'CONDITION', 'Silent Atrial Fibrillation'), (46, 61, 'CONDITION', 'Ischemic StrOke'), (319, 364, 'CONDITION', 'first-ever atherothrombotic or lacunar stroke'), (397, 416, 'CONDITION', 'atrial fibrillation'), (463, 465, 'CONDITION', 'AT'), (485, 487, 'CONDITION', 'AF'), (488, 491, 'CONDITION', 'AFL'), (492, 494, 'CONDITION', 'AT')]"
"['Pivotal', 'Study', 'of', 'the', 'Apnex', 'Medical', '', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'to', 'Treat', 'Obstructive', 'Sleep', 'Apnea', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'benefits', 'and', 'risks', 'of', 'hypoglossal', 'nerve', 'stimulation', 'with', 'the', 'Apnex', 'Medical', 'Hypoglossal', 'Nerve', 'Stimulation', '(', 'HGNS', ')', 'System', 'as', 'a', 'potential', 'therapeutic', 'option', 'for', 'individuals', 'with', 'moderate', 'to', 'severe', 'Obstructive', 'Sleep', 'Apnea', '(', 'OSA', ')', 'that', 'have', 'failed', 'or', 'do', 'not', 'tolerate', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'therapy', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01446601,NCT01446601,Pivotal Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea | The purpose of this study is to evaluate the benefits and risks of hypoglossal nerve stimulation with the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System as a potential therapeutic option for individuals with moderate to severe Obstructive Sleep Apnea (OSA) that have failed or do not tolerate positive airway pressure (PAP) therapy.,"[(21, 65, 'OTHER', 'Apnex Medical Hypoglossal Nerve Stimulation'), (67, 71, 'OTHER', 'HGNS'), (89, 112, 'CONDITION', 'Obstructive Sleep Apnea'), (182, 211, 'OTHER', 'hypoglossal nerve stimulation'), (221, 264, 'OTHER', 'Apnex Medical Hypoglossal Nerve Stimulation'), (266, 270, 'OTHER', 'HGNS'), (334, 376, 'CONDITION', 'moderate to severe Obstructive Sleep Apnea'), (378, 381, 'CONDITION', 'OSA')]"
"['An', 'Evaluation', 'of', 'the', 'Effect', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'Device', 'on', 'the', 'Symptons', 'of', 'Trigeminal', 'Neuralgia', '|', 'This', 'is', 'a', 'double', 'blinded', 'randomized', 'control', 'trial', 'of', 'a', 'Surface', 'Acoustic', 'Wave', 'Patch', 'device', 'for', 'the', 'treatment', 'of', 'Trigeminal', 'Neuralgia', '.', 'This', 'will', 'be', 'a', 'crossover', 'study', 'for', 'the', 'group', 'that', 'receives', 'the', 'sham', 'device', '.', 'Subjects', 'will', 'be', 'monitored', 'for', 'subjective', 'criteria', 'of', 'pain', 'and', 'quality', 'of', 'life', ',', 'as', 'well', 'as', 'objective', 'measurement', 'of', 'analgesic', 'usage', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02801630,NCT02801630,"An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia | This is a double blinded randomized control trial of a Surface Acoustic Wave Patch device for the treatment of Trigeminal Neuralgia. This will be a crossover study for the group that receives the sham device. Subjects will be monitored for subjective criteria of pain and quality of life, as well as objective measurement of analgesic usage.","[(33, 67, 'OTHER', 'Surface Acoustic Wave Patch Device'), (87, 107, 'CONDITION', 'Trigeminal Neuralgia'), (165, 199, 'OTHER', 'Surface Acoustic Wave Patch device'), (221, 241, 'CONDITION', 'Trigeminal Neuralgia'), (306, 317, 'CONTROL', 'sham device'), (373, 377, 'CONDITION', 'pain')]"
"['Recombinant', 'Human', 'Endostatin', 'Injection', 'Study', 'for', 'Patients', 'With', 'Neurofibromatosis', 'Type', '2', '(', 'NF2', ')', 'and', 'NF2', '-', 'Related', 'Tumors', 'by', 'Continuous', 'Intravenous', 'Pumping', '|', '1)Preliminarily', 'evaluate', 'the', 'treatment', 'effect', 'of', 'continuous', 'vein', 'injection', 'of', 'recombinant', 'human', 'endostatin', 'on', 'NF2', ';', '2)Preliminarily', 'evaluate', 'the', 'safety', 'and', 'the', 'patient', ""'s"", 'tolerance', 'of', 'the', 'treatment', 'of', 'endostatin', ';', '3)Provide', 'an', 'objective', 'basis', 'for', 'an', 'enlarged', 'randomized', 'double', '-', 'blind', 'trial', '.']","['B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02104323,NCT02104323,Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping | 1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.,"[(0, 28, 'DRUG', 'Recombinant Human Endostatin'), (63, 87, 'CONDITION', 'Neurofibromatosis Type 2'), (89, 92, 'CONDITION', 'NF2'), (98, 116, 'CONDITION', 'NF2-Related Tumors'), (231, 259, 'DRUG', 'recombinant human endostatin'), (263, 266, 'CONDITION', 'NF2'), (352, 362, 'DRUG', 'endostatin')]"
"['Study', 'to', 'Assess', 'the', 'Immunogenicity', 'and', 'Reactogenicity', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', 'Vaccine', 'Mixed', 'With', 'Hib', 'Vaccine', 'to', 'Healthy', 'Infants', 'at', '3', ',', '5', 'and', '11', 'Months', 'of', 'Age', ',', 'Compared', 'to', 'Each', 'Vaccine', 'Administered', 'Separately', '|', 'This', 'study', 'will', 'assess', 'the', 'immunogenicity', 'and', 'safety', 'of', 'GlaxoSmithKline', '(', 'GSK', ')', 'Biologicals', ""'"", '(', 'formerly', 'SB', 'Biologicals', ""'"", ')', 'DTPa', '-', 'HBV', '-', 'IPV', '/', 'Hib', '(', 'Infanrix', 'hexa', '', ')', 'vaccine', 'compared', 'with', 'separate', 'administration', 'of', 'DTPa', '-', 'HBV', '-', 'IPV', '(', 'Infanrix', 'penta', '', ')', 'and', 'Hib', '(', 'Hiberix', '', ')', 'vaccine', 'administered', 'at', '3', ',', '5', 'and', '11', '(', 'or', '12', ')', 'months', 'of', 'age', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01457508,NCT01457508,"Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately | This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' (formerly SB Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix penta) and Hib (Hiberix) vaccine administered at 3, 5 and 11 (or 12) months of age.","[(57, 77, 'DRUG', 'DTPa-HBV-IPV Vaccine'), (89, 100, 'DRUG', 'Hib Vaccine'), (319, 331, 'DRUG', 'DTPa-HBV-IPV'), (332, 335, 'DRUG', 'Hib'), (337, 350, 'DRUG', 'Infanrix hexa'), (402, 414, 'DRUG', 'DTPa-HBV-IPV'), (416, 430, 'DRUG', 'Infanrix penta'), (437, 440, 'DRUG', 'Hib'), (442, 449, 'DRUG', 'Hiberix')]"
"['Pilot', 'Study', 'to', 'Investigate', 'the', 'Efficacy', 'of', 'L', '-', 'arginine', 'Therapy', 'on', 'Endothelium', '-', 'dependent', 'Vasodilation', '&', 'Mitochondrial', 'Metabolism', 'in', 'MELAS', 'Syndrome', '.', '|', 'MELAS', 'patients', 'suffer', 'from', 'exercise', 'intolerance', ',', 'weakness', ',', 'poor', 'vision', 'or', 'blindness', ',', 'poor', 'growth', ',', 'developmental', 'delay', ',', 'and', 'deafness', '.', 'They', 'also', 'have', 'unique', ""'"", 'stroke', '-', 'like', ""'"", 'episodes', '(', 'SLEs', ')', 'which', 'are', 'not', 'due', 'to', 'blockages', 'of', 'large', 'or', 'medium', 'arteries', '.', 'These', ""'"", 'strokes', ""'"", 'are', 'thought', 'to', 'be', 'due', 'to', 'energy', 'failure', 'of', 'very', 'small', 'brain', 'blood', 'vessels', 'combined', 'with', 'energy', 'failure', 'in', 'the', 'mitochondria', '(', 'cell', 'battery', ')', 'of', 'the', 'brain', 'cells', ',', 'especially', 'in', 'the', 'back', 'region', 'of', 'the', 'brain', 'in', 'the', 'vision', 'centre', '.', 'This', 'leads', 'to', 'visual', 'loss', 'and', 'paralysis', '.', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'these', 'SLEs', 'at', 'the', 'level', 'of', 'the', 'brain', 'cells', 'and', 'small', 'blood', 'vessels', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01603446,NCT01603446,"Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome. | MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.","[(43, 53, 'DRUG', 'L-arginine'), (130, 144, 'CONDITION', 'MELAS Syndrome'), (148, 153, 'CONDITION', 'MELAS'), (303, 325, 'CONDITION', ""'stroke-like' episodes""), (327, 331, 'CONDITION', 'SLEs'), (400, 407, 'CONDITION', 'strokes'), (751, 755, 'CONDITION', 'SLEs')]"
"['Diet', 'and', 'Muscle', 'Function', 'In', 'Older', 'Adults', '|', 'This', 'research', 'study', 'was', 'conducted', 'to', 'investigate', 'the', 'effects', 'of', 'a', 'high', 'protein', 'diet', 'on', 'the', 'efficiency', 'of', 'energy', 'use', 'at', 'rest', 'and', 'at', 'low', '-', 'levels', 'of', 'physical', 'activity', '.', 'The', 'hypothesis', 'was', 'that', 'a', 'high', 'intake', 'of', 'dietary', 'protein', 'would', 'result', 'in', 'a', 'less', 'efficient', 'use', 'of', 'energy', 'in', 'skeletal', 'muscle', 'in', 'older', 'adults', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02069314,NCT02069314,Diet and Muscle Function In Older Adults | This research study was conducted to investigate the effects of a high protein diet on the efficiency of energy use at rest and at low-levels of physical activity. The hypothesis was that a high intake of dietary protein would result in a less efficient use of energy in skeletal muscle in older adults.,"[(109, 126, 'OTHER', 'high protein diet'), (233, 263, 'OTHER', 'high intake of dietary protein')]"
"['PeRiodontal', 'Treatment', 'to', 'Eliminate', 'Minority', 'InEquality', 'and', 'Rural', 'Disparities', 'in', 'Stroke', '|', 'The', 'PREMIERS', 'study', 'is', 'a', 'proposal', 'for', 'conducting', 'an', 'adequately', 'powered', 'two', 'center', 'phase', 'III', 'randomized', 'controlled', 'trial', 'to', 'test', 'whether', 'intensive', 'periodontal', 'treatment', 'reduces', 'the', 'risk', 'of', 'recurrent', 'vascular', 'events', 'among', 'ischemic', 'stroke', 'and', 'TIA', 'survivors', '.', 'The', 'study', 'uses', 'the', 'resources', 'in', 'both', 'states', 'including', 'established', 'dental', 'centers', ',', 'Joint', 'Commission', 'Certified', 'Stroke', 'Centers', ',', 'the', 'Schools', 'of', 'Public', 'Health', ',', 'and', 'the', 'Institute', 'for', 'Partnerships', 'to', 'Eliminate', 'Health', 'Disparities', '.', 'The', 'proposal', 'addresses', 'specific', 'issues', 'with', 'regards', 'to', 'recruitment', 'of', 'African', '-', 'American', 'and', 'rural', 'stroke', '/', 'TIA', 'patients', 'advocating', 'the', 'use', 'of', 'culturally', 'appropriate', 'strategies', 'to', 'educate', 'the', 'study', 'subjects', 'regarding', 'stroke', ',', 'periodontal', 'disease', 'and', 'the', 'periodontal', 'stroke', 'link', '.', '\n\n', 'The', 'study', 'proposes', 'to', 'utilize', 'economic', 'evaluation', 'of', 'the', 'periodontal', 'intervention', 'from', 'the', 'budgetary', 'perspective', '.', 'The', 'focus', 'will', 'be', 'on', 'the', 'financial', 'sustainability', 'of', 'providing', 'aggressive', 'periodontal', 'therapy', '(', 'with', 'certain', ',', 'although', 'relatively', 'low', 'expenditures', ')', 'in', 'exchange', 'for', 'a', 'reduction', 'of', 'uncertain', 'recurrent', 'vascular', 'events', 'that', 'may', 'require', 'high', 'cost', 'emergency', 'department', 'utilization', 'and/or', 'inpatient', 'care', '.', 'The', 'sustainability', 'of', 'the', 'proposed', 'intervention', 'after', 'the', 'completion', 'of', 'the', 'project', 'is', 'integrally', 'linked', 'to', 'the', 'health', 'economic', 'assessment', 'to', 'show', 'the', 'health', 'care', 'cost', 'savings', '.', 'By', 'integration', 'with', 'a', 'rural', 'primary', 'care', 'center', ',', 'with', 'an', 'African', 'American', 'majority', 'and', 'households', 'with', 'average', 'incomes', 'below', 'the', 'state', 'average', ',', 'the', 'study', 'ensures', 'that', 'the', 'proposed', 'intervention', 'to', 'reduce', 'stroke', 'disparity', 'is', 'applicable', 'to', 'this', 'target', 'population', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02541032,NCT02541032,"PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke | The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link.

The study proposes to utilize economic evaluation of the periodontal intervention from the budgetary perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events that may require high cost emergency department utilization and/or inpatient care. The sustainability of the proposed intervention after the completion of the project is integrally linked to the health economic assessment to show the health care cost savings. By integration with a rural primary care center, with an African American majority and households with average incomes below the state average, the study ensures that the proposed intervention to reduce stroke disparity is applicable to this target population.","[(0, 21, 'OTHER', 'PeRiodontal Treatment'), (80, 86, 'CONDITION', 'Stroke'), (224, 255, 'OTHER', 'intensive periodontal treatment'), (308, 323, 'CONDITION', 'ischemic stroke'), (328, 331, 'CONDITION', 'TIA'), (663, 669, 'CONDITION', 'stroke'), (670, 673, 'CONDITION', 'TIA'), (779, 785, 'CONDITION', 'stroke'), (787, 806, 'CONDITION', 'periodontal disease'), (815, 833, 'CONDITION', 'periodontal stroke'), (898, 922, 'OTHER', 'periodontal intervention'), (1018, 1048, 'OTHER', 'aggressive periodontal therapy'), (1632, 1638, 'CONDITION', 'stroke')]"
"['Transformation', 'of', 'Dormant', 'Spinal', 'Networks', 'to', 'Mitigate', 'Symptoms', 'of', 'Neurogenic', 'Bladder', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'SCONE', 'neuromodulation', 'therapy', 'after', '12', 'weeks', 'of', 'therapy', 'in', 'comparison', 'to', 'inactive', 'sham', 'control', 'in', 'improving', 'symptoms', 'of', 'Neurogenic', 'Lower', 'Urinary', 'Tract', 'Dysfunction']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT05301335,NCT05301335,Transformation of Dormant Spinal Networks to Mitigate Symptoms of Neurogenic Bladder | The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction,"[(0, 41, 'OTHER', 'Transformation of Dormant Spinal Networks'), (66, 84, 'CONDITION', 'Neurogenic Bladder'), (160, 189, 'OTHER', 'SCONE neuromodulation therapy'), (233, 246, 'CONTROL', 'inactive sham'), (280, 322, 'CONDITION', 'Neurogenic Lower Urinary Tract Dysfunction')]"
"['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Pramipexole', 'With', 'the', 'Dose', 'Range', 'From', '0.125', 'mg', 'to', '0.75', 'mg', 'Orally', 'Once', 'Daily', 'for', '6', 'Weeks', 'in', 'Patients', 'With', 'Primary', 'Restless', 'Legs', 'Syndrome', '.', '|', 'The', 'objective', 'of', 'this', 'trial', 'is', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'pramipexole', '(', '0.125', '-', '0.75', 'mg', ')', 'orally', 'once', 'daily', 'as', 'compared', 'with', 'placebo', 'for', '6', 'weeks', 'in', 'patients', 'with', 'primary', 'restless', 'legs', 'syndrome', '(', 'RLS', ')', 'and', 'to', 'investigate', 'the', 'reliability', 'of', 'the', 'Japanese', 'version', 'of', 'the', 'RLS', 'rating', 'scale', 'by', 'the', 'International', 'Restless', 'Legs', 'Syndrome', 'Study', 'Group', '(', 'IRLSSG', ')', 'as', 'a', 'sub', '-', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00152997,NCT00152997,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome. | The objective of this trial is to investigate the efficacy and safety of pramipexole (0.125-0.75 mg) orally once daily as compared with placebo for 6 weeks in patients with primary restless legs syndrome (RLS) and to investigate the reliability of the Japanese version of the RLS rating scale by the International Restless Legs Syndrome Study Group (IRLSSG) as a sub-study.","[(28, 35, 'CONTROL', 'Placebo'), (92, 103, 'DRUG', 'Pramipexole'), (196, 226, 'CONDITION', 'Primary Restless Legs Syndrome'), (303, 314, 'DRUG', 'pramipexole'), (366, 373, 'CONTROL', 'placebo'), (403, 433, 'CONDITION', 'primary restless legs syndrome'), (435, 438, 'CONDITION', 'RLS'), (506, 509, 'CONDITION', 'RLS')]"
"['Critical', 'Periods', 'After', 'Stroke', 'Study', '(', 'CPASS', ')', ';', 'Sensitive', 'Periods', 'and', 'Consumer', 'Preferences', ':', 'Optimizing', 'Upper', 'Extremity', 'Stroke', 'Rehabilitation', '|', 'To', 'perform', 'an', 'exploratory', 'single', 'center', 'randomized', 'study', 'that', 'will', 'form', 'the', 'basis', 'for', 'a', 'larger', 'scale', ',', 'more', 'definitive', 'randomized', 'clinical', 'trial', 'to', 'determine', 'the', 'optimal', 'time', 'after', 'stroke', 'for', 'intensive', 'motor', 'training', '.', 'The', 'investigators', 'will', 'perform', 'a', 'prospective', 'exploratory', 'study', 'of', 'upper', 'extremity', '(', 'UE', ')', 'motor', 'training', 'delivered', 'at', 'higher', 'than', 'usual', 'intensity', 'at', 'three', 'different', 'time', 'points', 'after', 'stroke', ':', '\n\n', 'early', '(', 'initiated', 'within', '30', 'days', ')', '\n', 'subacute', '/', 'outpatient', '(', 'initiated', 'within', '2', '-', '3', 'months', ')', '\n', 'chronic', '(', 'initiated', 'within', '6', '-', '9', 'months', ')', '\n\n', 'The', 'control', 'group', 'will', 'not', 'receive', 'the', 'therapy', 'intervention', 'during', 'the', '1', '-', 'year', 'study', '.', '\n\n', 'Outcome', 'measures', 'will', 'be', 'assessed', 'at', 'baseline', ',', 'pre', '-', 'treatment', ',', 'post', '-', 'treatment', ',', '6', 'months', 'and', 'one', 'year', 'after', 'stroke', 'onset', '.', '\n\n', 'Compared', 'to', 'individuals', 'randomized', 'during', 'the', 'outpatient', '(', '2', '-', '3', 'months', 'after', 'stroke', 'onset', ')', 'or', 'chronic', '(', '6', '-', '9', 'months', 'after', 'stroke', 'onset', ')', 'time', 'points', ',', 'participants', 'randomized', 'to', 'early', 'intensive', 'motor', 'training', 'will', 'show', 'greater', 'upper', 'extremity', 'motor', 'improvement', 'measured', 'at', 'one', 'year', 'post', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT02235974,NCT02235974,"Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation | To perform an exploratory single center randomized study that will form the basis for a larger scale, more definitive randomized clinical trial to determine the optimal time after stroke for intensive motor training. The investigators will perform a prospective exploratory study of upper extremity (UE) motor training delivered at higher than usual intensity at three different time points after stroke:

early (initiated within 30 days)
subacute/outpatient (initiated within 2-3 months)
chronic (initiated within 6-9 months)

The control group will not receive the therapy intervention during the 1-year study.

Outcome measures will be assessed at baseline, pre-treatment, post-treatment, 6 months and one year after stroke onset.

Compared to individuals randomized during the outpatient (2-3 months after stroke onset) or chronic (6-9 months after stroke onset) time points, participants randomized to early intensive motor training will show greater upper extremity motor improvement measured at one year post stroke.","[(116, 122, 'CONDITION', 'Stroke'), (320, 326, 'CONDITION', 'stroke'), (331, 355, 'PHYSICAL', 'intensive motor training'), (423, 458, 'PHYSICAL', 'upper extremity (UE) motor training'), (537, 543, 'CONDITION', 'stroke'), (691, 714, 'CONTROL', 'not receive the therapy'), (860, 866, 'CONDITION', 'stroke'), (950, 956, 'CONDITION', 'stroke'), (1053, 1077, 'PHYSICAL', 'intensive motor training'), (1156, 1162, 'CONDITION', 'stroke')]"
"['""', 'Cognitus', '&', 'Moi', '""', ':', 'a', 'New', 'Cognitive', 'Remediation', 'Tool', 'for', 'Children', 'With', 'Intellectual', 'Deficiency', 'With', 'Behavioral', 'Disorders', '|', 'Holders', 'children', 'with', 'intellectual', 'disabilities', 'have', 'great', 'difficulty', 'in', 'adapting', 'to', 'social', 'situations', 'and', 'relationships', '.', 'Cognitive', 'impairment', 'associated', 'with', 'intellectual', 'disability', 'are', 'important', 'factors', 'to', 'understand', 'their', 'difficulties', 'in', 'processing', 'social', 'information', '.', 'In', 'the', 'field', 'of', 'recognition', 'of', 'facial', 'emotions', 'in', 'particular', ',', 'basic', 'cognitive', 'processes', 'such', 'as', 'visuospatial', 'and', 'attentional', 'functions', ',', 'are', 'heavily', 'involved', '.', 'Cognitive', 'remediation', 'is', 'a', 'management', 'tool', 'widely', 'used', 'by', 'practitioners', 'to', 'help', 'patients', 'who', 'experience', 'cognitive', 'difficulties', '.', 'Currently', ',', 'no', 'program', 'can', 'meet', 'specific', 'and', 'validated', 'the', 'problems', 'are', 'children', 'with', 'intellectual', 'disabilities', 'manner', 'in', 'their', 'daily', 'functioning', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02797418,NCT02797418,"""Cognitus & Moi"": a New Cognitive Remediation Tool for Children With Intellectual Deficiency With Behavioral Disorders | Holders children with intellectual disabilities have great difficulty in adapting to social situations and relationships.Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved.Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are children with intellectual disabilities manner in their daily functioning.","[(1, 15, 'OTHER', 'Cognitus & Moi'), (24, 50, 'OTHER', 'Cognitive Remediation Tool'), (69, 92, 'CONDITION', 'Intellectual Deficiency'), (98, 118, 'CONDITION', 'Behavioral Disorders'), (143, 168, 'CONDITION', 'intellectual disabilities'), (242, 262, 'CONDITION', 'Cognitive impairment'), (279, 302, 'CONDITION', 'intellectual disability'), (549, 570, 'OTHER', 'Cognitive remediation'), (653, 675, 'CONDITION', 'cognitive difficulties'), (762, 787, 'CONDITION', 'intellectual disabilities')]"
"['Measurement', 'and', 'Modification', 'of', 'Threat', 'Interpretation', 'Bias', 'in', 'Neurodegenerative', 'Movement', 'Disorders', '(', 'Aims', '2', '&', '3', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'conduct', 'a', 'pilot', 'open', 'trial', 'of', 'a', 'web', '-', 'based', 'cognitive', 'bias', 'modification', 'intervention', 'to', 'reduce', 'anxiety', 'symptoms', 'in', 'persons', 'with', 'Huntington', ""'s"", 'disease', 'and', 'persons', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05126862,NCT05126862,Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3) | The purpose of this study is conduct a pilot open trial of a web-based cognitive bias modification intervention to reduce anxiety symptoms in persons with Huntington's disease and persons with Parkinson's disease.,"[(16, 58, 'BEHAVIOURAL', 'Modification of Threat Interpretation Bias'), (62, 98, 'CONDITION', 'Neurodegenerative Movement Disorders'), (175, 225, 'BEHAVIOURAL', 'web-based cognitive bias modification intervention'), (236, 243, 'CONDITION', 'anxiety'), (269, 289, 'CONDITION', ""Huntington's disease""), (307, 326, 'CONDITION', ""Parkinson's disease"")]"
"['An', 'Open', '-', 'Label', ',', 'Safety', 'and', 'Tolerability', 'Study', 'of', 'Chronic', 'Intermittent', 'Use', 'of', 'Diazepam', 'Buccal', 'Film', '(', 'DBF', ')', 'in', 'Pediatric', ',', 'Adolescent', 'and', 'Adult', 'Subjects', 'With', 'Epilepsy', '|', 'This', 'Phase', '3', ',', 'multicenter', ',', 'open', '-', 'label', 'study', 'of', 'chronic', ',', 'intermittent', 'use', 'of', 'study', 'drug', '(', 'DBF', ')', 'is', 'designed', 'to', 'evaluate', 'the', 'safety', 'and', 'tolerability', 'of', 'the', 'buccal', 'formulation', 'of', 'diazepam', 'in', 'children', ',', 'adolescents', 'and', 'adults', 'with', 'intermittent', ',', 'stereotypic', 'episodes', 'of', 'frequent', 'seizure', 'activity', '(', 'eg', ',', 'seizure', 'clusters', ')', 'that', 'are', 'distinct', 'from', 'the', 'subject', ""'s"", 'usual', 'seizure', 'pattern', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT03428360,NCT03428360,"An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Film (DBF) in Pediatric, Adolescent and Adult Subjects With Epilepsy | This Phase 3, multicenter, open-label study of chronic, intermittent use of study drug (DBF) is designed to evaluate the safety and tolerability of the buccal formulation of diazepam in children, adolescents and adults with intermittent, stereotypic episodes of frequent seizure activity (eg, seizure clusters) that are distinct from the subject's usual seizure pattern.","[(76, 84, 'DRUG', 'Diazepam'), (98, 101, 'DRUG', 'DBF'), (152, 160, 'CONDITION', 'Epilepsy'), (251, 254, 'DRUG', 'DBF'), (337, 345, 'DRUG', 'diazepam'), (387, 450, 'CONDITION', 'intermittent, stereotypic episodes of frequent seizure activity'), (456, 472, 'CONDITION', 'seizure clusters'), (517, 524, 'CONDITION', 'seizure')]"
"['Local', 'Site', 'Tolerability', 'of', 'Multiple', 'Dose', 'Treatment', 'With', 'Deltoid', 'Intramuscular', 'Injection', 'of', 'RISPERDAL', 'CONSTA', 'in', 'Subjects', 'With', 'Chronic', 'Schizophrenia', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'the', 'discontinuation', 'rate', 'of', 'schizophrenia', 'patients', 'receiving', 'multiple', 'sequential', '2', 'mL', 'injections', 'of', 'long', 'acting', 'injectable', 'risperidone', '(', 'an', 'atypical', 'antipsychotic', 'medication', ')', 'when', 'administered', 'into', 'the', 'deltoid', 'muscle', 'once', 'every', '2', 'weeks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00828958,NCT00828958,Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia. | The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when administered into the deltoid muscle once every 2 weeks.,"[(91, 100, 'DRUG', 'RISPERDAL'), (125, 146, 'CONDITION', 'Chronic Schizophrenia'), (218, 231, 'CONDITION', 'schizophrenia'), (313, 324, 'DRUG', 'risperidone')]"
"['A', 'Double', 'Blind', 'Placebo', 'Controlled', 'Study', 'of', 'Guanfacine', 'Adjunctive', 'Treatment', 'to', 'Atypical', 'Antipsychotics', 'for', 'Cognitive', 'Dysfunction', 'in', 'Schizophrenia', '|', 'Our', 'overall', 'aim', 'is', 'to', 'determine', 'if', 'the', 'administration', 'of', 'guanfacine', 'in', 'combination', 'with', 'aripiprazole', ',', 'olanzapine', ',', 'quetiapine', ',', 'and/or', 'risperidone', 'is', 'significantly', 'more', 'effective', 'than', 'any', 'of', 'those', 'medications', 'alone', 'in', 'treating', 'some', 'of', 'the', 'cognitive', 'impairment', 'in', 'schizophrenia', '.']","['O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00469664,NCT00469664,"A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia | Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.","[(15, 22, 'CONTROL', 'Placebo'), (43, 53, 'DRUG', 'Guanfacine'), (131, 144, 'CONDITION', 'Schizophrenia'), (204, 214, 'DRUG', 'guanfacine'), (235, 247, 'DRUG', 'aripiprazole'), (249, 259, 'DRUG', 'olanzapine'), (261, 271, 'DRUG', 'quetiapine'), (280, 291, 'DRUG', 'risperidone'), (384, 404, 'CONDITION', 'cognitive impairment'), (408, 421, 'CONDITION', 'schizophrenia')]"
"['Digital', 'Gaming', 'Used', 'to', 'Improve', 'the', 'Cognitive', 'Functioning', 'and', 'Well', '-', 'being', 'of', 'People', 'With', 'Traumatic', 'Brain', 'Injury', ':', 'a', 'Feasibility', 'Study', '|', 'The', 'purpose', 'of', 'this', 'feasibility', 'study', 'is', 'to', 'determine', 'whether', 'digital', 'games', 'are', 'effective', 'and', 'acceptable', 'in', 'the', 'treatment', 'for', 'patients', 'with', 'traumatic', 'brain', 'injury', '.']","['B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02425527,NCT02425527,Digital Gaming Used to Improve the Cognitive Functioning and Well-being of People With Traumatic Brain Injury: a Feasibility Study | The purpose of this feasibility study is to determine whether digital games are effective and acceptable in the treatment for patients with traumatic brain injury.,"[(0, 14, 'OTHER', 'Digital Gaming'), (87, 109, 'CONDITION', 'Traumatic Brain Injury'), (195, 208, 'OTHER', 'digital games'), (273, 295, 'CONDITION', 'traumatic brain injury')]"
"['A', 'Pilot', 'Feasibility', 'Study', 'of', 'a', 'Co', '-', 'constructed', 'Program', '(', 'Patients', '-', 'Experts', ')', 'of', 'Mindfulness', 'Meditation', 'Adapted', 'to', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'feasibility', '(', 'primary', 'objective', ')', 'and', 'the', 'effects', '(', 'secondary', 'objectives', ')', 'of', 'an', 'Mindfulness', 'Based', 'Stress', 'Reduction', '(', 'MBSR', ')', 'program', 'adapted', 'specifically', 'for', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05622396,NCT05622396,A Pilot Feasibility Study of a Co-constructed Program (Patients - Experts) of Mindfulness Meditation Adapted to Patients With Parkinson's Disease. | The objective of this study is to determine the feasibility (primary objective) and the effects (secondary objectives) of an Mindfulness Based Stress Reduction (MBSR) program adapted specifically for patients with Parkinson's disease.,"[(78, 100, 'BEHAVIOURAL', 'Mindfulness Meditation'), (126, 145, 'CONDITION', ""Parkinson's Disease""), (274, 308, 'BEHAVIOURAL', 'Mindfulness Based Stress Reduction'), (310, 314, 'BEHAVIOURAL', 'MBSR'), (363, 382, 'CONDITION', ""Parkinson's disease"")]"
"['Pilot', 'Phase', '1', 'Clinical', 'Trial', 'of', 'PET', 'Scanning', 'in', 'Tau', 'Protein', 'Deposition', 'and', 'Connectome', 'Analysis', 'in', 'Traumatic', 'Encephalopathy', 'Syndrome', '(', 'TES', ')', 'Cohort', 'With', 'a', 'Probable', 'Chronic', 'Traumatic', 'Encephalopathy', '(', 'CTE', ')', 'Pattern', 'of', 'Neurodegenerative', 'Disease', '|', 'This', 'pilot', 'study', 'aims', 'to', 'assess', 'if', 'participants', 'that', 'meet', 'the', 'criteria', 'for', 'a', 'TES', 'diagnosis', 'have', 'a', 'specific', 'tau', 'deposition', 'profile', 'on', 'PET', 'scanning', 'using', 'the', 'PET', 'tau', 'binding', 'ligand', '-', '[', '18F', ']', 'PI-2620', '.', 'It', 'is', 'hoped', 'this', 'study', 'will', 'highlight', 'potential', 'diagnostic', 'tests', 'of', 'TES', 'diagnosis', ',', 'the', 'in', '-', 'life', 'correlate', 'of', 'CTE', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05490576,NCT05490576,"Pilot Phase 1 Clinical Trial of PET Scanning in Tau Protein Deposition and Connectome Analysis in Traumatic Encephalopathy Syndrome (TES) Cohort With a Probable Chronic Traumatic Encephalopathy (CTE) Pattern of Neurodegenerative Disease | This pilot study aims to assess if participants that meet the criteria for a TES diagnosis have a specific tau deposition profile on PET scanning using the PET tau binding ligand - [18F] PI-2620. It is hoped this study will highlight potential diagnostic tests of TES diagnosis, the in-life correlate of CTE.","[(98, 131, 'CONDITION', 'Traumatic Encephalopathy Syndrome'), (133, 136, 'CONDITION', 'TES'), (161, 193, 'CONDITION', 'Chronic Traumatic Encephalopathy'), (195, 198, 'CONDITION', 'CTE'), (316, 319, 'CONDITION', 'TES'), (503, 506, 'CONDITION', 'TES'), (543, 546, 'CONDITION', 'CTE')]"
"['An', 'Open', 'Label', ',', 'Prospective', ',', 'Pilot', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Best', 'Physician', ""'s"", 'Choice', 'of', 'Standard', 'of', 'Care', 'Combined', 'With', 'NaviFUS', 'System', 'in', 'Patients', 'With', 'Recurrent', 'Glioblastoma', 'Multiforme', '|', 'This', 'is', 'a', 'prospective', ',', 'single', '-', 'arm', ',', 'two', 'stages', ',', 'open', '-', 'label', ',', 'pilot', 'study', 'to', 'investigate', 'the', 'efficacy', 'and', 'safety', 'of', 'FUS', 'add', '-', 'on', 'bevacizumab', '(', 'BEV', ')', 'in', 'rGBM', 'patients', '.', 'The', 'BEV', 'is', 'the', 'best', 'physician', ""'s"", 'choice', 'of', 'standard', 'of', 'care', 'for', 'rGBM', 'after', 'prior', 'radiotherapy', 'and', 'temozolomide', 'chemotherapy', 'in', 'the', 'LinKou', 'Chang', 'Gung', 'Memorial', 'Hospital', '.', 'Eligible', 'patients', 'will', 'be', 'enrolled', 'through', 'the', 'process', 'of', 'informed', 'consent', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-RADIO', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04446416,NCT04446416,"An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme | This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients. The BEV is the best physician's choice of standard of care for rGBM after prior radiotherapy and temozolomide chemotherapy in the LinKou Chang Gung Memorial Hospital. Eligible patients will be enrolled through the process of informed consent.","[(137, 151, 'OTHER', 'NaviFUS System'), (169, 202, 'CONDITION', 'Recurrent Glioblastoma Multiforme'), (318, 328, 'OTHER', 'FUS add-on'), (329, 340, 'DRUG', 'bevacizumab'), (342, 345, 'DRUG', 'BEV'), (350, 354, 'CONDITION', 'rGBM'), (369, 372, 'DRUG', 'BEV'), (428, 432, 'CONDITION', 'rGBM'), (445, 457, 'RADIOTHERAPY', 'radiotherapy'), (462, 474, 'DRUG', 'temozolomide')]"
"['Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'Program', 'at', 'OHSU', 'Hospital', '|', 'The', 'purpose', 'of', 'this', 'investigation', 'is', 'to', 'assess', 'the', 'effectiveness', 'of', 'a', 'multi', '-', 'disciplinary', 'Acute', 'Care', 'for', 'Elders', '(', 'ACE', ')', 'program', 'dedicated', 'to', 'the', 'care', 'of', 'patients', 'age', '70', 'and', 'older', 'admitted', 'to', 'Oregon', 'Health', '&', 'Science', 'University', ""'s"", 'hospital', 'medicine', 'service', '.', 'The', 'ACE', 'program', 'will', 'aim', 'to', 'improve', 'the', 'quality', 'of', 'care', 'of', 'older', 'patients', 'in', 'the', 'investigators', 'hospital', 'by', 'implementing', 'focused', 'interventions', 'and', 'recommendations', 'specific', 'to', 'geriatric', 'needs', 'and', 'syndromes', ',', 'including', ':', 'reduced', 'fall', 'rate', ',', 'decreased', 'incidence', 'and', 'duration', 'of', 'delirium', ',', 'early', 'recognition', 'and', 'treatment', 'of', 'impaired', 'mobility', 'and', 'function', ',', 'careful', 'minimization', 'of', 'medication', 'use', ',', 'prevention', 'of', 'unnecessary', 'catheter', 'and', 'restraint', 'use', ',', 'decreased', 'hospital', 'readmission', 'rates', ',', 'improved', 'transitional', 'care', 'following', 'hospital', 'discharge', ',', 'and', 'high', 'levels', 'of', 'patient', 'and', 'referring', 'physician', 'satisfaction', '.', 'Additionally', ',', 'the', 'ACE', 'program', 'aims', 'to', 'improve', 'resident', 'and', 'student', 'competence', 'in', 'treating', 'geriatric', 'syndromes', ',', 'and', 'to', 'improve', 'staff', 'and', 'learner', 'satisfaction', 'with', 'caring', 'for', 'older', 'adults', '.', 'ACE', 'programs', 'have', 'been', 'well', 'studied', 'at', 'other', 'institutions', ',', 'so', 'the', 'investigators', 'will', 'be', 'implementing', 'a', 'program', 'that', 'is', 'already', 'standard', 'of', 'care', ',', 'and', 'studying', 'the', 'elements', 'that', 'are', 'unique', 'to', 'OHSU', '.', '\n\n', 'This', 'will', 'be', 'a', 'quality', 'improvement', 'project', '.', 'Study', 'participants', 'will', 'be', 'a', 'convenience', 'sample', 'of', 'OHSU', 'faculty', ',', 'staff', ',', 'residents', 'and', 'students', 'who', 'are', 'employed', 'by', 'or', 'on', 'rotation', 'with', 'General', 'Medicine', 'Team', '1', 'of', 'the', 'Medicine', 'Teaching', 'Service', '.', 'Faculty', ',', 'staff', ',', 'and', 'learners', '(', 'ACE', 'team', 'members', ')', 'will', 'receive', 'the', 'ACE', 'training', '.', 'Study', 'personnel', 'will', 'conduct', 'prospective', 'and', 'retrospective', 'chart', 'review', 'of', 'patients', 'admitted', 'to', 'the', 'ACE', 'service', 'to', 'determine', 'outcomes', 'as', 'noted', 'above', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02119078,NCT02119078,"Acute Care for Elders (ACE) Program at OHSU Hospital | The purpose of this investigation is to assess the effectiveness of a multi-disciplinary Acute Care for Elders (ACE) program dedicated to the care of patients age 70 and older admitted to Oregon Health & Science University's hospital medicine service. The ACE program will aim to improve the quality of care of older patients in the investigators hospital by implementing focused interventions and recommendations specific to geriatric needs and syndromes, including: reduced fall rate, decreased incidence and duration of delirium, early recognition and treatment of impaired mobility and function, careful minimization of medication use, prevention of unnecessary catheter and restraint use, decreased hospital readmission rates, improved transitional care following hospital discharge, and high levels of patient and referring physician satisfaction. Additionally, the ACE program aims to improve resident and student competence in treating geriatric syndromes, and to improve staff and learner satisfaction with caring for older adults. ACE programs have been well studied at other institutions, so the investigators will be implementing a program that is already standard of care, and studying the elements that are unique to OHSU.

This will be a quality improvement project. Study participants will be a convenience sample of OHSU faculty, staff, residents and students who are employed by or on rotation with General Medicine Team 1 of the Medicine Teaching Service. Faculty, staff, and learners (ACE team members) will receive the ACE training. Study personnel will conduct prospective and retrospective chart review of patients admitted to the ACE service to determine outcomes as noted above.","[(0, 35, 'OTHER', 'Acute Care for Elders (ACE) Program'), (144, 179, 'OTHER', 'Acute Care for Elders (ACE) program'), (311, 322, 'OTHER', 'ACE program'), (927, 938, 'OTHER', 'ACE program'), (1096, 1108, 'OTHER', 'ACE programs'), (1560, 1563, 'OTHER', 'ACE'), (1595, 1607, 'OTHER', 'ACE training'), (1709, 1720, 'OTHER', 'ACE service')]"
"['Effects', 'of', 'Attention', 'Training', 'Interventions', 'on', 'Depression', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'study', 'the', 'effects', 'of', 'attention', 'training', 'interventions', 'on', 'symptoms', 'and', 'brain', 'function', 'in', 'major', 'depressive', 'disorder', '.']","['O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04184206,NCT04184206,Effects of Attention Training Interventions on Depression | The purpose of this study is to study the effects of attention training interventions on symptoms and brain function in major depressive disorder.,"[(11, 43, 'BEHAVIOURAL', 'Attention Training Interventions'), (47, 57, 'CONDITION', 'Depression'), (113, 145, 'BEHAVIOURAL', 'attention training interventions'), (180, 205, 'CONDITION', 'major depressive disorder')]"
"['The', 'Effectiveness', 'of', 'Supplementing', 'Supported', 'Employment', 'With', 'Behavioral', 'Skills', 'Training', '|', 'This', 'study', 'will', 'compare', 'employment', 'support', 'with', 'behavioral', 'skills', 'training', 'to', 'employment', 'support', 'alone', 'in', 'schizophrenia', 'patients', 'taking', 'either', 'risperidone', 'or', 'olanzapine', 'to', 'determine', 'which', 'is', 'more', 'effective', 'in', 'helping', 'the', 'patients', 'maintain', 'a', 'job', '.']","['O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00183625,NCT00183625,The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training | This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients maintain a job.,"[(35, 87, 'BEHAVIOURAL', 'Supported Employment With Behavioral Skills Training'), (114, 164, 'BEHAVIOURAL', 'employment support with behavioral skills training'), (168, 186, 'CONTROL', 'employment support'), (196, 209, 'CONDITION', 'schizophrenia'), (233, 244, 'DRUG', 'risperidone'), (248, 258, 'DRUG', 'olanzapine')]"
"['Study', 'of', 'Dexmedetomidine', 'as', 'an', 'Effective', 'Sedative', 'to', 'Treat', 'Acute', 'ICU', 'Delirium', '|', 'The', 'purpose', 'of', 'the', 'research', 'is', 'to', 'see', 'if', 'dexmedetomidine', '(', 'a', 'drug', 'that', 'has', 'a', 'calming', 'effect', '-', 'a', 'sedative', ')', 'is', 'effective', 'for', 'the', 'treatment', 'of', 'acute', 'delirium']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT00351299,NCT00351299,Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium | The purpose of the research is to see if dexmedetomidine (a drug that has a calming effect - a sedative) is effective for the treatment of acute delirium,"[(9, 24, 'DRUG', 'Dexmedetomidine'), (59, 77, 'CONDITION', 'Acute ICU Delirium'), (121, 136, 'DRUG', 'dexmedetomidine'), (219, 233, 'CONDITION', 'acute delirium')]"
"['Acute', 'Effect', 'of', 'Topical', 'Menthol', 'on', 'Pain', 'Symptoms', 'in', 'Slaughterhouse', 'Workers', 'With', 'Symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', ':', 'Randomized', 'Controlled', 'Trial', '|', 'Topical', 'menthol', 'gels', 'are', 'classified', ""'"", 'topical', 'analgesics', ""'"", 'and', 'are', 'used', 'to', 'relieve', 'pain', 'of', 'the', 'musculoskeletal', 'system', '.', 'However', ',', 'double', '-', 'blind', 'randomized', 'controlled', 'trials', 'are', 'lacking', '.', 'Here', 'the', 'investigators', 'examine', '-', 'in', 'a', 'double', '-', 'blind', 'randomized', 'controlled', 'cross', '-', 'over', 'trial', '-', 'the', 'acute', 'effect', 'of', 'topical', 'menthol', '(', 'Biofreeze', ')', 'and', 'placebo', '(', 'gel', 'with', 'a', 'menthol', 'scent', ')', 'on', 'pain', 'symptoms', 'in', 'slaughterhouse', 'workers', 'with', 'symptoms', 'of', 'Carpal', 'Tunnel', 'Syndrome', '.']","['O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01716767,NCT01716767,"Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial | Topical menthol gels are classified 'topical analgesics' and are used to relieve pain of the musculoskeletal system. However, double-blind randomized controlled trials are lacking. Here the investigators examine - in a double-blind randomized controlled cross-over trial - the acute effect of topical menthol (Biofreeze) and placebo (gel with a menthol scent) on pain symptoms in slaughterhouse workers with symptoms of Carpal Tunnel Syndrome.","[(24, 31, 'DRUG', 'Menthol'), (35, 39, 'CONDITION', 'Pain'), (92, 114, 'CONDITION', 'Carpal Tunnel Syndrome'), (154, 161, 'DRUG', 'menthol'), (227, 231, 'CONDITION', 'pain'), (447, 454, 'DRUG', 'menthol'), (456, 465, 'DRUG', 'Biofreeze'), (480, 504, 'CONTROL', 'gel with a menthol scent'), (509, 513, 'CONDITION', 'pain'), (566, 588, 'CONDITION', 'Carpal Tunnel Syndrome')]"
"['Multiparametric', 'Biomarkers', 'to', 'Predict', 'the', 'Response', 'to', 'Different', 'Protocols', 'of', 'Motor', '-', 'cognitive', 'Rehabilitation', 'in', 'Parkinson', ""'s"", 'Disease', 'Subjects', 'With', 'Postural', 'Instability', 'and', 'Gait', 'Disorders', '|', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'compare', 'the', 'effects', 'of', '2', 'different', 'dosages', 'and', 'modalities', 'of', 'motor', '-', 'cognitive', 'rehabilitation', 'in', 'Parkinson', ""'s"", 'disease', 'with', 'postural', 'instability', 'and', 'gait', 'disorders', '(', 'PD', '-', 'PIGD', ')', 'on', 'clinical', 'features', ',', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'at', 'short', '-', 'term', '(', '2', 'months', ')', 'and', 'long', '-', 'term', '(', '7', 'months', ')', 'follow', '-', 'up', '.', 'Fifty', 'subjects', 'with', 'PD', '-', 'PIGD', 'will', 'be', 'randomized', 'in', '2', 'training', 'groups', ':', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'the', 'DUAL', '-', 'TASK', 'groups', '.', 'The', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'group', 'will', 'perform', 'a', 'dual', '-', 'task', 'gait', '/', 'balance', 'training', 'consisting', 'of', 'action', 'observation', 'training', '(', 'AOT', ')', 'and', 'motor', 'imagery', '(', 'MI', ')', 'combined', 'with', 'practicing', 'the', 'observed', '-', 'imagined', 'exercises', ';', 'DUAL', '-', 'TASK', 'group', 'will', 'perform', 'the', 'same', 'exercises', 'combined', 'with', 'watching', 'landscape', 'videos', '.', 'The', 'training', 'will', 'last', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'per', 'session', '.', '\n\n', 'Before', 'and', 'after', 'training', '(', 'W6', ')', ',', 'all', 'the', 'patients', 'will', 'undergo', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'magnetic', 'resonance', 'imaging', '(', 'MRI', ')', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'Neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', 'and', 'serum', 'biomarkers', 'will', 'be', 'also', 'repeated', 'at', 'the', '14', '-', 'week', 'follow', '-', 'up', '(', 'W14', ')', 'to', 'assess', 'maintenance', 'of', 'results', '.', '\n\n', 'Patients', 'of', 'both', 'DUAL', '-', 'TASK+AOT', '-', 'MI', 'and', 'DUAL', '-', 'TASK', 'groups', 'will', 'be', 'further', 'randomized', 'to', 'repeat', 'the', 'training', '(', '6', 'weeks', ',', '3', 'times', '/', 'week', ',', '1', 'hour', 'each', 'session', ')', 'starting', 'at', 'W14', '(', 'DUAL', '-', 'TASK+AOT', '-', 'MI_DOUBLE', 'and', 'DUAL', '-', 'TASK_DOUBLE', 'groups', ')', '.', 'After', 'six', 'weeks', '(', 'W20', ')', 'all', 'the', 'subjects', 'repeating', 'the', 'training', 'will', 'be', 'evaluated', '(', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', 'assessments', ')', '.', 'At', '28', '-', 'week', 'follow', '-', 'up', '(', 'W28', ')', ',', 'the', 'whole', 'sample', 'of', 'patients', 'will', 'be', 'assessed', 'with', 'neurological', ',', 'gait', '/', 'balance', ',', 'cognitive', '/', 'behavioral', ',', 'MRI', 'and', 'serum', 'biomarkers', 'evaluations', '.', 'All', 'MRI', 'scans', 'will', 'be', 'acquired', 'at', 'least', '12', 'hours', 'after', 'last', 'dopaminergic', 'therapy', 'administration', 'to', 'mitigate', 'the', 'pharmacological', 'effects', 'on', 'neural', 'activity', '.', 'Twenty', 'age-', 'and', 'sex', '-', 'matched', 'healthy', 'controls', 'will', 'be', 'recruited', 'to', 'perform', 'gait', '/', 'balance', 'and', 'cognitive', '/', 'behavioral', 'assessments', ',', 'blood', 'sample', 'and', 'brain', 'MRI', 'acquisition', 'at', 'baseline', '.', 'The', 'secondary', 'aims', 'of', 'the', 'study', 'are', 'to', 'define', 'the', 'neuroimaging', 'and', 'blood', '-', 'based', 'biomarkers', 'of', 'PD', '-', 'PIGD', 'patients', 'presenting', 'different', 'clinical', 'features', '(', 'e.g.', 'presence', 'of', 'mild', 'cognitive', 'impairment', ',', 'freezing', 'of', 'gait', ',', 'falls', 'and', 'mood', 'disturbances', ')', 'and', 'to', 'evaluate', 'the', 'role', 'of', 'blood', '-', 'based', 'and', 'neuroimaging', 'biomarkers', ',', 'together', 'with', 'clinical', 'characteristics', ',', 'in', 'predicting', 'the', 'response', 'to', 'different', 'dosages', 'of', 'rehabilitation', 'in', 'PD', '-', 'PIGD', 'throughout', 'the', 'development', 'of', 'a', 'machine', '-', 'learning', 'algorithm', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05799690,NCT05799690,"Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders | The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session.

Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results.

Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.","[(77, 107, 'OTHER', 'Motor-cognitive Rehabilitation'), (111, 130, 'CONDITION', ""Parkinson's Disease""), (145, 165, 'CONDITION', 'Postural Instability'), (170, 184, 'CONDITION', 'Gait Disorders'), (275, 305, 'OTHER', 'motor-cognitive rehabilitation'), (309, 328, 'CONDITION', ""Parkinson's disease""), (334, 354, 'CONDITION', 'postural instability'), (359, 373, 'CONDITION', 'gait disorders'), (375, 382, 'CONDITION', 'PD-PIGD'), (527, 534, 'CONDITION', 'PD-PIGD'), (576, 592, 'OTHER', 'DUAL-TASK+AOT-MI'), (601, 610, 'OTHER', 'DUAL-TASK'), (623, 639, 'OTHER', 'DUAL-TASK+AOT-MI'), (661, 692, 'PHYSICAL', 'dual-task gait/balance training'), (707, 734, 'OTHER', 'action observation training'), (736, 739, 'OTHER', 'AOT'), (745, 758, 'OTHER', 'motor imagery'), (760, 762, 'OTHER', 'MI'), (822, 831, 'OTHER', 'DUAL-TASK'), (884, 909, 'OTHER', 'watching landscape videos'), (1344, 1360, 'OTHER', 'DUAL-TASK+AOT-MI'), (1365, 1374, 'OTHER', 'DUAL-TASK'), (2285, 2292, 'CONDITION', 'PD-PIGD'), (2359, 2384, 'CONDITION', 'mild cognitive impairment'), (2386, 2402, 'CONDITION', 'freezing of gait'), (2404, 2409, 'CONDITION', 'falls'), (2414, 2431, 'CONDITION', 'mood disturbances'), (2611, 2618, 'CONDITION', 'PD-PIGD')]"
"['Paired', 'Integrative', 'Exercise', 'Program', 'for', 'People', 'With', 'Dementia', 'and', 'Caregivers', '|', 'Preventing', 'Loss', 'of', 'Independence', 'through', 'Exercise', '(', 'PLI', ')', 'is', 'a', 'unique', ',', 'multimodal', 'movement', 'program', 'for', 'people', 'with', 'dementia', '(', 'affected', 'individuals', ')', 'that', 'is', 'taught', 'by', 'trained', 'instructors', 'and', 'combines', 'physical', ',', 'mental', 'and', 'social', 'activities', '.', 'The', 'Paired', 'PLI', 'Program', 'is', 'an', 'adapted', 'version', 'designed', 'for', 'pairs', 'of', 'affected', 'individuals', 'and', 'care', 'partners', '.', 'The', 'goal', 'of', 'this', 'study', 'is', 'to', 'perform', 'a', 'randomized', ',', 'controlled', 'trial', '(', 'RCT', ')', 'with', 'a', 'delayed', 'start', 'design', 'to', 'examine', 'the', 'effects', 'of', 'the', 'Paired', 'PLI', 'Program', 'on', 'function', 'and', 'quality', 'of', 'life', 'in', 'affected', 'individuals', 'and', 'care', 'partners', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02729311,NCT02729311,"Paired Integrative Exercise Program for People With Dementia and Caregivers | Preventing Loss of Independence through Exercise (PLI) is a unique, multimodal movement program for people with dementia (affected individuals) that is taught by trained instructors and combines physical, mental and social activities. The Paired PLI Program is an adapted version designed for pairs of affected individuals and care partners. The goal of this study is to perform a randomized, controlled trial (RCT) with a delayed start design to examine the effects of the Paired PLI Program on function and quality of life in affected individuals and care partners.","[(0, 35, 'PHYSICAL', 'Paired Integrative Exercise Program'), (52, 60, 'CONDITION', 'Dementia'), (78, 126, 'PHYSICAL', 'Preventing Loss of Independence through Exercise'), (128, 132, 'PHYSICAL', 'PLI'), (191, 199, 'CONDITION', 'dementia'), (318, 337, 'PHYSICAL', 'Paired PLI Program'), (554, 573, 'PHYSICAL', 'Paired PLI Program')]"
"['Effects', 'of', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'Those', 'With', 'CI', 'and', 'HA', 'Users', '.', '|', 'The', 'goal', 'of', 'the', 'proposed', 'project', 'is', 'to', 'create', 'an', 'Audiobooks', 'for', 'Hearing', 'Loss', '(', 'HL', ')', 'App', '-', 'an', 'audiobook', 'App', 'that', 'has', 'a', 'wide', 'array', 'of', 'user', '-', 'selectable', 'features', 'designed', 'to', 'provide', 'auditory', 'training', '.', 'The', 'effects', 'of', 'the', 'Audiobooks', 'for', 'Hearing', 'Loss', 'App', 'as', 'Auditory', 'Training', 'for', 'those', 'With', 'CI', 'and', 'HA', 'Users', 'was', 'measured', 'with', 'a', '6', '-', 'week', 'trial', 'of', 'using', 'the', 'app', 'and', 'measuring', 'changes', 'in', 'listener', 'abilities', 'and', 'adherence', 'to', 'the', 'program', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04231396,NCT04231396,Effects of Audiobooks for Hearing Loss App as Auditory Training for Those With CI and HA Users. | The goal of the proposed project is to create an Audiobooks for Hearing Loss (HL) App - an audiobook App that has a wide array of user-selectable features designed to provide auditory training. The effects of the Audiobooks for Hearing Loss App as Auditory Training for those With CI and HA Users was measured with a 6-week trial of using the app and measuring changes in listener abilities and adherence to the program.,"[(11, 42, 'OTHER', 'Audiobooks for Hearing Loss App'), (46, 63, 'OTHER', 'Auditory Training'), (79, 94, 'CONDITION', 'CI and HA Users'), (147, 183, 'OTHER', 'Audiobooks for Hearing Loss (HL) App'), (273, 290, 'OTHER', 'auditory training'), (311, 342, 'OTHER', 'Audiobooks for Hearing Loss App'), (379, 394, 'CONDITION', 'CI and HA Users')]"
"['Telehealth', 'Virtual', 'Reality', 'Exergaming', 'and', 'Peer', 'Networking', 'Among', 'People', 'With', 'Spinal', 'Cord', 'Injury', '|', 'This', 'pilot', 'feasibility', 'study', 'aims', 'to', 'test', 'whether', 'youth', 'and', 'adults', 'with', 'spinal', 'cord', 'injury', 'can', 'use', 'a', 'group', 'virtual', 'reality', 'gaming', 'intervention', 'to', 'exercise', '.', 'A', 'second', 'purpose', 'is', 'to', 'examine', 'whether', 'there', 'are', 'potential', 'benefits', 'to', 'cardiometabolic', 'health', 'and', 'psychosocial', 'health', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05318079,NCT05318079,Telehealth Virtual Reality Exergaming and Peer Networking Among People With Spinal Cord Injury | This pilot feasibility study aims to test whether youth and adults with spinal cord injury can use a group virtual reality gaming intervention to exercise. A second purpose is to examine whether there are potential benefits to cardiometabolic health and psychosocial health.,"[(0, 37, 'PHYSICAL', 'Telehealth Virtual Reality Exergaming'), (42, 57, 'OTHER', 'Peer Networking'), (76, 94, 'CONDITION', 'Spinal Cord Injury'), (169, 187, 'CONDITION', 'spinal cord injury'), (198, 251, 'PHYSICAL', 'group virtual reality gaming intervention to exercise')]"
"['Solian', 'Solution', 'to', 'Treat', 'Schizophrenic', 'Patients', 'During', 'an', 'Acute', 'Episode', '|', 'During', 'this', 'study', 'the', 'efficacy', 'and', 'safety', 'profile', 'will', 'be', 'evaluated', 'of', 'the', 'use', 'of', 'amisulpride', 'in', 'the', 'form', 'of', 'a', 'solution', 'in', 'schizophrenic', 'patients', 'with', 'an', 'acute', 'episode', '.', '\n\n', 'The', 'main', 'purpose', 'of', 'the', 'study', 'is', 'to', 'observe', 'the', 'anti', '-', 'psychotic', 'effect', 'of', 'amisulpride', 'as', 'a', 'solution', 'during', 'the', 'first', 'days', 'of', 'an', 'acute', 'episode', 'of', 'schizophrenia', '.']","['B-DRUG', 'I-DRUG', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O']",NCT00245674,NCT00245674,"Solian Solution to Treat Schizophrenic Patients During an Acute Episode | During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.

The main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.","[(0, 15, 'DRUG', 'Solian Solution'), (25, 38, 'CONDITION', 'Schizophrenic'), (58, 71, 'CONDITION', 'Acute Episode'), (156, 167, 'DRUG', 'amisulpride'), (197, 210, 'CONDITION', 'schizophrenic'), (228, 241, 'CONDITION', 'acute episode'), (317, 328, 'DRUG', 'amisulpride'), (371, 384, 'CONDITION', 'acute episode'), (388, 401, 'CONDITION', 'schizophrenia')]"
"['Facing', 'Eating', 'Disorder', 'Fears', 'for', 'Anorexia', 'Nervosa', ':', 'A', 'Virtual', 'Relapse', 'Prevention', 'Program', 'Targeted', 'at', 'Approach', 'and', 'Avoidance', 'Behaviors', '|', 'FED', '-', 'F', 'is', 'a', 'modular', 'treatment', 'that', 'enhances', 'exposure', 'therapy', 'with', 'psychoeducation', 'and', 'cognitive', 'skills', 'teaching', 'how', 'to', 'face', 'fears', 'of', '(', 'a', ')', 'food', ',', '(', 'b', ')', 'weight', 'gain', ',', '(', 'c', ')', 'interoception', '/', 'body', ',', 'and', '(', 'd', ')', 'social', 'situations', '.', 'The', 'study', 'goals', 'are', 'to', '(', '1', ')', 'refine', 'and', 'test', 'the', 'acceptability', 'and', 'feasibility', 'of', 'FED', '-', 'F', 'treatment', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'test', 'if', 'this', 'treatment', 'outperforms', 'treatment', 'as', 'usual', '(', 'TAU', ')', 'delivered', 'post', '-', 'acute', 'treatment', 'as', 'adjunctive', 'to', 'stepdown', 'specialty', 'care', '(', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'to', 'examine', 'if', 'treatment', 'targets', 'the', 'hypothesized', 'mechanism', 'of', 'action', ':', 'approach', 'behaviors', '(', 'Phase', 'II', ')', '.', 'These', 'goals', 'will', 'lead', 'to', 'a', 'highly', 'deployable', 'and', 'accessible', 'virtual', 'treatment', 'targeted', 'at', 'core', 'AN', 'mechanisms', 'that', 'predict', 'relapse', '.', 'Specific', 'aims', 'are', 'to', '(', '1', ')', 'refine', 'FED', '-', 'F', 'into', 'a', 'fully', 'virtual', 'format', 'with', 'input', 'from', 'patients', 'and', 'stakeholders', 'and', 'collect', 'preliminary', 'data', '(', 'N=10', ')', 'on', 'its', 'feasibility', 'and', 'acceptability', '(', 'Phase', 'I', ')', ',', '(', '2', ')', 'conduct', 'a', 'small', 'pilot', 'RCT', '(', 'randomized', 'controlled', 'trial', ')', 'of', 'FED', '-', 'F', '(', 'n=30', ')', 'as', 'compared', 'to', 'TAU', '(', 'n=30', ';', 'Phase', 'II', ')', ',', 'and', '(', '3', ')', 'examine', 'if', 'FED', '-', 'F', 'targets', 'approach', '/', 'avoidance', 'behaviors', 'and', 'test', 'if', 'this', 'mechanism', 'is', 'associated', 'with', 'clinical', 'outcomes', '(', 'Phase', 'II', ')', '.']","['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05596799,NCT05596799,"Facing Eating Disorder Fears for Anorexia Nervosa: A Virtual Relapse Prevention Program Targeted at Approach and Avoidance Behaviors | FED-F is a modular treatment that enhances exposure therapy with psychoeducation and cognitive skills teaching how to face fears of (a) food, (b) weight gain, (c) interoception/body, and (d) social situations. The study goals are to (1) refine and test the acceptability and feasibility of FED-F treatment (Phase I), (2) test if this treatment outperforms treatment as usual (TAU) delivered post-acute treatment as adjunctive to stepdown specialty care (Phase II), and (3) to examine if treatment targets the hypothesized mechanism of action: approach behaviors (Phase II). These goals will lead to a highly deployable and accessible virtual treatment targeted at core AN mechanisms that predict relapse. Specific aims are to (1) refine FED-F into a fully virtual format with input from patients and stakeholders and collect preliminary data (N=10) on its feasibility and acceptability (Phase I), (2) conduct a small pilot RCT (randomized controlled trial) of FED-F (n=30) as compared to TAU (n=30; Phase II), and (3) examine if FED-F targets approach/avoidance behaviors and test if this mechanism is associated with clinical outcomes (Phase II).","[(7, 28, 'CONDITION', 'Eating Disorder Fears'), (33, 49, 'CONDITION', 'Anorexia Nervosa'), (53, 87, 'BEHAVIOURAL', 'Virtual Relapse Prevention Program'), (135, 140, 'BEHAVIOURAL', 'FED-F'), (258, 263, 'CONDITION', 'fears'), (425, 440, 'BEHAVIOURAL', 'FED-F treatment'), (491, 509, 'CONTROL', 'treatment as usual'), (511, 514, 'CONTROL', 'TAU'), (804, 806, 'CONDITION', 'AN'), (872, 877, 'BEHAVIOURAL', 'FED-F'), (1095, 1100, 'BEHAVIOURAL', 'FED-F'), (1123, 1126, 'CONTROL', 'TAU'), (1164, 1169, 'BEHAVIOURAL', 'FED-F')]"
"['Effects', 'of', 'Aerobic', 'Dance', 'Training', 'on', 'Cognitive', 'Functions', ',', 'Mood', 'and', 'Physical', 'Functions', 'in', 'Community', 'Elderly', 'Persons', 'With', 'Cerebral', 'Small', 'Vessel', 'Disease', '|', 'Introduction', ':', 'Cerebral', 'small', 'vessel', 'disease', '(', 'SVD', ')', 'is', 'associated', 'with', 'age', '-', 'related', 'disabilities', 'including', 'dementia', ',', 'depression', ',', 'physical', 'and', 'functional', 'impairment', '.', 'Chinese', 'are', 'more', 'prone', 'to', 'developing', 'SVD', 'than', 'Caucasians', '.', 'Physical', 'exercise', 'may', 'improve', 'multiple', 'negative', 'consequences', 'associated', 'with', 'SVD', '.', '\n\n', 'Objective', 'and', 'hypothesis', 'to', 'be', 'tested', ':', 'To', 'examine', 'the', 'effects', 'of', 'a', '24', '-', 'week', 'structured', 'aerobic', 'dance', 'training', 'on', 'cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'in', 'stroke', 'and', 'dementia', 'free', 'older', 'adults', 'with', 'SVD', ',', 'and', 'whether', 'such', 'effects', 'are', 'mediated', 'through', 'improved', 'cerebral', 'vasomotor', 'reactivity', '(', 'CVR', ')', ',', 'a', 'marker', 'of', 'cerebral', 'autoregulation', 'which', 'is', 'impaired', 'in', 'SVD', '.', '\n\n', 'Design', 'and', 'subjects', ':', 'Rater', '-', 'blind', 'RCT', 'comparing', 'the', 'effects', 'of', '24', '-', 'week', 'of', 'structured', 'aerobic', 'dance', 'training', 'upon', 'cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'on', '110', 'community', 'dwelling', ',', 'stroke-', 'and', 'dementia', '-', 'free', 'persons', 'aged', '65', 'with', 'MRI', 'evidence', 'of', 'significant', 'SVD', ',', 'defined', 'as', 'the', 'presence', 'of', 'multiple', '(', '2', ')', 'lacunes', 'and/or', 'early', 'confluent', 'or', 'confluent', 'WML', '.', '\n\n', 'Interventions', ':', 'Participants', 'are', 'randomized', 'in', 'a', '1:1', 'ratio', 'into', 'a', '24', '-', 'week', 'of', 'structured', 'therapist', '-', 'led', 'group', 'aerobic', 'dance', 'training', 'with', 'home', 'practice', 'or', 'simple', 'stretching', 'plus', 'health', 'education', 'control', 'group', '.', '\n\n', 'Main', 'outcome', 'measures', ':', 'Cognition', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'and', 'CVR', 'measured', 'using', 'Transcranial', 'Doppler', 'at', 'baseline', ',', 'weeks', '12', ',', '24', 'and', '36', '.', '\n\n', 'Data', 'analysis', ':', 'Intent', '-', 'to', '-', 'treat', 'with', 'multiple', 'imputations', 'with', 'treatment', 'efficacy', 'analyzed', 'using', 'mixed', 'effects', 'models', '.', 'Mediation', 'effects', 'of', 'CVR', 'between', 'aerobic', 'dance', 'training', 'and', 'treatment', 'outcomes', 'tested', 'using', 'mediation', 'models', '.', '\n\n', 'Expected', 'results', ':', 'In', 'persons', 'with', 'significant', 'SVD', ',', 'aerobic', 'dance', 'training', 'improves', 'cognitive', ',', 'mood', ',', 'physical', 'and', 'daily', 'functions', 'and', 'such', 'effects', 'are', 'mediated', 'by', 'changes', 'in', 'CVR', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02730065,NCT02730065,"Effects of Aerobic Dance Training on Cognitive Functions, Mood and Physical Functions in Community Elderly Persons With Cerebral Small Vessel Disease | Introduction: Cerebral small vessel disease (SVD) is associated with age-related disabilities including dementia, depression, physical and functional impairment. Chinese are more prone to developing SVD than Caucasians. Physical exercise may improve multiple negative consequences associated with SVD.

Objective and hypothesis to be tested: To examine the effects of a 24-week structured aerobic dance training on cognition, mood, physical and daily functions in stroke and dementia free older adults with SVD, and whether such effects are mediated through improved cerebral vasomotor reactivity (CVR), a marker of cerebral autoregulation which is impaired in SVD.

Design and subjects: Rater-blind RCT comparing the effects of 24-week of structured aerobic dance training upon cognition, mood, physical and daily functions on 110 community dwelling, stroke- and dementia-free persons aged 65 with MRI evidence of significant SVD, defined as the presence of multiple (2) lacunes and/or early confluent or confluent WML.

Interventions: Participants are randomized in a 1:1 ratio into a 24-week of structured therapist-led group aerobic dance training with home practice or simple stretching plus health education control group.

Main outcome measures: Cognition, mood, physical and daily functions and CVR measured using Transcranial Doppler at baseline, weeks 12, 24 and 36.

Data analysis: Intent-to-treat with multiple imputations with treatment efficacy analyzed using mixed effects models. Mediation effects of CVR between aerobic dance training and treatment outcomes tested using mediation models.

Expected results: In persons with significant SVD, aerobic dance training improves cognitive, mood, physical and daily functions and such effects are mediated by changes in CVR.","[(11, 33, 'PHYSICAL', 'Aerobic Dance Training'), (120, 149, 'CONDITION', 'Cerebral Small Vessel Disease'), (166, 195, 'CONDITION', 'Cerebral small vessel disease'), (197, 200, 'CONDITION', 'SVD'), (351, 354, 'CONDITION', 'SVD'), (449, 452, 'CONDITION', 'SVD'), (541, 563, 'PHYSICAL', 'aerobic dance training'), (659, 662, 'CONDITION', 'SVD'), (813, 816, 'CONDITION', 'SVD'), (903, 925, 'PHYSICAL', 'aerobic dance training'), (1080, 1083, 'CONDITION', 'SVD'), (1283, 1324, 'PHYSICAL', 'aerobic dance training with home practice'), (1328, 1345, 'CONTROL', 'simple stretching'), (1351, 1367, 'CONTROL', 'health education'), (1683, 1705, 'PHYSICAL', 'aerobic dance training'), (1807, 1810, 'CONDITION', 'SVD'), (1812, 1834, 'PHYSICAL', 'aerobic dance training')]"
"['Gypenosides', 'Treatment', 'for', 'Optic', 'Neuritis', ':', 'a', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'gypenosides', 'are', 'neuroprotective', 'in', 'patients', 'with', 'acute', 'optic', 'neuritis', '.']","['B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02976766,NCT02976766,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial | The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.","[(0, 11, 'DRUG', 'Gypenosides'), (26, 40, 'CONDITION', 'Optic Neuritis'), (70, 77, 'CONTROL', 'Placebo'), (147, 158, 'DRUG', 'gypenosides'), (196, 216, 'CONDITION', 'acute optic neuritis')]"
"['Evaluate', 'the', 'Safety', 'and', 'Immunogenicity', 'of', 'a', 'Vero', 'Cell', '-', 'Derived', 'Inactivated', 'Japanese', 'Encephalitis', 'Vaccine', '(', 'JECEVAX', ')', 'Produced', 'by', 'VABIOTECH', '(', 'Vietnam', ')', 'in', 'Vietnamese', 'Children', 'Aged', '9', '-', '24', 'Months', '|', 'A', 'study', 'of', 'the', 'study', 'vaccine', '(', 'JECEVAX-', 'VABIOTECH', '-', 'Vietnam', ')', 'and', 'a', 'licensed', 'vaccine', '(', 'JEVAX', '-', 'VABIOTECH', '-', 'Vietnam', ')', 'is', 'conducted', 'in', 'Vietnamese', 'children', ',', 'aged', '9', 'to', '24', 'months', 'to', 'assess', 'the', 'safety', 'of', 'the', 'study', 'vaccine', 'compares', 'to', 'licenced', 'vaccine', '.', 'Two', 'hundred', 'and', 'twenty', 'children', 'are', 'enrolled', 'and', 'randomly', 'assigned', 'into', '2', 'groups', '(', '110', 'children', '/', 'group', ')', ',', 'each', 'of', 'which', 'receive', '2', 'doses', 'of', 'study', '/', 'control', 'vaccine', 'subcutaneously', ',', 'at', '28', '-', '34', 'days', 'interval', '.', 'Safety', 'data', 'included', 'immediate', 'reaction', 'at', 'the', 'injection', 'site', 'and', 'systemic', 'reaction', 'within', '30', 'min', 'of', 'administration', ',', 'solicited', 'and', 'unsolicited', 'adverse', 'events', 'occurs', 'from', 'the', '1st', 'dose', 'to', '28', '-', '34', 'days', 'after', 'first', 'dose', 'and', 'from', 'the', 'second', 'dose', 'to', '28', '-', '34', 'days', 'after', '2nd', 'dose', '.', 'SAE', '(', 'from', 'start', 'of', 'first', 'dose', 'to', '28', '-', '34', 'days', 'after', 'second', 'dose', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03282370,NCT03282370,"Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months | A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced vaccine. Two hundred and twenty children are enrolled and randomly assigned into 2 groups (110 children/group), each of which receive 2 doses of study / control vaccine subcutaneously, at 28-34 days interval. Safety data included immediate reaction at the injection site and systemic reaction within 30 min of administration, solicited and unsolicited adverse events occurs from the 1st dose to 28-34 days after first dose and from the second dose to 28-34 days after 2nd dose. SAE (from start of first dose to 28-34 days after second dose).","[(44, 105, 'DRUG', 'Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine'), (107, 114, 'DRUG', 'JECEVAX'), (220, 228, 'DRUG', 'JECEVAX-'), (254, 270, 'CONTROL', 'licensed vaccine'), (272, 277, 'DRUG', 'JEVAX'), (408, 424, 'CONTROL', 'licenced vaccine')]"
"['A', '48', '-', 'Week', ',', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Evaluation', 'of', 'the', 'Comparative', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Exelon', '', '10', 'and', '15', 'cm^2', 'Patch', 'in', 'Patients', 'With', 'Mild', 'to', 'Moderate', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'Showing', 'Functional', 'and', 'Cognitive', 'Decline', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'support', 'the', 'optimal', 'use', 'of', 'rivastigmine', 'patch', 'in', 'long', '-', 'term', 'treatment', 'of', 'Alzheimer', ""'s"", 'Disease', 'in', 'patients', 'demonstrating', 'functional', 'and', 'cognitive', 'decline', 'at', 'the', 'target', 'maintenance', 'dose', 'of', 'rivastigmine', 'patch', '10', 'cm^2', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT00506415,NCT00506415,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline | The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm^2.","[(133, 139, 'DRUG', 'Exelon'), (179, 215, 'CONDITION', ""Mild to Moderate Alzheimer's Disease""), (217, 219, 'CONDITION', 'AD'), (229, 261, 'CONDITION', 'Functional and Cognitive Decline'), (324, 336, 'DRUG', 'rivastigmine'), (369, 388, 'CONDITION', ""Alzheimer's Disease""), (415, 447, 'CONDITION', 'functional and cognitive decline'), (482, 494, 'DRUG', 'rivastigmine')]"
"['A', 'Phase', 'III', ',', 'Randomized', ',', 'Multicenter', ',', 'Parallel', '-', 'group', ',', 'Open', '-', 'Label', 'Study', 'Evaluating', 'the', 'Efficacy', ',', 'Safety', ',', 'and', 'Tolerability', 'of', 'Long', '-', 'Acting', 'Intramuscular', 'Cabotegravir', 'and', 'Rilpivirine', 'for', 'Maintenance', 'of', 'Virologic', 'Suppression', 'Following', 'Switch', 'From', 'an', 'Integrase', 'Inhibitor', 'Single', 'Tablet', 'Regimen', 'in', 'HIV-1', 'Infected', 'Antiretroviral', 'Therapy', 'Naive', 'Adult', 'Participants', '|', 'The', 'First', 'Long', '-', 'Acting', 'Injectable', 'Regimen', '(', 'FLAIR', ')', 'study', 'is', 'being', 'conducted', 'to', 'establish', 'if', 'human', 'immunodeficiency', 'virus', 'type-1', '(', 'HIV-1', ')', 'infected', 'adult', 'participants', 'whose', 'virus', 'is', 'virologically', 'suppressed', 'on', 'an', 'integrase', 'inhibitor', 'single', 'tablet', 'regimen', '(', 'INI', 'STR', ')', 'will', 'remain', 'suppressed', 'after', 'switching', 'to', 'a', 'two', '-', 'drug', 'intramuscular', '(', 'IM', ')', 'long', '-', 'acting', '(', 'LA', ')', 'regimen', 'of', 'cabotegravir', '(', 'CAB', ')', 'and', 'rilpivirine', '(', 'RPV', ')', '.', 'In', 'this', 'study', ',', 'the', 'INI', 'STR', 'will', 'be', 'limited', 'to', 'abacavir', '/', 'dolutegravir', '/', 'lamivudine', '(', 'ABC', '/', 'DTG/3TC', ')', '.', 'FLAIR', 'is', 'a', 'Phase', '3', ',', 'multi', '-', 'phase', ',', 'randomized', ',', 'open', 'label', ',', 'active', '-', 'controlled', ',', 'multicenter', ',', 'parallel', '-', 'group', ',', 'non', '-', 'inferiority', 'study', 'in', 'HIV-1', ',', 'anti', '-', 'retroviral', 'therapy', '(', 'ART)-nave', 'adult', 'participants', '.', 'This', 'study', 'is', 'designed', 'to', 'demonstrate', 'the', 'non', '-', 'inferior', 'antiviral', 'activity', 'of', 'switching', 'to', 'a', 'two', 'drug', 'CAB', 'LA', '400', 'mg', '+', 'RPV', 'LA', '600', 'mg', 'regimen', 'every', '4', 'weeks', '(', 'Q4W', ':', 'monthly', ')', 'compared', 'to', 'remaining', 'on', 'ABC', '/', 'DTG/3TC', 'over', '48', 'weeks', '(', '4', 'weeks', 'oral', 'CAB', '+', 'RPV', ',', '44', 'weeks', 'LA', 'therapy', ')', '.', 'Participants', 'who', 'are', 'HLA', '-', 'B*5701', 'positive', 'at', 'Screening', 'may', 'enroll', 'into', 'the', 'study', 'and', 'receive', 'DTG', 'plus', 'a', 'non', '-', 'abacavir', 'containing', 'dual', 'nucleoside', 'reverse', 'transcriptase', 'inhibitor', '(', 'NRTI', ')', 'regimen', '.', 'Eligible', 'participants', 'will', 'enroll', 'into', 'the', 'Induction', 'Phase', 'of', 'the', 'study', 'and', 'receive', 'ABC', '/', 'DTG/3TC', 'for', '20', 'weeks', '(', 'Week', '[', '-20', ']', 'to', 'Day', '1', ')', '.', 'Participants', 'who', 'have', 'an', 'HIV', '1', 'ribose', 'nucleic', 'acid', '(', 'RNA', ')', '<', '50', 'copies', 'per', 'milliliter', '(', 'c', '/', 'mL', ')', 'at', 'Week', '(', '-4', ')', 'will', 'be', 'randomized', '(', '1:1', ')', 'into', 'the', 'Maintenance', 'Phase', 'at', 'Day', '1', 'to', 'either', 'continue', 'ABC', '/', 'DTG/3TC', 'or', 'to', 'discontinue', 'ABC', '/', 'DTG/3TC', 'and', 'begin', 'oral', 'therapy', 'with', 'CAB', '30', 'mg', '+', 'RPV', '25', 'mg', 'once', 'daily', 'for', 'approximately', '4', 'Weeks', ',', 'followed', 'by', 'monthly', 'CAB', 'LA', '+', 'RPV', 'LA', 'injections', 'from', 'visit', 'Week', '4b', 'until', 'study', 'completion', 'or', 'withdrawal', '.', 'Participants', 'who', 'successfully', 'complete', 'Week', '100', '(', 'without', 'meeting', 'study', 'defined', 'withdrawal', 'criteria', 'and', 'who', 'remain', 'virologically', 'suppressed', 'through', 'Week', '96', ':', 'HIV-1', 'RNA', '<', '50', 'c', '/', 'mL', ')', 'will', 'be', 'given', 'the', 'option', 'to', 'switch', 'to', 'the', 'LA', 'arm', 'in', 'the', 'Extension', 'Phase', '(', 'using', 'an', 'optional', 'oral', 'lead', '-', 'in', 'with', 'CAB', '+', 'RPV', ')', 'or', 'be', 'withdrawn', 'from', 'the', 'study', '.', 'Participants', 'will', 'continue', 'to', 'receive', 'injections', 'every', '4', 'weeks', 'during', 'the', 'Extension', 'Phase', 'until', 'CAB', 'LA', 'and', 'RPV', 'LA', 'are', 'either', 'locally', 'approved', 'and', 'commercially', 'available', ',', 'the', 'participant', 'no', 'longer', 'derives', 'clinical', 'benefit', ',', 'the', 'participant', 'meets', 'a', 'protocol', '-', 'defined', 'reason', 'for', 'discontinuation', ',', 'or', 'until', 'development', 'of', 'either', 'CAB', 'LA', 'or', 'RPV', 'LA', 'is', 'terminated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O']",NCT02938520,NCT02938520,"A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants | The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor single tablet regimen (INI STR) will remain suppressed after switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). In this study, the INI STR will be limited to abacavir/dolutegravir/lamivudine (ABC/DTG/3TC). FLAIR is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, anti-retroviral therapy (ART)-nave adult participants. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared to remaining on ABC/DTG/3TC over 48 weeks (4 weeks oral CAB + RPV, 44 weeks LA therapy). Participants who are HLA-B*5701 positive at Screening may enroll into the study and receive DTG plus a non-abacavir containing dual nucleoside reverse transcriptase inhibitor (NRTI) regimen. Eligible participants will enroll into the Induction Phase of the study and receive ABC/DTG/3TC for 20 weeks (Week [-20] to Day 1). Participants who have an HIV 1 ribose nucleic acid (RNA) <50 copies per milliliter (c/mL) at Week (-4) will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue ABC/DTG/3TC or to discontinue ABC/DTG/3TC and begin oral therapy with CAB 30 mg + RPV 25 mg once daily for approximately 4 Weeks, followed by monthly CAB LA + RPV LA injections from visit Week 4b until study completion or withdrawal. Participants who successfully complete Week 100 (without meeting study defined withdrawal criteria and who remain virologically suppressed through Week 96: HIV-1 RNA <50 c/mL) will be given the option to switch to the LA arm in the Extension Phase (using an optional oral lead-in with CAB + RPV) or be withdrawn from the study. Participants will continue to receive injections every 4 weeks during the Extension Phase until CAB LA and RPV LA are either locally approved and commercially available, the participant no longer derives clinical benefit, the participant meets a protocol-defined reason for discontinuation, or until development of either CAB LA or RPV LA is terminated.","[(150, 162, 'DRUG', 'Cabotegravir'), (167, 178, 'DRUG', 'Rilpivirine'), (245, 264, 'DRUG', 'Integrase Inhibitor'), (290, 295, 'CONDITION', 'HIV-1'), (305, 333, 'CONDITION', 'Antiretroviral Therapy Naive'), (445, 480, 'CONDITION', 'human immunodeficiency virus type-1'), (482, 487, 'CONDITION', 'HIV-1'), (563, 582, 'DRUG', 'integrase inhibitor'), (715, 727, 'DRUG', 'cabotegravir'), (729, 732, 'DRUG', 'CAB'), (738, 749, 'DRUG', 'rilpivirine'), (751, 754, 'DRUG', 'RPV'), (803, 811, 'DRUG', 'abacavir'), (812, 824, 'DRUG', 'dolutegravir'), (825, 835, 'DRUG', 'lamivudine'), (837, 840, 'DRUG', 'ABC'), (841, 848, 'DRUG', 'DTG/3TC'), (981, 986, 'CONDITION', 'HIV-1'), (1145, 1148, 'DRUG', 'CAB'), (1161, 1164, 'DRUG', 'RPV'), (1237, 1240, 'DRUG', 'ABC'), (1241, 1248, 'DRUG', 'DTG/3TC'), (1277, 1280, 'DRUG', 'CAB'), (1283, 1286, 'DRUG', 'RPV'), (1331, 1350, 'CONDITION', 'HLA-B*5701 positive'), (1402, 1405, 'DRUG', 'DTG'), (1437, 1484, 'DRUG', 'dual nucleoside reverse transcriptase inhibitor'), (1486, 1490, 'DRUG', 'NRTI'), (1585, 1588, 'DRUG', 'ABC'), (1589, 1596, 'DRUG', 'DTG/3TC'), (1658, 1663, 'CONDITION', 'HIV 1'), (1816, 1819, 'DRUG', 'ABC'), (1820, 1827, 'DRUG', 'DTG/3TC'), (1846, 1849, 'DRUG', 'ABC'), (1850, 1857, 'DRUG', 'DTG/3TC'), (1886, 1889, 'DRUG', 'CAB'), (1898, 1901, 'DRUG', 'RPV'), (1966, 1969, 'DRUG', 'CAB'), (1975, 1978, 'DRUG', 'RPV'), (2206, 2211, 'CONDITION', 'HIV-1'), (2335, 2338, 'DRUG', 'CAB'), (2341, 2344, 'DRUG', 'RPV'), (2474, 2477, 'DRUG', 'CAB'), (2485, 2488, 'DRUG', 'RPV'), (2700, 2703, 'DRUG', 'CAB'), (2710, 2713, 'DRUG', 'RPV')]"
"['A', 'Phase', 'II', 'Open', 'and', 'Parallel', 'Safety', ',', 'Immunogenicity', 'and', 'Reactogenicity', 'Trial', 'of', 'Mencevax', 'ACW135', 'Polysaccharide', 'Vaccine', 'Comparing', 'Three', 'Groups', ':', '2', '-', '4', 'Year', ',', '5', '-', '14', 'Year', 'and', '15', '-', '29', 'Year', 'Old', 'Ethiopians', '|', 'Primary', 'objective', ':', '\n\n', 'To', 'assess', 'the', 'immunogenicity', 'of', 'the', 'Mencevax', 'ACW135', 'polysaccharide', 'vaccine', 'at', '28', 'days', '(', '+6days', ')', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', 'and', 'compare', 'the', 'immunogenicity', 'between', 'these', 'age', 'groups', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'estimate', 'the', 'incidence', 'of', 'common', 'adverse', 'events', 'following', 'immunization', '(', 'AEFI', ')', 'of', 'GSK', 'Nm', 'ACW135', 'polysaccharide', 'vaccine', 'at', '1h', ',', '1d', ',', '2d', ',', '3d', ',', '7d', 'and', '28', 'days', 'post', '-', 'vaccination', '\n', 'To', 'assess', 'the', 'persistence', 'of', 'antibody', 'against', 'meningitis', 'A', ',', 'C', 'and', 'W135', 'at', '11', 'and', '23', 'months', 'post', 'vaccination', 'in', '2', '-', '4', ',', '5', '-', '14', ',', '15', '-', '29', 'year', 'age', 'groups', '\n\n', 'Study', 'site', ':', 'Two', 'rural', 'communities', '(', 'Kebele', ')', 'in', 'Butajira', 'district', ',', 'Ethiopia', '.', '\n\n', 'Methods', ':', '\n\n', 'Phase', 'II', ',', 'open', 'and', 'parallel', 'safety', 'and', 'immunogenicity', 'trial', '.', '\n', '234', 'younger', 'children', '(', '2', '-', '4', 'years', ')', ',', '145', 'older', 'children', '(', '5', '-', '14', 'years', ')', 'and', '33', 'adults', '(', '15', '-', '29', 'years', 'of', 'age', ')', 'were', 'randomly', 'selected', 'from', 'the', 'demographic', 'surveillance', 'database', 'and', 'enrolled', 'after', 'screening', 'and', 'consenting', '.', '\n', 'Study', 'participant', 'received', 'Mencevax', 'ACW', 'polysaccharide', 'vaccine', '50', 'mg', 'in', '0.5ml', 'subcutaneously', '.', '\n', 'Blood', 'samples', 'for', 'measuring', 'SBA', 'titres', 'were', 'collected', 'at', 'pre', 'vaccination', 'and', 'on', 'day', '28', '(', '+6', 'days', ')', 'post', 'vaccination', '.', '\n', 'Active', 'follow', 'up', 'for', 'AEFI', 'on', 'post', 'vaccination', 'day', '0', ',', '1', ',', '2', ',', '3', ',', '7', ',', '&', '28', '.', '\n', 'Primary', 'end', 'point', 'was', 'vaccine', 'response', 'defined', 'as', 'sero', '-', 'conversion', '(', 'in', 'subjects', 'initially', 'seronegative', ')', 'or', 'a', '4', 'fold', 'increase', '(', 'in', 'subjects', 'initially', 'seropositive', ')', 'in', 'serum', 'bactericidal', 'antibodies', '(', 'SBA', ')', 'against', 'serogroups', 'Men', 'A', ',', 'C', 'and', 'W135', ')', 'on', 'post', 'vaccination', 'day', '28', '.', 'In', 'addition', 'seroconversion', 'was', 'assessed', 'by', 'ELISA', 'Men', 'A', 'IgG', 'on', 'day', '0', 'and', 'day', '28', 'post', 'vaccination', '.', '\n', 'Secondary', 'endpoints', 'were', 'incidence', 'of', 'general', 'and', 'local', 'symptoms', 'and', 'other', 'adverse', 'events', 'following', 'immunisation', 'during', 'the', 'post', 'vaccination', 'period', 'day', '0', 'to', '28', 'and', 'immune', 'persistence', 'on', 'post', 'vaccination', 'month-11', 'and', 'month-23', '.', '\n\n', 'Results', ':', '\n\n', 'No', 'significant', 'difference', 'in', 'the', 'incidence', 'of', 'general', 'or', 'local', 'AEFI', 'was', 'observed', 'between', 'the', 'age', 'groups', '\n', 'The', 'statistical', 'analysis', 'for', 'the', 'Immunogenicity', 'data', 'is', 'in', 'progress']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00994695,NCT00994695,"A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians | Primary objective:

To assess the immunogenicity of the Mencevax ACW135 polysaccharide vaccine at 28 days (+6days) post vaccination in 2-4, 5-14, 15-29 year age groups and compare the immunogenicity between these age groups.

Secondary Objectives:

To estimate the incidence of common adverse events following immunization (AEFI) of GSK Nm ACW135 polysaccharide vaccine at 1h, 1d, 2d, 3d, 7d and 28 days post-vaccination
To assess the persistence of antibody against meningitis A, C and W135 at 11 and 23 months post vaccination in 2-4, 5-14, 15-29 year age groups

Study site:Two rural communities (Kebele) in Butajira district, Ethiopia.

Methods:

Phase II, open and parallel safety and immunogenicity trial.
234 younger children (2-4 years), 145 older children (5-14 years) and 33 adults (15-29 years of age) were randomly selected from the demographic surveillance database and enrolled after screening and consenting.
Study participant received Mencevax ACW polysaccharide vaccine 50 mg in 0.5ml subcutaneously.
Blood samples for measuring SBA titres were collected at pre vaccination and on day 28 (+6 days) post vaccination.
Active follow up for AEFI on post vaccination day 0, 1, 2, 3, 7, & 28.
Primary end point was vaccine response defined as sero-conversion (in subjects initially seronegative) or a 4 fold increase (in subjects initially seropositive) in serum bactericidal antibodies (SBA) against serogroups Men A, C and W135) on post vaccination day 28. In addition seroconversion was assessed by ELISA Men A IgG on day 0 and day 28 post vaccination.
Secondary endpoints were incidence of general and local symptoms and other adverse events following immunisation during the post vaccination period day 0 to 28 and immune persistence on post vaccination month-11 and month-23.

Results:

No significant difference in the incidence of general or local AEFI was observed between the age groups
The statistical analysis for the Immunogenicity data is in progress","[(80, 118, 'DRUG', 'Mencevax ACW135 Polysaccharide Vaccine'), (257, 295, 'DRUG', 'Mencevax ACW135 polysaccharide vaccine'), (541, 570, 'DRUG', 'ACW135 polysaccharide vaccine'), (668, 692, 'CONDITION', 'meningitis A, C and W135'), (1152, 1187, 'DRUG', 'Mencevax ACW polysaccharide vaccine'), (1624, 1641, 'CONDITION', 'Men A, C and W135'), (1720, 1725, 'CONDITION', 'Men A')]"
"['Modular', 'Scheduled', 'Telephone', 'Intervention', 'for', 'Caregivers', 'of', 'Persons', 'With', 'Traumatic', 'Brain', 'Injury', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'seeks', 'to', 'determine', 'if', 'problem', '-', 'based', 'telephone', 'counseling', 'improves', 'quality', 'of', 'life', 'and', 'emotional', 'well', '-', 'being', 'for', 'caregivers', 'of', 'persons', 'with', 'moderate', 'to', 'severe', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00692575,NCT00692575,Modular Scheduled Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury: A Randomized Controlled Trial | This study seeks to determine if problem-based telephone counseling improves quality of life and emotional well-being for caregivers of persons with moderate to severe traumatic brain injury (TBI).,"[(0, 40, 'BEHAVIOURAL', 'Modular Scheduled Telephone Intervention'), (161, 195, 'BEHAVIOURAL', 'problem-based telephone counseling')]"
"['Comparative', 'Effectiveness', 'of', 'Two', 'Self', '-', 'guided', 'Web', '-', 'based', 'Interventions', 'for', 'Youth', 'and', 'Young', 'Adults', 'With', 'Migraine', '|', 'This', 'randomized', 'controlled', 'trial', 'will', 'compare', 'the', 'effectiveness', 'of', 'two', 'online', 'self', '-', 'guided', 'programs', 'for', 'youth', 'and', 'young', 'adults', 'with', 'migraine', 'against', 'usual', 'care', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-CTRL', 'I-CTRL', 'O']",NCT03504150,NCT03504150,Comparative Effectiveness of Two Self-guided Web-based Interventions for Youth and Young Adults With Migraine | This randomized controlled trial will compare the effectiveness of two online self-guided programs for youth and young adults with migraine against usual care.,"[(33, 68, 'OTHER', 'Self-guided Web-based Interventions'), (101, 109, 'CONDITION', 'Migraine'), (183, 210, 'OTHER', 'online self-guided programs'), (243, 251, 'CONDITION', 'migraine'), (260, 270, 'CONTROL', 'usual care')]"
"['Video', 'Game', 'Rehabilitation', 'for', 'Outpatient', 'Stroke', '(', 'VIGoROUS', '):', 'A', 'Multi', '-', 'center', 'Comparative', 'Effectiveness', 'Trial', 'of', 'In', '-', 'home', 'Gamified', 'Constraint', '-', 'induced', 'Movement', 'Therapy', 'for', 'Rehabilitation', 'of', 'Chronic', 'Upper', 'Extremity', 'Hemiparesis', '.', '|', 'The', 'current', 'proposal', 'aims', 'to', 'conduct', 'a', 'multi', '-', 'site', 'randomized', 'controlled', 'trial', 'comparing', 'virtual', '-', 'reality', 'gaming', 'delivery', 'of', 'Constraint', 'Induced', 'Movement', 'therapy', '(', 'CI', 'therapy', ')', 'with', '(', '1', ')', 'traditional', 'clinic', '-', 'based', 'CI', 'therapy', 'of', 'equal', 'total', 'active', 'therapy', 'duration', 'and', '(', '2', ')', 'a', 'control', 'group', 'equating', 'the', 'dose', 'of', 'in', '-', 'person', 'therapy', '.', 'Individuals', 'with', 'chronic', 'stroke', 'will', 'be', 'randomized', 'to', 'one', 'of', 'four', 'different', 'interventions', ':', '(', '1', ')', 'traditional', 'clinic', '-', 'based', 'CI', 'therapy', '(', '35', 'therapist', '/', 'client', 'contact', 'hours', ')', ',', '(', '2', ')', 'therapist', '-', 'as', '-', 'consultant', 'virtual', 'reality', 'CI', 'therapy', '(', '5', 'therapist', '/', 'client', 'contact', 'hours', 'in', 'the', 'clinic', 'and', '15', 'hours', 'of', 'independent', 'game', 'play', 'at', 'home', ')', ',', '(', '3', ')', 'therapist', '-', 'as', '-', 'consultant', 'virtual', 'reality', 'CI', 'therapy', 'with', 'additional', 'therapist', 'contact', 'via', 'telerehabilitation', '(', '5', 'therapist', '/', 'client', 'contact', 'hours', 'in', 'the', 'clinic', ',', '2.6', 'therapist', 'contact', 'hours', 'via', 'teleconference', ',', 'and', '15', 'hours', 'of', 'independent', 'game', 'play', 'in', 'the', 'home', ')', ',', 'and', '(', '4', ')', '5', 'hours', 'of', 'standard', 'occupational', 'therapy', '(', 'OT', ')', '/', 'physical', 'therapy', '(', 'PT', ')', '.', 'After', '6', '-', 'month', 'follow', '-', 'up', ',', 'individuals', 'assigned', 'to', 'standard', 'OT', '/', 'PT', 'will', 'cross', 'over', 'to', 'a', 'modified', 'gaming', 'therapy', 'condition', '(', 'a', 'stand', '-', 'alone', 'application', 'of', 'the', 'rehabilitation', 'game', 'without', 'additional', 'therapist', 'contact', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02631850,NCT02631850,"Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): A Multi-center Comparative Effectiveness Trial of In-home Gamified Constraint-induced Movement Therapy for Rehabilitation of Chronic Upper Extremity Hemiparesis. | The current proposal aims to conduct a multi-site randomized controlled trial comparing virtual-reality gaming delivery of Constraint Induced Movement therapy (CI therapy) with (1) traditional clinic-based CI therapy of equal total active therapy duration and (2) a control group equating the dose of in-person therapy. Individuals with chronic stroke will be randomized to one of four different interventions: (1) traditional clinic-based CI therapy (35 therapist/client contact hours), (2) therapist-as-consultant virtual reality CI therapy (5 therapist/client contact hours in the clinic and 15 hours of independent game play at home), (3) therapist-as-consultant virtual reality CI therapy with additional therapist contact via telerehabilitation (5 therapist/client contact hours in the clinic, 2.6 therapist contact hours via teleconference, and 15 hours of independent game play in the home), and (4) 5 hours of standard occupational therapy (OT) / physical therapy (PT). After 6-month follow-up, individuals assigned to standard OT/PT will cross over to a modified gaming therapy condition (a stand-alone application of the rehabilitation game without additional therapist contact).","[(41, 47, 'CONDITION', 'Stroke'), (118, 162, 'PHYSICAL', 'Gamified Constraint-induced Movement Therapy'), (185, 220, 'CONDITION', 'Chronic Upper Extremity Hemiparesis'), (312, 334, 'OTHER', 'virtual-reality gaming'), (347, 382, 'PHYSICAL', 'Constraint Induced Movement therapy'), (384, 394, 'PHYSICAL', 'CI therapy'), (405, 440, 'CONTROL', 'traditional clinic-based CI therapy'), (561, 575, 'CONDITION', 'chronic stroke'), (639, 674, 'CONTROL', 'traditional clinic-based CI therapy'), (716, 766, 'PHYSICAL', 'therapist-as-consultant virtual reality CI therapy'), (867, 917, 'PHYSICAL', 'therapist-as-consultant virtual reality CI therapy'), (956, 974, 'OTHER', 'telerehabilitation'), (1152, 1172, 'OTHER', 'occupational therapy'), (1174, 1176, 'OTHER', 'OT'), (1180, 1196, 'PHYSICAL', 'physical therapy'), (1198, 1200, 'PHYSICAL', 'PT'), (1261, 1263, 'OTHER', 'OT'), (1264, 1266, 'PHYSICAL', 'PT'), (1288, 1311, 'OTHER', 'modified gaming therapy'), (1356, 1375, 'OTHER', 'rehabilitation game')]"
"['A', 'Phase', '4', ',', 'Open', '-', 'Label', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Daily', 'Dosing', 'of', 'Rimegepant', 'in', 'Episodic', 'Migraine', 'Prevention', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'further', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'daily', 'dosing', 'of', 'rimegepant', 'for', 'the', 'prevention', 'of', 'episodic', 'migraine', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT05207865,NCT05207865,"A Phase 4, Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention | The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.","[(87, 97, 'DRUG', 'Rimegepant'), (101, 118, 'CONDITION', 'Episodic Migraine'), (238, 248, 'DRUG', 'rimegepant'), (271, 288, 'CONDITION', 'episodic migraine')]"
"['Prospective', 'Study', 'on', 'the', 'Use', 'of', 'Middle', 'Meningeal', 'Artery', 'Embolization', 'for', 'Chronic', 'Subdural', 'Haematoma', '|', 'Subdural', 'haematoma', 'is', 'a', 'common', 'neurosurgical', 'condition', 'that', 'results', 'in', 'different', 'levels', 'of', 'neurological', 'deficits', 'in', 'patients', '.', 'It', 'can', 'be', 'further', 'classified', 'into', 'acute', 'and', 'chronic', ',', 'which', 'have', 'different', 'pathophysiology', '.', 'Acute', 'haematoma', 'is', 'a', 'common', 'result', 'of', 'traumatic', 'injuries', 'involving', 'the', 'tearing', 'of', 'the', 'bridging', 'veins', ',', 'while', 'chronic', 'subdural', 'haematoma', 'can', 'be', 'both', 'a', 'result', 'of', 'traumatic', 'injuries', 'or', 'recurrence', 'following', 'surgical', 'management', 'of', 'the', 'acute', 'counterpart', '.', 'For', 'symptomatic', 'patients', ',', 'they', 'are', 'often', 'surgically', 'managed', 'by', 'haematoma', 'drainage', 'via', 'burr', '-', 'hole', 'drainage', 'and', 'craniotomy', '.', 'Recurrent', 'bleeding', 'following', 'close', 'monitor', 'or', 'surgical', 'evacuation', 'of', 'haematoma', 'is', 'however', 'very', 'high', '.', 'Recent', 'studies', 'approximate', 'the', 'recurrence', 'rate', 'of', '2%-33.3', '%', '.', 'Recent', 'evidence', 'suggests', 'the', 'angiogenesis', 'of', 'middle', 'meningeal', 'arteries', '(', 'MMA', ')', 'in', 'response', 'to', 'inflammation', 'and', 'healing', 'process', 'contributes', 'to', 'the', 'development', 'of', 'chronic', 'subdural', 'haematoma', ',', 'and', 'its', 'high', 'recurrence', 'chance', '.', 'Several', 'studies', 'have', 'looked', 'into', 'the', 'use', 'of', 'middle', 'meningeal', 'artery', 'embolization', 'to', 'halt', 'the', 'bleeding', 'of', 'a', 'chronic', 'subdural', 'haematoma', ',', 'and', 'have', 'found', 'promising', 'results', 'in', 'terms', 'of', 'haematoma', 'reduction', 'and', 'prevention', 'of', 'surgical', 'rescues', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04500795,NCT04500795,"Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma | Subdural haematoma is a common neurosurgical condition that results in different levels of neurological deficits in patients. It can be further classified into acute and chronic, which have different pathophysiology. Acute haematoma is a common result of traumatic injuries involving the tearing of the bridging veins, while chronic subdural haematoma can be both a result of traumatic injuries or recurrence following surgical management of the acute counterpart. For symptomatic patients, they are often surgically managed by haematoma drainage via burr-hole drainage and craniotomy. Recurrent bleeding following close monitor or surgical evacuation of haematoma is however very high. Recent studies approximate the recurrence rate of 2%-33.3%. Recent evidence suggests the angiogenesis of middle meningeal arteries (MMA) in response to inflammation and healing process contributes to the development of chronic subdural haematoma, and its high recurrence chance. Several studies have looked into the use of middle meningeal artery embolization to halt the bleeding of a chronic subdural haematoma, and have found promising results in terms of haematoma reduction and prevention of surgical rescues.","[(32, 68, 'SURGICAL', 'Middle Meningeal Artery Embolization'), (73, 99, 'CONDITION', 'Chronic Subdural Haematoma'), (102, 120, 'CONDITION', 'Subdural haematoma'), (319, 334, 'CONDITION', 'Acute haematoma'), (427, 453, 'CONDITION', 'chronic subdural haematoma'), (630, 639, 'CONDITION', 'haematoma'), (757, 766, 'CONDITION', 'haematoma'), (1008, 1034, 'CONDITION', 'chronic subdural haematoma'), (1112, 1148, 'SURGICAL', 'middle meningeal artery embolization'), (1175, 1201, 'CONDITION', 'chronic subdural haematoma'), (1248, 1257, 'CONDITION', 'haematoma')]"
"['Examining', 'the', 'Effects', 'of', 'an', '8', '-', 'Week', 'Open', 'Label', 'Nature', '-', 'Based', 'Park', 'Visit', 'Program', 'on', 'the', 'Quality', 'of', 'Life', ',', 'Behaviors', 'and', 'Cognitive', 'Symptoms', 'of', 'Individuals', 'With', 'Dementia', 'and', 'Their', 'Caregivers', '|', 'The', 'overall', 'goals', 'of', 'our', 'project', 'is', 'to', 'understand', 'the', 'effects', 'of', 'participating', 'in', 'park', 'visits', 'and', 'nature', '-', 'based', 'activities', 'for', 'people', 'living', 'with', 'dementia', 'and', 'their', 'caregivers', '.', 'Nature', '-', 'based', 'activities', 'such', 'as', 'park', 'visits', 'can', 'have', 'beneficial', 'effects', 'on', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'physical', 'health', '.', 'However', ',', 'there', 'may', 'be', 'barriers', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'that', 'may', 'prevent', 'them', 'from', 'engaging', 'in', 'park', 'visits', '.', 'The', 'Nature', 'Connections', 'park', 'visit', 'program', 'will', 'provide', 'education', 'sessions', 'for', '10', 'persons', 'living', 'with', 'dementia', 'and', '10', 'caregivers', 'highlighting', 'the', 'beneficial', 'effects', 'of', 'park', 'visits', 'and', 'address', 'common', 'barriers', 'to', 'participating', 'in', 'park', 'visits', '.', 'Following', 'the', 'education', 'session', 'participants', 'will', 'be', 'provided', 'with', 'weekly', 'telephone', '/', 'internet', 'support', 'meetings', 'for', 'participants', 'to', 'share', 'their', 'experiences', 'with', 'park', 'visits', 'and', 'to', 'address', 'any', 'challenges', 'individuals', 'encountered', 'when', 'trying', 'to', 'complete', 'their', 'visits', '.', 'The', 'impact', 'of', 'park', 'visits', 'on', 'quality', 'of', 'life', ',', 'behaviours', ',', 'and', 'measures', 'of', 'stress', 'for', 'people', 'with', 'dementia', 'and', 'their', 'caregivers', 'will', 'be', 'assessed', 'over', '8', 'weeks', '.', 'Following', 'completion', 'of', 'the', 'program', 'participants', 'will', 'provide', 'an', 'evaluation', 'of', 'the', 'program', 'to', 'understand', 'their', 'experience', 'and', 'satisfaction', 'with', 'the', 'program', '.', 'This', 'project', 'will', 'provide', 'new', 'information', 'about', 'the', 'effects', 'of', 'park', 'visits', 'as', 'a', 'practical', 'strategy', 'to', 'improve', 'the', 'quality', 'of', 'life', ',', 'psychological', 'symptoms', 'and', 'measures', 'of', 'stress', 'for', 'both', 'people', 'with', 'dementia', 'and', 'caregivers', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT05527587,NCT05527587,"Examining the Effects of an 8-Week Open Label Nature-Based Park Visit Program on the Quality of Life, Behaviors and Cognitive Symptoms of Individuals With Dementia and Their Caregivers | The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers. Nature-based activities such as park visits can have beneficial effects on quality of life, psychological symptoms and physical health. However, there may be barriers for people with dementia and their caregivers that may prevent them from engaging in park visits. The Nature Connections park visit program will provide education sessions for 10 persons living with dementia and 10 caregivers highlighting the beneficial effects of park visits and address common barriers to participating in park visits. Following the education session participants will be provided with weekly telephone/internet support meetings for participants to share their experiences with park visits and to address any challenges individuals encountered when trying to complete their visits. The impact of park visits on quality of life, behaviours, and measures of stress for people with dementia and their caregivers will be assessed over 8 weeks. Following completion of the program participants will provide an evaluation of the program to understand their experience and satisfaction with the program. This project will provide new information about the effects of park visits as a practical strategy to improve the quality of life, psychological symptoms and measures of stress for both people with dementia and caregivers.","[(46, 77, 'OTHER', 'Nature-Based Park Visit Program'), (155, 163, 'CONDITION', 'Dementia'), (269, 280, 'OTHER', 'park visits'), (285, 308, 'OTHER', 'nature-based activities'), (332, 340, 'CONDITION', 'dementia'), (363, 386, 'OTHER', 'Nature-based activities'), (395, 406, 'OTHER', 'park visits'), (546, 554, 'CONDITION', 'dementia'), (615, 626, 'OTHER', 'park visits'), (632, 669, 'OTHER', 'Nature Connections park visit program'), (729, 737, 'CONDITION', 'dementia'), (795, 806, 'OTHER', 'park visits'), (855, 866, 'OTHER', 'park visits'), (935, 977, 'OTHER', 'weekly telephone/internet support meetings'), (1027, 1038, 'OTHER', 'park visits'), (1145, 1156, 'OTHER', 'park visits'), (1228, 1236, 'CONDITION', 'dementia'), (1509, 1520, 'OTHER', 'park visits'), (1644, 1652, 'CONDITION', 'dementia')]"
"['A', 'Multi', '-', 'center', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', 'Design', ',', 'Prospective', ',', 'Phase', 'II', 'Clinical', 'Trial', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Donepezil', 'and', 'Combined', 'With', 'GV1001', 'in', 'Alzheimer', 'Patients', '|', 'This', 'clinical', 'study', 'is', 'designed', 'as', 'a', 'multi', '-', 'center', ',', 'randomized', ',', 'double', '-', 'blind', ',', 'placebo', '-', 'controlled', ',', 'parallel', 'design', ',', 'prospective', ',', 'phase', 'II', 'clinical', 'trial', '.', '\n\n', 'An', 'eligible', 'subject', 'who', 'meets', 'inclusion', 'and', 'exclusion', 'criteria', 'is', 'randomly', 'assigned', 'to', 'three', 'groups', ':', 'study', 'group', '1', '(', 'GV1001', '0.56', 'mg', ')', ',', 'study', 'group', '2', '(', 'GV1001', '1.12', 'mg', ')', 'or', 'placebo', 'group', '.', 'A', 'randomized', 'subject', 'is', 'administered', 'either', 'GV1001', 'or', 'placebo', 'in', 'a', 'total', 'of', '14', 'times', 'and', 'will', 'be', 'evaluated', 'for', 'the', 'efficacy', 'and', 'safety', 'at', 'week', 'of', '24', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03184467,NCT03184467,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients | This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.

An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.","[(42, 49, 'CONTROL', 'Placebo'), (155, 164, 'DRUG', 'Donepezil'), (183, 189, 'DRUG', 'GV1001'), (193, 202, 'CONDITION', 'Alzheimer'), (291, 298, 'CONTROL', 'placebo'), (483, 489, 'DRUG', 'GV1001'), (515, 521, 'DRUG', 'GV1001'), (534, 541, 'CONTROL', 'placebo'), (593, 599, 'DRUG', 'GV1001'), (603, 610, 'CONTROL', 'placebo')]"
"['Multi', '-', 'Center', ',', 'Open', '-', 'Label', 'Study', 'of', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fabrazyme', 'in', 'Patients', 'With', 'Fabry', 'Disease', 'That', 'Previously', 'Participated', 'in', 'the', 'AGAL-008', '-', '00', 'Study', '|', 'People', 'with', 'Fabry', 'Disease', 'have', 'an', 'alteration', 'in', 'their', 'genetic', 'material', '(', 'DNA', ')', 'which', 'causes', 'a', 'deficiency', 'of', 'the', 'alpha', '-', 'galactosidase', 'A', 'enzyme', '.', 'Fabrazyme', '(', 'agalsidase', 'beta', ')', 'is', 'a', 'drug', 'that', 'helps', 'to', 'break', 'down', 'and', 'removes', 'certain', 'types', 'of', 'fatty', 'substances', 'called', '""', 'glycolipids', '""', '.', 'These', 'glycolipids', 'are', 'normally', 'present', 'within', 'the', 'body', 'in', 'most', 'cells', '.', 'In', 'Fabry', 'disease', ',', 'glycolipids', 'build', 'up', 'in', 'various', 'tissues', 'such', 'as', 'the', 'liver', ',', 'kidney', ',', 'skin', ',', 'and', 'blood', 'vessels', 'because', 'a', '-', 'galactosidase', 'A', 'is', 'not', 'present', ',', 'or', 'is', 'present', 'in', 'small', 'quantities', '.', 'The', 'build', 'up', 'of', 'glycolipid', '(', 'globatriaosylceramide', 'or', 'GL-3', ')', 'levels', 'in', 'these', 'tissues', 'in', 'particular', 'is', 'thought', 'to', 'cause', 'the', 'clinical', 'symptoms', 'that', 'are', 'common', 'to', 'Fabry', 'disease', '.', 'This', 'study', 'analyzed', 'the', 'safety', 'and', 'efficacy', 'of', 'Fabrazyme', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'Fabry', 'disease', 'that', 'previously', 'participated', 'in', 'the', 'AGAL-008', '-', '00', '(', 'NCT0074984', ')', 'study', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00081497,NCT00081497,"Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study | People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to break down and removes certain types of fatty substances called ""glycolipids"". These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globatriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study analyzed the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease that previously participated in the AGAL-008-00 (NCT0074984) study.","[(61, 70, 'DRUG', 'Fabrazyme'), (88, 101, 'CONDITION', 'Fabry Disease'), (170, 183, 'CONDITION', 'Fabry Disease'), (298, 307, 'DRUG', 'Fabrazyme'), (309, 324, 'DRUG', 'agalsidase beta'), (502, 515, 'CONDITION', 'Fabry disease'), (843, 856, 'CONDITION', 'Fabry disease'), (905, 914, 'DRUG', 'Fabrazyme'), (949, 962, 'CONDITION', 'Fabry disease')]"
"['Evaluating', 'Tools', 'for', 'Health', 'Promotion', 'and', 'Disease', 'Prevention', '|', 'The', 'study', 'will', 'evaluate', 'the', 'effect', 'of', 'familial', 'risk', 'assessment', 'and', 'prevention', 'prompts', 'tailored', 'to', 'familial', 'risk', 'on', 'health', 'behaviors', 'and', 'use', 'of', 'preventive', 'services', 'among', 'adults', 'who', 'are', 'members', 'of', 'primary', 'care', 'practices', 'in', 'the', 'U.S.']","['O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00164658,NCT00164658,Evaluating Tools for Health Promotion and Disease Prevention | The study will evaluate the effect of familial risk assessment and prevention prompts tailored to familial risk on health behaviors and use of preventive services among adults who are members of primary care practices in the U.S.,"[(11, 60, 'BEHAVIOURAL', 'Tools for Health Promotion and Disease Prevention'), (101, 125, 'OTHER', 'familial risk assessment'), (130, 174, 'BEHAVIOURAL', 'prevention prompts tailored to familial risk')]"
"['A', 'Phase', 'I', ',', 'Open', '-', 'Label', 'Study', 'of', 'CERE-120', '(', 'Adeno', '-', 'Associated', 'Virus', 'Serotype', '2', '[', 'AAV2]-Neurturin[NTN', ']', 'to', 'Assess', 'the', 'Safety', 'and', 'Tolerability', 'of', 'Intrastriatal', 'Delivery', 'to', 'Subjects', 'With', 'Idiopathic', 'Parkinson', ""'s"", 'Disease', '|', 'This', 'is', 'a', 'Phase', 'I', 'dose', 'escalating', 'open', '-', 'label', 'study', 'designed', 'to', 'assess', 'the', 'safety', ',', 'tolerability', 'and', 'biologic', 'activity', 'of', 'an', 'in', 'vivo', 'AAV2', 'mediated', 'delivery', 'of', 'the', 'gene', 'encoding', 'NTN', '(', 'CERE-120', ')', '.', '\n\n', 'Twelve', '(', 'up', 'to', '18', ')', 'subjects', 'will', 'receive', 'one', 'of', 'two', 'open', '-', 'label', 'doses', 'of', 'CERE-120', 'via', 'bilateral', 'stereotactic', 'injections', 'targeting', 'the', 'putaminal', 'region', 'of', 'the', 'brain', '.', 'Subjects', 'will', 'be', 'enrolled', 'in', 'one', 'of', 'two', 'cohorts', ',', 'a', 'low', '-', 'dose', 'cohort', 'of', 'six', 'subjects', 'followed', 'by', 'a', 'high', 'dose', 'cohort', 'of', 'six', 'subjects', '.', '\n\n', 'The', 'design', 'of', 'this', 'study', 'is', 'such', 'that', 'the', 'primary', 'objective', ',', 'the', 'evaluation', 'of', 'safety', 'and', 'tolerability', ',', 'will', 'be', 'assessed', 'by', 'frequent', 'observations', 'for', 'adverse', 'events', ',', 'clinical', 'laboratory', 'test', 'results', ',', 'imaging', '(', 'MRI', ')', ',', 'neuropsychometric', 'testing', ',', 'and', 'evaluations', 'of', 'disease', 'status', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00252850,NCT00252850,"A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease | This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).

Twelve (up to 18) subjects will receive one of two open-label doses of CERE-120 via bilateral stereotactic injections targeting the putaminal region of the brain. Subjects will be enrolled in one of two cohorts, a low-dose cohort of six subjects followed by a high dose cohort of six subjects.

The design of this study is such that the primary objective, the evaluation of safety and tolerability, will be assessed by frequent observations for adverse events, clinical laboratory test results, imaging (MRI), neuropsychometric testing, and evaluations of disease status.","[(31, 39, 'OTHER', 'CERE-120'), (41, 96, 'OTHER', 'Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN]'), (178, 208, 'CONDITION', ""Idiopathic Parkinson's Disease""), (334, 389, 'OTHER', 'in vivo AAV2 mediated delivery of the gene encoding NTN'), (391, 399, 'OTHER', 'CERE-120'), (474, 482, 'OTHER', 'CERE-120')]"
"['Safety', 'and', 'Therapeutic', 'Measures', 'of', 'Cathodal', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'Tdcs', ')', 'in', 'Patients', 'With', 'Refractory', 'Focal', 'Epilepsy', '|', 'This', 'is', 'a', 'single', 'site', ',', 'non', '-', 'randomized', ',', 'prospective', ',', 'open', '-', 'label', ',', 'interventional', 'pilot', '/', 'feasibility', 'study', '.', 'Patients', 'recruited', 'will', 'have', 'medically', '-', 'refractory', 'focal', 'neocortical', 'epilepsy', ',', 'defined', 'on', 'the', 'basis', 'of', 'presence', 'of', 'focal', 'spikes', 'and', '(', 'if', 'available', ')', 'focal', 'seizure', 'onsets', 'originating', 'from', 'the', 'lateral', 'cortical', 'surface', 'of', 'any', 'lobe', '.', 'All', 'patients', 'and', 'referring', 'physicians', 'will', 'be', 'requested', 'to', 'maintain', 'their', 'current', 'antiepileptic', 'drugs', 'throughout', 'the', 'study', 'with', 'changes', 'after', 'enrollment', 'permitted', 'only', 'to', 'maintain', 'pre', '-', 'enrollment', 'drug', 'levels', ',', 'or', 'if', 'clinically', 'necessary', '.', 'The', 'primary', 'outcome', 'measure', 'will', 'be', 'the', 'change', 'in', 'seizure', 'frequency', '(', 'seizures', '/', 'week', ')', 'as', 'compared', 'to', 'baseline', '.', '\n\n', 'Patients', 'with', 'medically', '-', 'refractory', 'neocortical', 'epilepsy', 'will', 'receive', 'cathodal', 'tDCS', 'administered', 'to', 'the', 'seizure', 'focus', 'for', '10', 'sessions', 'over', 'a', '2', '-', 'week', 'period', 'with', 'the', 'allowance', 'of', 'make', '-', 'up', 'sessions', 'in', 'week', 'three', '.', 'Subjects', 'will', 'be', 'evaluated', 'at', 'baseline', ',', 'during', 'the', 'stimulation', 'sessions', ',', 'and', '8', 'weeks', 'after', 'the', 'completion', 'of', 'the', 'tDCS', 'visits']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O']",NCT02866240,NCT02866240,"Safety and Therapeutic Measures of Cathodal Transcranial Direct Current Stimulation (Tdcs) in Patients With Refractory Focal Epilepsy | This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral cortical surface of any lobe. All patients and referring physicians will be requested to maintain their current antiepileptic drugs throughout the study with changes after enrollment permitted only to maintain pre-enrollment drug levels, or if clinically necessary. The primary outcome measure will be the change in seizure frequency (seizures/week) as compared to baseline.

Patients with medically-refractory neocortical epilepsy will receive cathodal tDCS administered to the seizure focus for 10 sessions over a 2-week period with the allowance of make-up sessions in week three. Subjects will be evaluated at baseline, during the stimulation sessions, and 8 weeks after the completion of the tDCS visits","[(35, 83, 'OTHER', 'Cathodal Transcranial Direct Current Stimulation'), (85, 89, 'OTHER', 'Tdcs'), (108, 133, 'CONDITION', 'Refractory Focal Epilepsy'), (269, 316, 'CONDITION', 'medically-refractory focal neocortical epilepsy'), (386, 399, 'CONDITION', 'focal seizure'), (752, 759, 'CONDITION', 'seizure'), (771, 779, 'CONDITION', 'seizures'), (826, 867, 'CONDITION', 'medically-refractory neocortical epilepsy'), (881, 894, 'OTHER', 'cathodal tDCS'), (915, 922, 'CONDITION', 'seizure'), (1133, 1137, 'OTHER', 'tDCS')]"
"['A', 'Randomized', ',', 'Open', 'Label', 'Clinical', 'Trial', 'of', 'Sustained', 'Hypernatremia', 'for', 'the', 'Prevention', 'and', 'Treatment', 'of', 'Cerebral', 'Edema', 'in', 'Traumatic', 'Brain', 'Injury', '|', 'Cerebral', 'edema', 'is', 'seen', 'heterogenous', 'group', 'of', 'neurological', 'disease', 'states', 'that', 'mainly', 'fall', 'under', 'the', 'categories', 'of', 'metabolic', ',', 'infectious', ',', 'neoplasia', ',', 'cerebrovascular', ',', 'and', 'traumatic', 'brain', 'injury', 'disease', 'states', '.', 'Regardless', 'of', 'the', 'driving', 'force', ',', 'cerebral', 'edema', 'is', 'defined', 'as', 'the', 'accumulation', 'of', 'fluid', 'in', 'the', 'brain', ""'s"", 'intracellular', 'and', 'extracellular', 'spaces', '.', 'This', 'occurs', 'secondary', 'to', 'alterations', 'in', 'the', 'complex', 'interplay', 'between', 'four', 'distinct', 'fluid', 'compartments', 'within', 'the', 'cranium', '.', 'In', 'any', 'human', 'cranium', ';', 'fluid', 'is', 'contained', 'in', 'the', 'blood', ',', 'the', 'cerebrospinal', 'fluid', ',', 'interstitial', 'fluid', 'of', 'the', 'brain', 'parenchyma', ',', 'and', 'the', 'intracellular', 'fluid', 'of', 'the', 'neurons', 'and', 'glia', '.', 'Fluid', 'movement', 'occurs', 'normally', 'between', 'these', 'compartments', 'and', 'depends', 'on', 'specific', 'concentrations', 'of', 'solutes', '(', 'such', 'as', 'sodium', ')', 'and', 'water', '.', 'In', 'brain', '-', 'injured', 'states', ',', 'the', 'normal', 'regulation', 'of', 'this', 'process', 'is', 'disturbed', 'and', 'cerebral', 'edema', 'can', 'develop', '.', 'Cerebral', 'edema', 'leads', 'to', 'increased', 'intracranial', 'pressure', 'and', 'mortality', 'secondary', 'to', 'brain', 'tissue', 'compression', ',', 'given', 'the', 'confines', 'of', 'the', 'fixed', '-', 'volume', 'cranium', '.', 'Additionally', ',', 'secondary', 'neuronal', 'dysfunction', 'or', 'death', 'can', 'occur', 'at', 'the', 'cellular', 'level', 'secondary', 'to', 'the', 'disruption', 'of', 'ion', 'gradients', 'that', 'control', 'metabolism', 'and', 'function', '.', '\n\n', 'While', 'studies', 'utilizing', 'bolus', 'dosing', 'of', 'hyperosmolar', 'therapy', 'to', 'target', 'signs', 'or', 'symptoms', 'of', 'increased', 'intracranial', 'pressure', 'secondary', 'to', 'cerebral', 'edema', 'are', 'numerous', ',', 'there', 'is', 'a', 'paucity', 'of', 'studies', 'relating', 'to', 'continuous', 'infusion', 'of', 'hyperosmolar', 'therapy', 'for', 'targeted', 'sustained', 'hypernatremia', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'cerebral', 'edema', '.', 'The', 'investigators', 'hypothesize', 'that', 'induced', ',', 'sustained', 'hypernatremia', 'following', 'traumatic', 'brain', 'injury', 'will', 'decrease', 'the', 'rate', 'of', 'cerebral', 'edema', 'formation', 'and', 'improve', 'patient', 'outcomes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01605357,NCT01605357,"A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury | Cerebral edema is seen heterogenous group of neurological disease states that mainly fall under the categories of metabolic, infectious, neoplasia, cerebrovascular, and traumatic brain injury disease states. Regardless of the driving force, cerebral edema is defined as the accumulation of fluid in the brain's intracellular and extracellular spaces. This occurs secondary to alterations in the complex interplay between four distinct fluid compartments within the cranium. In any human cranium; fluid is contained in the blood, the cerebrospinal fluid, interstitial fluid of the brain parenchyma, and the intracellular fluid of the neurons and glia. Fluid movement occurs normally between these compartments and depends on specific concentrations of solutes (such as sodium) and water. In brain-injured states, the normal regulation of this process is disturbed and cerebral edema can develop. Cerebral edema leads to increased intracranial pressure and mortality secondary to brain tissue compression, given the confines of the fixed-volume cranium. Additionally, secondary neuronal dysfunction or death can occur at the cellular level secondary to the disruption of ion gradients that control metabolism and function.

While studies utilizing bolus dosing of hyperosmolar therapy to target signs or symptoms of increased intracranial pressure secondary to cerebral edema are numerous, there is a paucity of studies relating to continuous infusion of hyperosmolar therapy for targeted sustained hypernatremia for the prevention and treatment of cerebral edema. The investigators hypothesize that induced, sustained hypernatremia following traumatic brain injury will decrease the rate of cerebral edema formation and improve patient outcomes.","[(43, 66, 'OTHER', 'Sustained Hypernatremia'), (103, 117, 'CONDITION', 'Cerebral Edema'), (121, 143, 'CONDITION', 'Traumatic Brain Injury'), (146, 160, 'CONDITION', 'Cerebral edema'), (315, 337, 'CONDITION', 'traumatic brain injury'), (387, 401, 'CONDITION', 'cerebral edema'), (936, 949, 'CONDITION', 'brain-injured'), (1013, 1027, 'CONDITION', 'cerebral edema'), (1041, 1055, 'CONDITION', 'Cerebral edema'), (1505, 1519, 'CONDITION', 'cerebral edema'), (1599, 1619, 'OTHER', 'hyperosmolar therapy'), (1633, 1656, 'OTHER', 'sustained hypernatremia'), (1693, 1707, 'CONDITION', 'cerebral edema'), (1753, 1776, 'OTHER', 'sustained hypernatremia'), (1787, 1809, 'CONDITION', 'traumatic brain injury'), (1836, 1850, 'CONDITION', 'cerebral edema')]"
"['The', 'Mediating', 'Role', 'of', 'Dissociative', 'Symptoms', 'and', 'Early', 'Maladaptive', 'Schemas', 'in', 'the', 'Relationship', 'Between', 'Childhood', 'Trauma', 'and', 'Auditory', 'Hallucinations', 'in', 'Schizophrenia', '|', 'BACKGROUND', 'It', 'is', 'demonstrated', 'that', 'strong', 'associations', 'between', 'trauma', 'suffered', 'in', 'childhood', 'and', 'having', 'schizophrenia', ',', 'and', 'more', 'specifically', 'to', 'experience', 'acoustic', '-', 'verbal', 'hallucinations', '(', 'AVH', ')', '.', 'A', 'second', 'generation', 'of', 'research', 'is', 'currently', 'examining', 'the', 'cognitive', 'and', 'affective', 'processes', 'likely', 'to', 'play', 'a', 'mediating', 'role', 'in', 'this', 'association', '.', 'These', 'mediators', 'appear', 'to', 'include', 'early', 'maladaptive', 'personality', 'patterns', 'and', 'dissociative', 'experiences', '.', 'Although', 'these', 'factors', 'have', 'most', 'often', 'been', 'explored', 'separately', ',', 'recent', 'research', 'indicates', 'that', 'they', 'could', 'be', 'associated', ',', 'and', 'thus', 'contribute', 'to', 'AVH', '.', 'More', 'specifically', ',', 'another', 'study', 'has', 'shown', 'that', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', 'but', 'depends', 'on', 'cognitive', 'factors', 'including', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociation', '.', 'However', ',', 'this', 'study', 'was', 'carried', 'out', 'on', 'a', 'non', '-', 'clinical', 'sample', 'of', 'subjects', 'with', 'a', 'predisposition', 'to', 'AVH', '.', '\n\n', 'OBJECTIVES', ':', 'testing', 'a', 'structural', 'model', 'of', 'AVH', ',', 'childhood', 'trauma', ',', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'large', 'multicentric', 'sample', 'of', 'inpatients', 'diagnosed', 'with', 'schizophrenia', 'and', 'AVH', '(', 'n=350', ')', '.', 'Secondary', 'objectives', 'are', '(', 'i', ')', 'test', 'in', 'the', 'model', 'the', 'role', 'of', 'all', 'the', 'early', 'patterns', 'described', 'by', 'Jeffrey', 'Young', 'instead', 'of', 'targeting', 'only', 'the', 'schemes', 'that', 'are', 'part', 'of', 'the', 'model', 'tested', 'in', 'previous', 'study', 'as', 'the', 'one', 'by', 'Bortolon', 'and', 'colleagues', ',', '(', 'ii', ')', 'compare', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'confirmatory', 'model', 'to', 'the', 'quality', 'of', 'the', 'adjustment', 'of', 'the', 'exploratory', 'model', '.', '\n\n', 'METHODS', ':', 'one', 'single', 'visit', 'in', 'which', 'subjects', 'will', 'receive', 'self', '-', 'reported', 'questionnaires', '(', 'Childhood', 'trauma', 'questionnaire', ',', 'The', 'Young', 'schema', 'questionnaire', 'short', 'form', ',', 'Dissociative', 'experiences', 'scale', ',', 'Launay', '-', 'Slade', 'hallucination', 'scale', 'and', 'Cardiff', 'Anomalous', 'Perceptions', 'Scale', '.', '\n\n', 'ANALYSES', ':', 'Structural', 'equation', 'model', 'performed', 'additional', 'analysis', 'using', 'Partial', 'Least', 'Squares', 'Structural', 'Equation', 'Modelling', '.', 'The', 'primary', 'endpoint', 'corresponds', 'to', 'significant', 'associations', 'between', 'the', 'variables', '.', 'The', 'quality', 'of', 'the', 'model', 'will', 'be', 'assessed', 'using', 'a', 'fit', 'quality', 'measure', '.', 'The', 'secondary', 'endpoints', 'are', 'significant', 'associations', 'between', 'the', 'different', 'variables', '(', 'p', '<', '0.05', ')', 'and', 'the', 'model', 'quality', 'assessed', 'with', 'a', 'quality', 'measure', 'of', 'the', 'fit', '.', '\n\n', 'MAIN', 'HYPOTHESIS', ':', 'the', 'association', 'between', 'childhood', 'trauma', 'and', 'predisposition', 'to', 'AVH', 'is', 'not', 'direct', ',', 'but', 'depends', 'on', 'the', 'impact', 'of', 'violence', 'suffered', 'during', 'childhood', 'on', 'early', 'maladaptive', 'schemas', 'and', 'dissociative', 'symptoms', 'in', 'patients', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04481217,NCT04481217,"The Mediating Role of Dissociative Symptoms and Early Maladaptive Schemas in the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia | BACKGROUND It is demonstrated that strong associations between trauma suffered in childhood and having schizophrenia, and more specifically to experience acoustic-verbal hallucinations (AVH). A second generation of research is currently examining the cognitive and affective processes likely to play a mediating role in this association. These mediators appear to include early maladaptive personality patterns and dissociative experiences. Although these factors have most often been explored separately, recent research indicates that they could be associated, and thus contribute to AVH. More specifically, another study has shown that the association between childhood trauma and predisposition to AVH is not direct but depends on cognitive factors including the impact of violence suffered during childhood on early maladaptive schemas and dissociation. However, this study was carried out on a non-clinical sample of subjects with a predisposition to AVH.

OBJECTIVES: testing a structural model of AVH, childhood trauma, early maladaptive schemas and dissociative symptoms in large multicentric sample of inpatients diagnosed with schizophrenia and AVH (n=350). Secondary objectives are (i) test in the model the role of all the early patterns described by Jeffrey Young instead of targeting only the schemes that are part of the model tested in previous study as the one by Bortolon and colleagues, (ii) compare the quality of the adjustment of the confirmatory model to the quality of the adjustment of the exploratory model.

METHODS: one single visit in which subjects will receive self-reported questionnaires (Childhood trauma questionnaire, The Young schema questionnaire short form, Dissociative experiences scale, Launay-Slade hallucination scale and Cardiff Anomalous Perceptions Scale.

ANALYSES: Structural equation model performed additional analysis using Partial Least Squares Structural Equation Modelling. The primary endpoint corresponds to significant associations between the variables. The quality of the model will be assessed using a fit quality measure. The secondary endpoints are significant associations between the different variables (p <0.05) and the model quality assessed with a quality measure of the fit.

MAIN HYPOTHESIS: the association between childhood trauma and predisposition to AVH is not direct, but depends on the impact of violence suffered during childhood on early maladaptive schemas and dissociative symptoms in patients with schizophrenia.","[(123, 146, 'CONDITION', 'Auditory Hallucinations'), (150, 163, 'CONDITION', 'Schizophrenia'), (269, 282, 'CONDITION', 'schizophrenia'), (320, 350, 'CONDITION', 'acoustic-verbal hallucinations'), (352, 355, 'CONDITION', 'AVH'), (752, 755, 'CONDITION', 'AVH'), (868, 871, 'CONDITION', 'AVH'), (1123, 1126, 'CONDITION', 'AVH'), (1171, 1174, 'CONDITION', 'AVH'), (1224, 1245, 'CONDITION', 'dissociative symptoms'), (1304, 1317, 'CONDITION', 'schizophrenia'), (1322, 1325, 'CONDITION', 'AVH'), (2493, 2496, 'CONDITION', 'AVH'), (2648, 2661, 'CONDITION', 'schizophrenia')]"
"['A', 'Phase', '2a', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo-', 'and', 'Active', '-', 'Controlled', ',', 'Parallel', '-', 'Group', ',', 'Multicenter', 'Study', 'to', 'Assess', 'the', 'Safety', 'and', 'Efficacy', 'of', 'ADL5859', '100', 'mg', 'BID', 'in', 'Subjects', 'With', 'Neuropathic', 'Pain', 'Associated', 'With', 'Diabetic', 'Peripheral', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'ADL5859', 'in', 'relieving', 'the', 'pain', 'associated', 'with', 'diabetic', 'peripheral', 'neuropathy', '(', 'DPN', ')', 'compared', 'with', 'placebo', 'and', 'duloxetine', '(', 'a', 'marketed', 'drug', 'approved', 'for', 'the', 'treatment', 'of', 'painful', 'DPN', ')', '.', 'The', 'pain', 'symptoms', 'of', 'DPN', 'are', 'thought', 'to', 'be', 'due', 'to', 'damage', 'to', 'nerves', 'caused', 'by', 'the', 'diabetes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00603265,NCT00603265,"A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes.","[(38, 46, 'CONTROL', 'Placebo-'), (141, 148, 'DRUG', 'ADL5859'), (177, 193, 'CONDITION', 'Neuropathic Pain'), (210, 240, 'CONDITION', 'Diabetic Peripheral Neuropathy'), (305, 312, 'DRUG', 'ADL5859'), (330, 334, 'CONDITION', 'pain'), (351, 381, 'CONDITION', 'diabetic peripheral neuropathy'), (383, 386, 'CONDITION', 'DPN'), (402, 409, 'CONTROL', 'placebo'), (414, 424, 'DRUG', 'duloxetine'), (480, 483, 'CONDITION', 'DPN'), (490, 494, 'CONDITION', 'pain'), (507, 510, 'CONDITION', 'DPN'), (567, 575, 'CONDITION', 'diabetes')]"
"['Effect', 'of', 'Fentanyl', 'Given', 'Approximately', 'Ten', 'Minutes', 'to', 'the', 'End', 'of', 'Surgery', 'on', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Adeno', '-', 'tonsilectomy', 'at', 'Kenyatta', 'National', 'Hospital', ':', 'A', 'Randomized', 'Placebo', 'Controlled', 'Clinical', 'Trial', '|', 'This', 'study', 'will', 'be', 'a', 'randomized', 'double', 'blind', 'placebo', 'controlled', 'clinical', 'trial', 'among', 'children', 'undergoing', 'adeno', '-', 'tonsillectomy', 'in', 'KNH', '.', 'The', 'intervention', 'arm', 'will', 'comprise', 'Fentanyl', 'given', 'at', 'a', 'dose', 'of', '1ug', '/', 'while', 'the', 'placebo', 'arm', 'will', 'be', 'given', 'normal', 'saline', 'at', 'a', 'volume', 'equivalent', 'to', 'Fentanyl', 'dose', ',', 'treatment', 'will', 'be', 'administered', 'approximately', 'ten', 'minutes', 'to', 'the', 'end', 'of', 'surgery', 'determined', 'by', 'the', 'time', 'when', 'the', 'mouth', 'gag', 'will', 'be', 'removed', '.', 'The', 'main', 'outcome', 'will', 'be', 'incidence', 'of', 'ED', 'at', 'the', 'recovery', 'room', 'using', 'Watcha', 'scale', 'and', 'secondary', 'outcomes', 'will', 'be', 'delay', 'in', 'emergence', 'time', 'from', 'anaesthesia', 'and', 'effectiveness', 'of', 'fentanyl', 'in', 'preventing', 'ED', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'O']",NCT02753725,NCT02753725,"Effect of Fentanyl Given Approximately Ten Minutes to the End of Surgery on Emergence Delirium in Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital: A Randomized Placebo Controlled Clinical Trial | This study will be a randomized double blind placebo controlled clinical trial among children undergoing adeno-tonsillectomy in KNH. The intervention arm will comprise Fentanyl given at a dose of 1ug/while the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose, treatment will be administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed. The main outcome will be incidence of ED at the recovery room using Watcha scale and secondary outcomes will be delay in emergence time from anaesthesia and effectiveness of fentanyl in preventing ED.","[(10, 18, 'DRUG', 'Fentanyl'), (76, 94, 'CONDITION', 'Emergence Delirium'), (118, 136, 'CONDITION', 'Adeno-tonsilectomy'), (181, 188, 'CONTROL', 'Placebo'), (262, 269, 'CONTROL', 'placebo'), (322, 341, 'CONDITION', 'adeno-tonsillectomy'), (385, 393, 'DRUG', 'Fentanyl'), (427, 434, 'CONTROL', 'placebo'), (460, 466, 'CONTROL', 'saline'), (493, 501, 'DRUG', 'Fentanyl'), (684, 686, 'CONDITION', 'ED'), (820, 828, 'DRUG', 'fentanyl'), (843, 845, 'CONDITION', 'ED')]"
"['Hybrid', '-', 'FES', 'Exercise', 'to', 'Prevent', 'Cardiovascular', 'Declines', 'in', 'Acute', 'SCI', '|', 'Each', 'year', ',', '11,000', 'people', 'suffer', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', 'in', 'the', 'U.S.', 'Within', 'the', 'first', 'year', ',', 'there', 'are', 'profound', 'declines', 'in', 'physiologic', 'function', ',', 'forming', 'the', 'underlying', 'substrate', 'for', 'future', 'cardiovascular', 'disease', '.', 'In', 'fact', ',', 'acquired', 'cardiovascular', 'disease', 'is', 'an', 'increasingly', 'recognized', 'consequence', 'of', 'SCI', 'and', 'is', 'the', 'leading', 'cause', 'of', 'death', 'in', 'SCI', '.', 'Though', 'incompletely', 'understood', ',', 'the', 'almost', '10', '-', 'fold', 'prevalence', 'of', 'cardiovascular', 'disease', 'results', 'in', 'part', 'from', 'profound', 'physiologic', ""'"", 'detraining', ""'"", 'resulting', 'from', 'motor', 'impairment', 'and', 'immobility', '.', 'Currently', ',', 'effective', 'interventions', 'preventing', 'acute', 'declines', 'that', 'lead', 'to', 'cardiovascular', 'compromise', 'and', 'increased', 'risk', 'in', 'SCI', 'are', 'lacking', '-', 'exercise', 'therapy', 'for', 'those', 'with', 'SCI', 'is', 'challenging', 'and', 'when', 'employed', ',', 'is', 'typically', 'limited', 'to', 'the', 'upper', 'body', '.', 'Recently', ',', 'the', 'investigators', 'refined', 'a', 'unique', 'form', 'of', 'exercise', 'for', 'those', 'with', 'SCI', 'that', 'specifically', 'mirrors', 'exercise', 'performed', 'by', 'those', 'without', 'SCI', '.', 'Functional', 'Electrical', 'Stimulation', '(', 'FES', ')', 'Row', 'Training', '(', 'RT', ')', 'couples', 'volitional', 'arm', 'and', 'electrically', 'controlled', 'leg', 'exercise', ',', 'resulting', 'in', 'a', 'hemodynamic', 'profile', 'that', 'produces', 'the', 'beneficial', 'cardiac', 'loading', 'conditions', 'of', 'large', 'muscle', 'mass', 'exercise', '.', 'As', 'such', ',', 'FES', '-', 'RT', 'may', 'be', 'a', 'safe', 'and', 'effective', 'way', 'to', 'attenuate', 'cardiovascular', 'declines', 'following', 'SCI', '.', 'The', 'investigators', 'aims', 'are', 'to', 'test', 'the', 'overall', 'hypotheses', 'that', 'FES', '-', 'RT', 'will', ':', '1', ')', 'mitigate', 'against', 'increased', 'visceral', 'adiposity', 'and', 'reduced', 'insulin', 'sensitivity', ',', '2', ')', 'prevent', 'worsening', 'lipid', 'profile', 'and', 'compromised', 'baroreflex', 'function', ',', 'and', '3', ')', 'counter', 'ventricular', 'wall', 'thickening', 'and', 'declining', 'ventricular', 'function', 'occurring', 'with', 'acute', 'SCI', ',', 'and', 'that', 'these', 'effects', 'will', 'be', 'greater', 'than', 'that', 'observed', 'with', 'an', 'arms', '-', 'only', 'exercise', 'group', '.', 'Changes', 'with', 'FES', '-', 'RT', 'will', 'be', 'compared', 'to', 'a', 'time', '(', 'wait', '-', 'list', ')', 'control', 'and', 'to', 'arms', '-', 'only', '-', 'RT', '.', 'Individuals', 'with', 'an', 'SCI', 'within', 'the', 'last', '3', '-', '6', 'months', 'will', 'be', 'randomized', 'to', 'FES', '-', 'RT', ',', 'to', 'a', 'time', 'control', ',', 'or', 'arms', '-', 'only', '-', 'RT', '.', 'Measures', 'will', 'be', 'made', 'at', 'baseline', 'and', '6', 'months', '.', 'The', 'investigators', 'work', 'will', 'provide', 'results', 'that', 'clearly', 'delineate', 'potential', 'health', 'benefits', 'of', 'FES', '-', 'RT', ',', 'and', 'if', 'FES', '-', 'RT', 'is', 'effective', 'in', 'a', 'majority', 'of', 'those', 'with', 'SCI', ',', 'its', 'application', ',', 'implementation', ',', 'and', 'integration', 'could', 'be', 'easily', 'replicated', '.']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02139436,NCT02139436,"Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI | Each year, 11,000 people suffer a spinal cord injury (SCI) in the U.S. Within the first year, there are profound declines in physiologic function, forming the underlying substrate for future cardiovascular disease . In fact, acquired cardiovascular disease is an increasingly recognized consequence of SCI and is the leading cause of death in SCI. Though incompletely understood, the almost 10-fold prevalence of cardiovascular disease results in part from profound physiologic 'detraining' resulting from motor impairment and immobility. Currently, effective interventions preventing acute declines that lead to cardiovascular compromise and increased risk in SCI are lacking - exercise therapy for those with SCI is challenging and when employed, is typically limited to the upper body. Recently, the investigators refined a unique form of exercise for those with SCI that specifically mirrors exercise performed by those without SCI. Functional Electrical Stimulation (FES) Row Training (RT) couples volitional arm and electrically controlled leg exercise, resulting in a hemodynamic profile that produces the beneficial cardiac loading conditions of large muscle mass exercise. As such, FES-RT may be a safe and effective way to attenuate cardiovascular declines following SCI. The investigators aims are to test the overall hypotheses that FES-RT will: 1) mitigate against increased visceral adiposity and reduced insulin sensitivity, 2) prevent worsening lipid profile and compromised baroreflex function, and 3) counter ventricular wall thickening and declining ventricular function occurring with acute SCI, and that these effects will be greater than that observed with an arms-only exercise group. Changes with FES-RT will be compared to a time (wait-list) control and to arms-only-RT. Individuals with an SCI within the last 3-6 months will be randomized to FES-RT, to a time control, or arms-only-RT. Measures will be made at baseline and 6 months. The investigators work will provide results that clearly delineate potential health benefits of FES-RT, and if FES-RT is effective in a majority of those with SCI, its application, implementation, and integration could be easily replicated.","[(0, 19, 'PHYSICAL', 'Hybrid-FES Exercise'), (31, 54, 'CONDITION', 'Cardiovascular Declines'), (58, 67, 'CONDITION', 'Acute SCI'), (104, 122, 'CONDITION', 'spinal cord injury'), (124, 127, 'CONDITION', 'SCI'), (183, 215, 'CONDITION', 'declines in physiologic function'), (261, 283, 'CONDITION', 'cardiovascular disease'), (304, 326, 'CONDITION', 'cardiovascular disease'), (372, 375, 'CONDITION', 'SCI'), (413, 416, 'CONDITION', 'SCI'), (483, 505, 'CONDITION', 'cardiovascular disease'), (731, 734, 'CONDITION', 'SCI'), (781, 784, 'CONDITION', 'SCI'), (936, 939, 'CONDITION', 'SCI'), (1002, 1005, 'CONDITION', 'SCI'), (1007, 1064, 'PHYSICAL', 'Functional Electrical Stimulation (FES) Row Training (RT)'), (1261, 1267, 'PHYSICAL', 'FES-RT'), (1313, 1336, 'CONDITION', 'cardiovascular declines'), (1347, 1350, 'CONDITION', 'SCI'), (1415, 1421, 'PHYSICAL', 'FES-RT'), (1675, 1684, 'CONDITION', 'acute SCI'), (1752, 1770, 'CONTROL', 'arms-only exercise'), (1791, 1797, 'PHYSICAL', 'FES-RT'), (1820, 1844, 'CONTROL', 'time (wait-list) control'), (1852, 1864, 'CONTROL', 'arms-only-RT'), (1886, 1889, 'CONDITION', 'SCI'), (1939, 1945, 'PHYSICAL', 'FES-RT'), (1952, 1964, 'CONTROL', 'time control'), (1969, 1981, 'CONTROL', 'arms-only-RT'), (2127, 2133, 'PHYSICAL', 'FES-RT'), (2142, 2148, 'PHYSICAL', 'FES-RT'), (2190, 2193, 'CONDITION', 'SCI')]"
"['The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'gene', 'expression', 'and', 'activity', 'of', 'SIRT1', ',', 'and', 'forkhead', 'box', 'O3', 'pathway', 'by', 'means', 'of', 'investigating', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subjects', '.', 'Also', ',', 'we', 'investigate', 'the', 'effect', 'of', 'melatonin', 'on', 'interaction', 'between', 'SIRT1', 'activity', 'and', 'target', 'genes', 'MnSOD', 'and', 'catalase', 'in', 'multiple', 'sclerosis', 'and', 'healthy', 'subject', '.Additionally', ',', 'we', 'evaluate', 'effect', 'the', 'probable', 'effect', 'of', 'melatonin', 'treatment', 'on', 'gene', 'expression', 'and', 'activity', 'of', 'above', '-', 'mentioned', 'genes', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', 'of', 'healthy', 'subjects', '-', 'treated', 'with', 'H2O2', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02463318,NCT02463318,"The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.","[(176, 194, 'CONDITION', 'multiple sclerosis'), (252, 261, 'DRUG', 'melatonin'), (339, 357, 'CONDITION', 'multiple sclerosis'), (435, 444, 'DRUG', 'melatonin')]"
"['Comparing', 'the', 'Cognitive', 'Effects', 'of', 'Two', 'Exergame', 'Balance', 'Training', 'Systems', 'and', 'Traditional', 'Weight', 'Shifting', 'Training', 'in', 'Patients', 'With', 'Chronic', 'Stroke', '|', 'The', 'objective', 'of', 'this', 'study', 'was', 'to', ':', 'compare', 'the', 'training', 'and', 'maintenance', 'effects', 'of', '3', 'balance', 'training', 'programs', '(', '2', 'kinds', 'of', 'exergame', 'systems', 'and', '1', 'conventional', 'weight', '-', 'shifting', 'training', 'program', ')', 'on', 'cognitive', 'function', 'of', 'subjects', 'with', 'chronic', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02553993,NCT02553993,Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke | The objective of this study was to: compare the training and maintenance effects of 3 balance training programs (2 kinds of exergame systems and 1 conventional weight-shifting training program) on cognitive function of subjects with chronic stroke.,"[(39, 64, 'PHYSICAL', 'Exergame Balance Training'), (77, 113, 'PHYSICAL', 'Traditional Weight Shifting Training'), (131, 145, 'CONDITION', 'Chronic Stroke'), (234, 259, 'PHYSICAL', 'balance training programs'), (272, 288, 'PHYSICAL', 'exergame systems'), (308, 332, 'PHYSICAL', 'weight-shifting training'), (381, 395, 'CONDITION', 'chronic stroke')]"
"['Efficacy', 'of', 'Moxibustion', 'in', 'Diabetes', 'Peripheral', 'Neuropathy', '|', 'This', 'pragmatic', 'randomized', 'controlled', 'study', 'aimed', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'safety', 'of', 'moxibustion', 'therapy', 'on', 'diabetes', 'peripheral', 'neuropathy', '.']","['O', 'O', 'B-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'B-COND', 'I-COND', 'O']",NCT04894461,NCT04894461,Efficacy of Moxibustion in Diabetes Peripheral Neuropathy | This pragmatic randomized controlled study aimed to evaluate the effectiveness and safety of moxibustion therapy on diabetes peripheral neuropathy.,"[(12, 23, 'OTHER', 'Moxibustion'), (27, 35, 'CONDITION', 'Diabetes'), (36, 57, 'CONDITION', 'Peripheral Neuropathy'), (153, 172, 'OTHER', 'moxibustion therapy'), (176, 184, 'CONDITION', 'diabetes'), (185, 206, 'CONDITION', 'peripheral neuropathy')]"
"['Effectiveness', 'and', 'Clinical', 'Application', 'of', 'Multidisciplinary', 'Combined', 'Exercise', 'and', 'Nutrition', 'Intervention', 'for', 'Sarcopenic', 'Older', 'Adults', 'With', 'Metabolic', 'Syndrome', ':', 'Multicenter', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'aims', 'to', 'demonstrate', 'the', 'effect', 'of', 'combined', 'exercise', '-', 'nutrition', 'intervention', 'in', 'old', 'adults', 'with', 'sarcopenia', '.', 'This', 'study', 'will', 'be', 'conducted', 'with', 'prospectively', 'randomized', 'controlled', 'trial', 'comparing', 'outcome', 'of', 'combined', 'exercise', '-', 'nutrition', 'intervention', 'with', 'conventional', 'medical', 'care', '.', 'Handgrip', 'strength', ',', 'gait', 'speed', ',', 'knee', 'extensor', 'muscle', 'power', ',', 'physical', 'performance', ',', 'muscle', 'mass', 'using', 'DEXA', ',', 'quality', 'of', 'life', ',', 'activities', 'of', 'daily', 'living', ',', 'sarcopenia', 'screening', 'questionnaire', ',', 'nutritional', 'assessment', 'will', 'be', 'evaluated', 'on', 'baseline', ',', '12', '-', 'weeks', 'and', '24', '-', 'weeks', 'after', 'intervention', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04948736,NCT04948736,"Effectiveness and Clinical Application of Multidisciplinary Combined Exercise and Nutrition Intervention for Sarcopenic Older Adults With Metabolic Syndrome: Multicenter Randomized Controlled Trial | This study aims to demonstrate the effect of combined exercise-nutrition intervention in old adults with sarcopenia. This study will be conducted with prospectively randomized controlled trial comparing outcome of combined exercise-nutrition intervention with conventional medical care. Handgrip strength, gait speed, knee extensor muscle power, physical performance, muscle mass using DEXA, quality of life, activities of daily living, sarcopenia screening questionnaire, nutritional assessment will be evaluated on baseline, 12-weeks and 24-weeks after intervention.","[(42, 77, 'PHYSICAL', 'Multidisciplinary Combined Exercise'), (82, 104, 'OTHER', 'Nutrition Intervention'), (109, 119, 'CONDITION', 'Sarcopenic'), (138, 156, 'CONDITION', 'Metabolic Syndrome'), (245, 285, 'OTHER', 'combined exercise-nutrition intervention'), (305, 315, 'CONDITION', 'sarcopenia'), (414, 454, 'OTHER', 'combined exercise-nutrition intervention'), (460, 485, 'CONTROL', 'conventional medical care'), (637, 647, 'CONDITION', 'sarcopenia')]"
"['An', 'Open', 'Label', 'Study', 'of', 'the', 'Effects', 'of', 'Eculizumab', 'in', 'Neuromyelitis', 'Optica', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'the', 'drug', 'eculizumab', 'reduces', 'the', 'attack', 'rate', 'and', 'improves', 'outcome', 'in', 'patients', 'with', 'neuromyelitis', 'optica', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00904826,NCT00904826,An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.,"[(38, 48, 'DRUG', 'Eculizumab'), (52, 72, 'CONDITION', 'Neuromyelitis Optica'), (129, 139, 'DRUG', 'eculizumab'), (202, 222, 'CONDITION', 'neuromyelitis optica')]"
"['Analysis', 'of', 'Cutaneous', 'Nerve', 'Biopsies', 'in', 'Gastrointestinal', 'Motility', 'Disorders', '|', 'This', 'study', 'is', 'being', 'done', 'to', 'evaluate', 'cutaneous', 'nerve', 'biopsies', 'from', 'patients', 'with', 'refractory', 'gastrointestinal', 'motility', 'disorders', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'skin', 'biopsies', 'for', 'signs', 'of', 'small', 'fiber', 'neuropathy', 'in', 'GI', 'dysmotility', 'patients', ',', 'which', 'may', 'provide', 'a', 'better', 'understanding', 'of', 'the', 'underlying', 'pathology', 'of', 'their', 'condition', '.', 'Specifically', ',', 'identifying', 'any', 'small', 'fiber', 'neuropathy', 'that', 'may', 'exist', 'in', 'the', 'peripheral', 'nervous', 'system', 'may', 'help', 'us', 'to', 'better', 'understand', 'the', 'mechanism', 'of', 'presumed', 'enteric', 'neuropathy', 'that', 'may', 'be', 'involved', 'in', 'causing', 'GI', 'dysmotility', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04872452,NCT04872452,"Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders | This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders. The purpose of the study is to evaluate skin biopsies for signs of small fiber neuropathy in GI dysmotility patients, which may provide a better understanding of the underlying pathology of their condition. Specifically, identifying any small fiber neuropathy that may exist in the peripheral nervous system may help us to better understand the mechanism of presumed enteric neuropathy that may be involved in causing GI dysmotility.","[(40, 75, 'CONDITION', 'Gastrointestinal Motility Disorders'), (159, 205, 'CONDITION', 'refractory gastrointestinal motility disorders'), (274, 296, 'CONDITION', 'small fiber neuropathy'), (300, 314, 'CONDITION', 'GI dysmotility'), (444, 466, 'CONDITION', 'small fiber neuropathy'), (574, 592, 'CONDITION', 'enteric neuropathy'), (625, 639, 'CONDITION', 'GI dysmotility')]"
"['Systematic', 'Search', 'for', 'Primary', 'Immunodeficiency', 'in', 'Adults', 'With', 'Unexplained', 'Recurrent', 'and/or', 'Severe', 'Infections', 'With', 'Encapsulated', 'Bacteria', '|', 'Antibody', 'deficiencies', 'and', 'complement', 'deficiencies', 'are', 'the', 'most', 'frequent', 'Primary', 'immunodeficiencies', '(', 'PIDs', ')', 'in', 'adults', ',', 'and', 'are', 'associated', 'with', 'greatly', 'increased', 'susceptibility', 'to', 'recurrent', 'and/or', 'severe', 'bacterial', 'infections', '-', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', 'and', 'meningitis', '.', 'The', 'literature', 'data', 'suggest', 'that', 'PIDs', 'are', 'under', '-', 'diagnosed', 'in', 'adults', '.', 'The', 'current', 'European', 'and', 'US', 'guidelines', 'advocate', 'screening', 'adults', 'for', 'PIDs', 'if', 'they', 'present', 'recurrent', 'benign', 'especially', 'upper', 'and', 'lower', 'respiratory', 'tract', 'infections', ',', 'or', 'if', 'they', 'have', 'experienced', 'at', 'least', 'two', 'severe', 'bacterial', 'infections', 'and/or', 'have', 'a', 'recurrent', 'need', 'for', 'intravenous', 'antibiotics', '.', 'The', 'objective', 'of', 'the', 'demonstrate', 'the', 'interest', 'of', 'PIDs', 'screening', 'in', 'adult', 'patients', 'who', 'present', 'such', 'recurrent', 'infections', 'and/or', 'after', 'the', 'first', 'severe', 'bacterial', 'infection', ',', 'especially', 'when', 'the', 'patients', 'do', 'not', 'present', 'with', 'known', ',', 'etiologically', 'relevant', 'comorbidities', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02972281,NCT02972281,"Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria | Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections - especially upper and lower respiratory tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in adults. The current European and US guidelines advocate screening adults for PIDs if they present recurrent benign especially upper and lower respiratory tract infections, or if they have experienced at least two severe bacterial infections and/or have a recurrent need for intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in adult patients who present such recurrent infections and/or after the first severe bacterial infection, especially when the patients do not present with known, etiologically relevant comorbidities.","[(22, 46, 'CONDITION', 'Primary Immunodeficiency'), (62, 135, 'CONDITION', 'Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria'), (138, 159, 'CONDITION', 'Antibody deficiencies'), (164, 187, 'CONDITION', 'complement deficiencies'), (210, 236, 'CONDITION', 'Primary immunodeficiencies'), (238, 242, 'CONDITION', 'PIDs'), (315, 359, 'CONDITION', 'recurrent and/or severe bacterial infections'), (467, 471, 'CONDITION', 'PIDs'), (572, 576, 'CONDITION', 'PIDs'), (621, 665, 'CONDITION', 'upper and lower respiratory tract infections'), (715, 735, 'CONDITION', 'bacterial infections'), (843, 847, 'CONDITION', 'PIDs'), (893, 913, 'CONDITION', 'recurrent infections'), (937, 963, 'CONDITION', 'severe bacterial infection')]"
"['Brain', 'Single', 'Photon', 'Emission', 'Computed', 'Tomography', 'and', 'Quantitative', 'Electroencephalography', 'In', 'Former', 'NFL', 'Players', ':', 'A', 'Single', '-', 'Site', 'Exploratory', 'Pilot', 'Study', '|', 'The', 'investigators', 'primary', 'objective', 'is', 'to', 'acquire', 'preliminary', 'data', 'on', 'one', '-', 'hundred', 'former', 'NFL', 'veterans', 'with', 'at', 'least', 'one', 'full', 'year', 'of', 'professional', 'service', 'using', 'brain', 'SPECT', 'imaging', 'in', 'order', 'to', 'assess', 'the', 'degree', 'to', 'which', 'NFL', 'football', 'puts', 'players', 'at', 'risk', 'for', 'traumatic', 'brain', 'injury', '(', 'TBI', ')', '.', 'TBI', 'severity', 'shall', 'be', 'gauged', 'via', 'visual', 'inspection', 'by', 'a', 'clinician', 'trained', 'in', 'neuroanatomy', ',', 'and', 'also', 'by', 'a', 'statistical', 'comparison', 'of', 'subjects', ""'"", 'brains', 'to', 'an', 'in', '-', 'house', 'proprietary', 'database', 'comprised', 'of', 'the', 'brains', 'of', 'healthy', 'subjects', '.', '\n\n', 'The', 'investigators', 'secondary', 'objective', 'is', 'to', 'acquire', 'additional', 'data', 'on', 'these', 'players', 'such', 'that', 'investigators', 'may', 'establish', 'causative', 'factors', 'and', 'risks', 'associated', 'with', 'said', 'TBI', '.', '\n\n', 'The', 'investigators', 'tertiary', 'objective', 'is', 'to', 'acquire', 'data', 'on', 'subjects', 'using', 'various', 'mental', 'health', 'metrics', 'in', 'order', 'to', 'determine', 'the', 'effects', 'of', 'TBI', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01515839,NCT01515839,"Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study | The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL football puts players at risk for traumatic brain injury (TBI). TBI severity shall be gauged via visual inspection by a clinician trained in neuroanatomy, and also by a statistical comparison of subjects' brains to an in-house proprietary database comprised of the brains of healthy subjects.

The investigators secondary objective is to acquire additional data on these players such that investigators may establish causative factors and risks associated with said TBI.

The investigators tertiary objective is to acquire data on subjects using various mental health metrics in order to determine the effects of TBI.","[(409, 431, 'CONDITION', 'traumatic brain injury'), (433, 436, 'CONDITION', 'TBI'), (439, 442, 'CONDITION', 'TBI'), (841, 844, 'CONDITION', 'TBI'), (988, 991, 'CONDITION', 'TBI')]"
"['Effect', 'of', 'Extubation', 'Under', 'Deep', 'Anesthesia', 'on', 'Emergence', 'Agitation', 'of', 'Nasal', 'Surgery', '|', 'This', 'study', 'analyzed', 'the', 'relationship', 'between', 'extubation', 'timing', 'and', 'Emergence', 'agitation', 'in', '18', '-', '60', 'years', 'old', 'adults', 'undergoing', 'nasal', 'surgery', ',', 'such', 'as', 'nasal', 'septum', 'correction', ',', 'endoscopic', 'sinus', 'surgery', ',', 'and', 'nasal', 'bone', 'fracture', 'reduction', '.', 'The', 'number', 'of', 'agitation', ',', 'sedation', 'score', ',', 'pain', 'score', ',', 'operation', 'method', ',', 'analgesic', 'drugs', 'and', 'other', 'data', 'were', 'recorded', 'to', 'analyze', 'the', 'effect', 'of', 'deep', 'anesthesia', 'extubation', 'on', 'agitation', 'in', 'patients', 'with', 'nasal', 'surgery', '.', 'It', 'also', 'provides', 'a', 'clinical', 'basis', 'for', 'the', 'prevention', 'and', 'treatment', 'of', 'agitation', 'during', 'the', 'recovery', 'period', 'of', 'such', 'operations', 'in', 'adults', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04844333,NCT04844333,"Effect of Extubation Under Deep Anesthesia on Emergence Agitation of Nasal Surgery | This study analyzed the relationship between extubation timing and Emergence agitation in 18-60 years old adults undergoing nasal surgery, such as nasal septum correction, endoscopic sinus surgery, and nasal bone fracture reduction. The number of agitation, sedation score, pain score, operation method, analgesic drugs and other data were recorded to analyze the effect of deep anesthesia extubation on agitation in patients with nasal surgery. It also provides a clinical basis for the prevention and treatment of agitation during the recovery period of such operations in adults.","[(46, 65, 'CONDITION', 'Emergence Agitation'), (69, 82, 'CONDITION', 'Nasal Surgery'), (152, 171, 'CONDITION', 'Emergence agitation'), (209, 222, 'CONDITION', 'nasal surgery'), (232, 255, 'CONDITION', 'nasal septum correction'), (257, 281, 'CONDITION', 'endoscopic sinus surgery'), (287, 316, 'CONDITION', 'nasal bone fracture reduction'), (332, 341, 'CONDITION', 'agitation'), (516, 529, 'CONDITION', 'nasal surgery'), (601, 610, 'CONDITION', 'agitation')]"
"['Subthalamic', 'Nucleus', 'Stimulation', 'Effect', 'on', 'Gait', 'Symmetry', 'and', 'Freezing', 'of', 'Gait', '|', 'Impact', 'of', 'unilateral', 'modulation', 'of', 'deep', 'brain', 'stimulation', 'of', 'the', 'subthalamic', 'nucleus', 'on', 'freezing', 'of', 'gait', 'in', 'Parkinson', ""'s"", 'disease']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT02704195,NCT02704195,Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait | Impact of unilateral modulation of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease,"[(0, 31, 'OTHER', 'Subthalamic Nucleus Stimulation'), (60, 76, 'CONDITION', 'Freezing of Gait'), (114, 163, 'OTHER', 'deep brain stimulation of the subthalamic nucleus'), (167, 183, 'CONDITION', 'freezing of gait'), (187, 206, 'CONDITION', ""Parkinson's disease"")]"
"['The', 'Neural', 'Coding', 'of', 'Speech', 'Across', 'Human', 'Languages', '|', 'The', 'overall', 'goal', 'of', 'this', 'study', 'is', 'to', 'reveal', 'the', 'fundamental', 'neural', 'mechanisms', 'that', 'underlie', 'comprehension', 'across', 'human', 'spoken', 'languages', '.', 'An', 'understanding', 'of', 'how', 'speech', 'is', 'coded', 'in', 'the', 'brain', 'has', 'significant', 'implications', 'for', 'the', 'development', 'of', 'new', 'diagnostic', 'and', 'rehabilitative', 'strategies', 'for', 'language', 'disorders', '(', 'e.g.', 'aphasia', ',', 'dyslexia', ',', 'autism', ',', 'et', 'alia', ')', '.', 'The', 'basic', 'mechanisms', 'underlying', 'comprehension', 'of', 'spoken', 'language', 'are', 'unknown', '.', 'Researchers', 'are', 'only', 'beginning', 'to', 'understand', 'how', 'the', 'human', 'brain', 'extracts', 'the', 'most', 'fundamental', 'linguistic', 'elements', '(', 'consonants', 'and', 'vowels', ')', 'from', 'a', 'complex', 'and', 'highly', 'variable', 'acoustic', 'signal', '.', 'Traditional', 'theories', 'have', 'posited', 'a', ""'"", 'universal', ""'"", 'phonetic', 'inventory', 'shared', 'by', 'all', 'humans', ',', 'but', 'this', 'has', 'been', 'challenged', 'by', 'other', 'newer', 'theories', 'that', 'each', 'language', 'has', 'its', 'own', 'unique', 'and', 'specialized', 'code', '.', 'An', 'investigation', 'of', 'the', 'cortical', 'representation', 'of', 'speech', 'sounds', 'across', 'languages', 'can', 'likely', 'shed', 'light', 'on', 'this', 'fundamental', 'question', '.', 'Previous', 'research', 'has', 'implicated', 'the', 'superior', 'temporal', 'cortex', 'in', 'the', 'processing', 'of', 'speech', 'sounds', '.', 'Most', 'of', 'this', 'work', 'has', 'been', 'entirely', 'carried', 'out', 'in', 'English', '.', 'The', 'recording', 'of', 'neural', 'activity', 'directly', 'from', 'the', 'cortical', 'surface', 'from', 'individuals', 'with', 'different', 'language', 'experience', 'is', 'a', 'promising', 'approach', 'since', 'it', 'can', 'provide', 'both', 'high', 'spatial', 'and', 'temporal', 'resolution', '.', 'This', 'study', 'will', 'examine', 'the', 'mechanisms', 'of', 'phonetic', 'encoding', ',', 'by', 'utilizing', 'neurophysiological', 'recordings', 'obtained', 'during', 'neurosurgical', 'procedures', '.', 'High', '-', 'density', 'electrode', 'arrays', ',', 'advanced', 'signal', 'processing', ',', 'and', 'direct', 'electrocortical', 'stimulation', 'will', 'be', 'utilized', 'to', 'unravel', 'both', 'local', 'and', 'population', 'encoding', 'of', 'speech', 'sounds', 'in', 'the', 'lateral', 'temporal', 'cortex', '.', 'This', 'study', 'will', 'also', 'examine', 'the', 'neural', 'encoding', 'of', 'speech', 'in', 'patients', 'who', 'are', 'monolingual', 'and', 'bilingual', 'in', 'Mandarin', ',', 'Spanish', ',', 'and', 'English', ',', 'the', 'most', 'common', 'spoken', 'languages', 'worldwide', ',', 'and', 'feature', 'important', 'contrastive', 'differences', 'of', 'pitch', ',', 'formant', ',', 'and', 'temporal', 'envelope', '.', 'A', 'cross', '-', 'linguistic', 'approach', 'is', 'critical', 'for', 'a', 'true', 'understanding', 'of', 'language', ',', 'while', 'also', 'striving', 'to', 'achieve', 'a', 'broader', 'approach', 'of', 'diversity', 'and', 'inclusion', 'in', 'neuroscience', 'of', 'language', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05014841,NCT05014841,"The Neural Coding of Speech Across Human Languages | The overall goal of this study is to reveal the fundamental neural mechanisms that underlie comprehension across human spoken languages. An understanding of how speech is coded in the brain has significant implications for the development of new diagnostic and rehabilitative strategies for language disorders (e.g. aphasia, dyslexia, autism, et alia). The basic mechanisms underlying comprehension of spoken language are unknown. Researchers are only beginning to understand how the human brain extracts the most fundamental linguistic elements (consonants and vowels) from a complex and highly variable acoustic signal. Traditional theories have posited a 'universal' phonetic inventory shared by all humans, but this has been challenged by other newer theories that each language has its own unique and specialized code. An investigation of the cortical representation of speech sounds across languages can likely shed light on this fundamental question. Previous research has implicated the superior temporal cortex in the processing of speech sounds. Most of this work has been entirely carried out in English. The recording of neural activity directly from the cortical surface from individuals with different language experience is a promising approach since it can provide both high spatial and temporal resolution. This study will examine the mechanisms of phonetic encoding, by utilizing neurophysiological recordings obtained during neurosurgical procedures. High-density electrode arrays, advanced signal processing, and direct electrocortical stimulation will be utilized to unravel both local and population encoding of speech sounds in the lateral temporal cortex. This study will also examine the neural encoding of speech in patients who are monolingual and bilingual in Mandarin, Spanish, and English, the most common spoken languages worldwide, and feature important contrastive differences of pitch, formant, and temporal envelope. A cross-linguistic approach is critical for a true understanding of language, while also striving to achieve a broader approach of diversity and inclusion in neuroscience of language.",[]
"['A', 'Randomized', 'Phase', 'III', 'Study', 'of', 'Sodium', 'Thiosulfate', 'for', 'the', 'Prevention', 'of', 'Cisplatin', '-', 'Induced', 'Ototoxicity', 'in', 'Children', '|', 'RATIONALE', ':', 'Sodium', 'thiosulfate', 'may', 'reduce', 'or', 'prevent', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'cancer', '.', 'It', 'is', 'not', 'yet', 'known', 'whether', 'sodium', 'thiosulfate', 'is', 'more', 'effective', 'than', 'no', 'additional', 'treatment', 'in', 'preventing', 'hearing', 'loss', '.', '\n\n', 'PURPOSE', ':', 'This', 'randomized', 'phase', 'III', 'trial', 'is', 'studying', 'sodium', 'thiosulfate', 'to', 'see', 'how', 'well', 'it', 'works', 'in', 'preventing', 'hearing', 'loss', 'in', 'young', 'patients', 'receiving', 'cisplatin', 'for', 'newly', 'diagnosed', 'germ', 'cell', 'tumor', ',', 'hepatoblastoma', ',', 'medulloblastoma', ',', 'neuroblastoma', ',', 'osteosarcoma', ',', 'or', 'other', 'malignancy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O']",NCT00716976,NCT00716976,"A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children | RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss.

PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.","[(32, 50, 'DRUG', 'Sodium Thiosulfate'), (73, 102, 'CONDITION', 'Cisplatin-Induced Ototoxicity'), (128, 146, 'DRUG', 'Sodium thiosulfate'), (169, 181, 'CONDITION', 'hearing loss'), (210, 219, 'CONDITION', 'cisplatin'), (224, 230, 'CONDITION', 'cancer'), (260, 278, 'DRUG', 'sodium thiosulfate'), (340, 352, 'CONDITION', 'hearing loss'), (408, 426, 'DRUG', 'sodium thiosulfate'), (466, 478, 'CONDITION', 'hearing loss'), (507, 516, 'CONDITION', 'cisplatin'), (537, 552, 'CONDITION', 'germ cell tumor'), (554, 568, 'CONDITION', 'hepatoblastoma'), (570, 585, 'CONDITION', 'medulloblastoma'), (587, 600, 'CONDITION', 'neuroblastoma'), (602, 614, 'CONDITION', 'osteosarcoma'), (625, 635, 'CONDITION', 'malignancy')]"
"['Short', '-', 'Term', 'Effects', 'of', 'Whole', '-', 'Body', 'Vibration', 'on', 'Upper', 'Extremity', 'Function', 'in', 'Subjects', 'With', 'Poststroke', 'Hemiplegia', '|', 'To', 'investigate', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'upper', 'limb', 'motor', 'function', 'in', 'hemiplegic', 'patients', 'with', 'subacute', 'stroke']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND']",NCT03963258,NCT03963258,Short-Term Effects of Whole-Body Vibration on Upper Extremity Function in Subjects With Poststroke Hemiplegia | To investigate the effect of whole body vibration on upper limb motor function in hemiplegic patients with subacute stroke,"[(22, 42, 'OTHER', 'Whole-Body Vibration'), (88, 109, 'CONDITION', 'Poststroke Hemiplegia'), (141, 161, 'OTHER', 'whole body vibration'), (194, 204, 'CONDITION', 'hemiplegic'), (219, 234, 'CONDITION', 'subacute stroke')]"
"['Mild', 'Cognitive', 'Impairment', 'and', 'Endurance', 'Exercise', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'overall', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'how', 'high', 'intensity', 'endurance', 'exercise', 'affects', 'both', 'cognition', 'and', 'the', 'signs', 'and', 'symptoms', 'of', 'Parkinson', ""'s"", 'disease', 'as', 'well', 'as', 'if', 'certain', 'brain', 'structures', 'and', 'functions', 'also', 'change', 'with', 'this', 'exercise', '.']","['B-COND', 'I-COND', 'I-COND', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O']",NCT03542474,NCT03542474,Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease | The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change with this exercise.,"[(0, 25, 'CONDITION', 'Mild Cognitive Impairment'), (30, 48, 'PHYSICAL', 'Endurance Exercise'), (52, 71, 'CONDITION', ""Parkinson's Disease""), (130, 163, 'PHYSICAL', 'high intensity endurance exercise'), (217, 236, 'CONDITION', ""Parkinson's disease""), (312, 320, 'PHYSICAL', 'exercise')]"
"['A', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', ',', 'Parallel', 'Group', 'Study', 'of', 'Sativex', 'in', 'the', 'Treatment', 'of', 'Subjects', 'With', 'Pain', 'Due', 'to', 'Diabetic', 'Neuropathy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'Sativex', '', 'compared', 'with', 'placebo', 'in', 'relieving', 'pain', 'due', 'to', 'Diabetic', 'Neuropathy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00710424,NCT00710424,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy | The purpose of this study is to evaluate the efficacy of Sativex compared with placebo in relieving pain due to Diabetic Neuropathy.","[(28, 35, 'CONTROL', 'Placebo'), (72, 79, 'DRUG', 'Sativex'), (114, 118, 'CONDITION', 'Pain'), (126, 145, 'CONDITION', 'Diabetic Neuropathy'), (205, 212, 'DRUG', 'Sativex'), (228, 235, 'CONTROL', 'placebo'), (261, 280, 'CONDITION', 'Diabetic Neuropathy')]"
"['Improved', 'Orthostatic', 'Tolerance', '=', 'Better', 'Cognitive', 'Function', 'in', 'Parkinson', ""'s"", 'Disease', ':', 'Does', 'a', 'Successful', 'Treatment', 'of', 'Orthostatic', 'Hypotension', 'Measurably', 'Enhance', 'Attention', 'and', 'Memory', 'Functions', 'in', 'Parkinson', ""'s"", 'Disease', '|', 'Study', 'on', 'orthostatic', 'Hypotension', 'in', 'Parkinson', ""'s"", 'disease']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT03900000,NCT03900000,Improved Orthostatic Tolerance = Better Cognitive Function in Parkinson's Disease: Does a Successful Treatment of Orthostatic Hypotension Measurably Enhance Attention and Memory Functions in Parkinson's Disease | Study on orthostatic Hypotension in Parkinson's disease,"[(62, 81, 'CONDITION', ""Parkinson's Disease""), (101, 137, 'OTHER', 'Treatment of Orthostatic Hypotension'), (191, 210, 'CONDITION', ""Parkinson's Disease""), (249, 268, 'CONDITION', ""Parkinson's disease"")]"
"['Use', 'of', 'BCAA', '-', 'rich', 'Protein', 'Supplements', 'for', 'Chronic', 'Stroke', 'Patients', 'to', 'Improve', 'the', 'Functional', 'Performance', '|', 'In', 'the', 'past', 'few', 'years', ',', 'Branched', 'Chain', 'Amino', 'Acid', '(', 'BCAA', ')', 'supplements', 'have', 'gradually', 'used', 'on', 'different', 'groups', '.', 'From', 'training', 'athletes', ',', 'maintaining', 'functions', 'of', 'healthy', 'elders', 'to', 'preventing', 'disabilities', 'of', 'people', 'that', 'ca', ""n't"", 'do', 'intense', 'exercises', '.', 'BCAAs', 'are', 'now', 'considered', 'to', 'be', 'able', 'to', 'prevent', 'muscle', 'atrophy', 'and', 'strength', 'loss', ',', 'also', 'possible', 'to', 'increase', 'strength', 'and', 'muscle', 'mass', 'if', 'combined', 'with', 'resistance', 'exercises', '.', 'Stroke', 'patients', 'have', 'difficulties', 'with', 'moving', ',', 'which', 'led', 'to', 'multiple', 'disabilities', ',', 'are', 'more', 'likely', 'to', 'have', 'sarcopenia', 'and', 'strength', 'loss', '.', 'Furthermore', ',', 'reducing', 'the', 'will', 'of', 'moving', 'or', 'walking', '.', 'Recently', ',', 'studies', 'showed', 'that', 'combined', 'BCAAs', 'with', 'resistance', 'exercises', 'can', 'effectively', 'increase', 'muscle', 'mass', ',', 'thus', 'commonly', 'used', 'on', 'training', 'athletes', '.', '\n\n', 'Although', 'aerobic', 'exercises', 'are', 'proven', 'to', 'be', 'more', 'likely', 'to', 'improve', 'walking', 'ability', 'of', 'chronic', 'stroke', 'patients', 'than', 'traditional', 'rehabilitation', ',', 'BCAAs', ""'"", 'effects', 'are', 'yet', 'to', 'be', 'proven', '.', 'Therefore', ',', 'the', 'aim', 'of', 'this', 'study', 'is', 'to', 'explore', 'if', 'BCAAs', 'combined', 'with', 'moderate', 'intensity', 'exercises', 'can', 'prevent', 'muscle', 'atrophy', ',', 'loss', 'of', 'strength', 'and', 'cardiopulmonary', 'function', '.', '\n\n', 'This', 'is', 'a', 'randomized', 'control', 'trial', '.', 'Participants', 'are', 'randomly', 'assigned', 'to', 'either', 'experiment', 'or', 'control', 'groups', '.', 'Both', 'group', 'received', 'aerobic', 'exercise', '(', '30', 'min', 'in', 'a', 'session', ',', '3', 'days', 'a', 'week', ',', 'and', 'for', '8', 'weeks', ')', '.', 'Experiment', 'group', 'received', 'BCAA', 'supplement', 'immediately', 'after', 'the', 'exercise', 'while', 'the', 'control', 'group', 'receive', 'sham', 'product', '(', 'vitamins', ')', '.', 'The', 'outcome', 'measurements', '(', 'including', 'muscle', 'mass', ',', 'functional', 'measures', ',', 'and', 'quality', 'of', 'life', ')', 'are', 'performed', 'before', '(', '0', '-', 'wk', ')', 'and', 'after', '(', '8', '-', 'wk', ')', 'the', 'interventions', ',', 'also', 'after', 'interventions', 'in', '3', 'months', 'and', '6', 'months', 'for', 'follow', 'up', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03244527,NCT03244527,"Use of BCAA-rich Protein Supplements for Chronic Stroke Patients to Improve the Functional Performance | In the past few years, Branched Chain Amino Acid (BCAA) supplements have gradually used on different groups. From training athletes, maintaining functions of healthy elders to preventing disabilities of people that can't do intense exercises. BCAAs are now considered to be able to prevent muscle atrophy and strength loss, also possible to increase strength and muscle mass if combined with resistance exercises. Stroke patients have difficulties with moving, which led to multiple disabilities, are more likely to have sarcopenia and strength loss. Furthermore, reducing the will of moving or walking. Recently, studies showed that combined BCAAs with resistance exercises can effectively increase muscle mass, thus commonly used on training athletes.

Although aerobic exercises are proven to be more likely to improve walking ability of chronic stroke patients than traditional rehabilitation, BCAAs' effects are yet to be proven. Therefore, the aim of this study is to explore if BCAAs combined with moderate intensity exercises can prevent muscle atrophy, loss of strength and cardiopulmonary function.

This is a randomized control trial. Participants are randomly assigned to either experiment or control groups. Both group received aerobic exercise (30 min in a session, 3 days a week, and for 8 weeks). Experiment group received BCAA supplement immediately after the exercise while the control group receive sham product (vitamins). The outcome measurements (including muscle mass, functional measures, and quality of life) are performed before (0-wk) and after (8-wk) the interventions, also after interventions in 3 months and 6 months for follow up.","[(7, 11, 'DRUG', 'BCAA'), (41, 55, 'CONDITION', 'Chronic Stroke'), (128, 153, 'DRUG', 'Branched Chain Amino Acid'), (155, 159, 'DRUG', 'BCAA'), (348, 353, 'DRUG', 'BCAAs'), (519, 525, 'CONDITION', 'Stroke'), (748, 753, 'DRUG', 'BCAAs'), (946, 960, 'CONDITION', 'chronic stroke'), (1003, 1008, 'DRUG', 'BCAAs'), (1090, 1095, 'DRUG', 'BCAAs'), (1110, 1138, 'PHYSICAL', 'moderate intensity exercises'), (1346, 1362, 'PHYSICAL', 'aerobic exercise'), (1444, 1448, 'DRUG', 'BCAA')]"
"['A', 'Phase', '2', 'Double', 'Blind', ',', 'Randomized', ',', 'Placebo', 'Controlled', 'Trial', 'inVEstigating', 'the', 'Effect', 'and', 'Safety', 'of', 'Several', 'Dosing', 'Regimens', 'of', 'LY3056480', 'in', 'Patients', 'With', 'STAble', 'Sensorineural', 'Hearing', 'Loss', '|', 'A', 'phase', '2', 'trial', 'with', 'LY3056480', 'in', 'patients', 'with', 'stable', 'SNHL']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT05061758,NCT05061758,"A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss | A phase 2 trial with LY3056480 in patients with stable SNHL","[(36, 43, 'CONTROL', 'Placebo'), (127, 136, 'DRUG', 'LY3056480'), (154, 187, 'CONDITION', 'STAble Sensorineural Hearing Loss'), (211, 220, 'DRUG', 'LY3056480'), (238, 249, 'CONDITION', 'stable SNHL')]"
"['Does', 'Early', 'Supination', 'and', 'External', 'Rotation', 'Repositioning', 'in', 'Children', 'With', 'Birth', 'Related', 'Brachial', 'Plexus', 'Injury', 'Have', 'Benefit', '?', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'the', 'Sup', '-', 'ER', 'Protocol', '.', '|', 'This', 'study', 'evaluates', 'the', 'ability', 'of', 'a', 'supination', 'and', 'external', 'rotation', 'protocol', 'to', 'improve', 'the', 'arm', 'function', 'and', 'anatomy', 'of', 'children', 'with', 'birth', 'related', 'brachial', 'plexus', 'injuries', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT01933438,NCT01933438,Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol. | This study evaluates the ability of a supination and external rotation protocol to improve the arm function and anatomy of children with birth related brachial plexus injuries.,"[(5, 21, 'OTHER', 'Early Supination'), (26, 57, 'OTHER', 'External Rotation Repositioning'), (75, 111, 'CONDITION', 'Birth Related Brachial Plexus Injury'), (220, 230, 'OTHER', 'supination'), (235, 252, 'OTHER', 'external rotation'), (319, 357, 'CONDITION', 'birth related brachial plexus injuries')]"
"['Optimizing', 'Transcranial', 'Direct', 'Current', 'Stimulation', 'for', 'Motor', 'Recovery', 'From', 'Severe', 'Post', '-', 'stroke', 'Hemiparesis', '|', 'Individuals', 'who', 'experienced', 'a', 'stroke', 'over', 'one', 'year', 'ago', 'will', 'be', 'randomly', 'assigned', 'to', 'receive', '1', 'of', '4', 'different', 'conditions', 'of', 'brain', 'stimulation', '.', 'All', 'individuals', 'will', 'receive', 'therapy', 'of', 'the', 'hand', 'and', 'arm', 'following', 'the', 'stimulation', '.', 'This', 'study', 'will', 'try', 'to', 'determine', 'which', 'brain', 'stimulation', 'condition', 'leads', 'to', 'the', 'greatest', 'improvement', 'in', 'hand', 'and', 'arm', 'function', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04574973,NCT04574973,Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis | Individuals who experienced a stroke over one year ago will be randomly assigned to receive 1 of 4 different conditions of brain stimulation. All individuals will receive therapy of the hand and arm following the stimulation. This study will try to determine which brain stimulation condition leads to the greatest improvement in hand and arm function.,"[(11, 50, 'OTHER', 'Transcranial Direct Current Stimulation'), (75, 105, 'CONDITION', 'Severe Post-stroke Hemiparesis'), (138, 144, 'CONDITION', 'stroke'), (231, 248, 'OTHER', 'brain stimulation'), (373, 390, 'OTHER', 'brain stimulation')]"
"['Neuromuscular', 'and', 'Biomechanical', 'Control', 'of', 'Lower', 'Limb', 'Loading', 'in', 'Individuals', 'With', 'Chronic', 'Stroke', '|', 'Stroke', 'is', 'the', 'leading', 'cause', 'of', 'long', '-', 'term', 'disability', 'in', 'the', 'U.S.', 'Individuals', 'with', 'hemiparesis', 'due', 'to', 'stroke', 'often', 'have', 'difficulty', 'bearing', 'weight', 'on', 'their', 'legs', 'and', 'transferring', 'weight', 'from', 'one', 'leg', 'to', 'the', 'other', '.', 'The', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', 'is', 'important', 'during', 'functional', 'movements', 'such', 'as', 'rising', 'from', 'a', 'chair', ',', 'standing', 'and', 'walking', '.', 'Diminished', 'weight', 'transfer', 'contributes', 'to', 'asymmetries', 'during', 'walking', 'which', 'commonly', 'leads', 'to', 'greater', 'energy', 'expenditure', '.', 'Moreover', ',', 'deficits', 'in', 'bearing', 'weight', 'on', 'the', 'paretic', 'leg', 'contribute', 'to', 'lateral', 'instability', 'and', 'are', 'associated', 'with', 'decreased', 'walking', 'speed', 'and', 'increased', 'risk', 'of', 'falling', 'in', 'individuals', 'post', '-', 'stroke', '.', 'These', 'functional', 'limitations', 'affect', 'community', 'participation', 'and', 'life', 'quality', '.', 'Thus', ',', 'restoring', 'the', 'ability', 'to', 'bear', 'weight', 'on', 'the', 'legs', ',', 'i.e.', ',', 'limb', 'loading', ',', 'is', 'a', 'critical', 'goal', 'for', 'rehabilitation', 'post', '-', 'stroke', '.', 'The', 'purpose', 'of', 'this', 'research', 'is', 'to', 'identify', 'the', 'impairments', 'in', 'neuromechanical', 'mechanisms', 'of', 'limb', 'loading', 'and', 'determine', 'whether', 'limb', 'loading', 'responses', 'can', 'be', 'retrained', 'by', 'induced', 'forced', 'limb', 'loading', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O']",NCT03694028,NCT03694028,"Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke | Stroke is the leading cause of long-term disability in the U.S. Individuals with hemiparesis due to stroke often have difficulty bearing weight on their legs and transferring weight from one leg to the other. The ability to bear weight on the legs is important during functional movements such as rising from a chair, standing and walking. Diminished weight transfer contributes to asymmetries during walking which commonly leads to greater energy expenditure. Moreover, deficits in bearing weight on the paretic leg contribute to lateral instability and are associated with decreased walking speed and increased risk of falling in individuals post-stroke. These functional limitations affect community participation and life quality. Thus, restoring the ability to bear weight on the legs, i.e., limb loading, is a critical goal for rehabilitation post-stroke. The purpose of this research is to identify the impairments in neuromechanical mechanisms of limb loading and determine whether limb loading responses can be retrained by induced forced limb loading.","[(82, 96, 'CONDITION', 'Chronic Stroke'), (99, 105, 'CONDITION', 'Stroke'), (180, 191, 'CONDITION', 'hemiparesis'), (199, 205, 'CONDITION', 'stroke'), (743, 754, 'CONDITION', 'post-stroke'), (948, 959, 'CONDITION', 'post-stroke'), (1132, 1159, 'PHYSICAL', 'induced forced limb loading')]"
"['A', 'Prospective', ',', 'Randomized', ',', 'Controlled', 'Multicenter', 'Trial', 'of', 'Probiotics', 'and', 'Prebiotics', 'to', 'Improve', 'the', 'Efficacy', 'of', 'Antipsychotics', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'In', 'this', 'study', ',', 'investigators', 'will', 'evaluate', 'the', 'efficacy', 'and', 'related', 'mechanism', 'of', 'probiotics', 'and', 'prebiotics', 'as', 'an', 'add', '-', 'on', 'treatment', 'in', 'improving', 'the', 'antipsychotic', 'induced', 'psychotic', 'syndrome', ',', 'the', 'cognitive', 'impairment', ',', 'gastrointestinal', 'function', ',', 'and', 'metabolic', 'disorders', 'in', 'schizophrenia', 'patients', ',', 'through', 'genotype', 'identification', ',', 'psychopathology', ',', 'neuropsychology', ',', 'biochemical', 'evaluation', 'and', 'other', 'methods', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04291469,NCT04291469,"A Prospective, Randomized, Controlled Multicenter Trial of Probiotics and Prebiotics to Improve the Efficacy of Antipsychotics in Patients With Schizophrenia | In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment, gastrointestinal function, and metabolic disorders in schizophrenia patients, through genotype identification, psychopathology, neuropsychology, biochemical evaluation and other methods.","[(59, 69, 'OTHER', 'Probiotics'), (74, 84, 'OTHER', 'Prebiotics'), (144, 157, 'CONDITION', 'Schizophrenia'), (241, 251, 'OTHER', 'probiotics'), (256, 266, 'OTHER', 'prebiotics'), (307, 347, 'CONDITION', 'antipsychotic induced psychotic syndrome'), (429, 442, 'CONDITION', 'schizophrenia')]"
"['Feasibility', 'Study', 'of', 'Human', 'Umbilical', 'Cord', 'Tissue', '-', 'Derived', 'Mesenchymal', 'Stem', 'Cells', 'in', 'Patients', 'With', 'Multiple', 'Sclerosis', '|', 'Allogeneic', 'human', 'umbilical', 'cord', 'tissue', '-', 'derived', 'stem', 'cells', 'injected', 'intravenously', '(', 'IV', ')', 'once', 'per', 'day', 'for', '7', 'days', 'is', 'a', 'safe', 'and', 'will', 'induce', 'a', 'therapeutic', 'effect', 'in', 'multiple', 'sclerosis', '(', 'MS', ')', 'patients', '.']","['O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT02034188,NCT02034188,Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.,"[(21, 79, 'SURGICAL', 'Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells'), (97, 115, 'CONDITION', 'Multiple Sclerosis'), (118, 175, 'SURGICAL', 'Allogeneic human umbilical cord tissue-derived stem cells'), (278, 296, 'CONDITION', 'multiple sclerosis'), (298, 300, 'CONDITION', 'MS')]"
"['Influence', 'of', 'Apelin', 'Levels', 'on', 'Postoperative', 'Cognitive', 'Disorders', 'After', 'Orthopedic', 'Surgery', 'in', 'Elderlies', '|', 'No', 'successful', 'strategy', 'is', 'proposed', 'to', 'patients', 'submitted', 'to', 'important', 'surgery', 'to', 'reduce', 'the', 'incidence', 'of', 'postoperative', 'cognitive', 'disorders', '(', 'POCD', ')', 'onset', '.', 'This', 'project', 'propose', 'to', 'measure', 'plasma', 'levels', 'of', 'apelin', 'in', 'wide', 'population', 'submitted', 'to', 'orthopedic', 'surgery', '.', 'Apelin', 'could', 'be', 'involved', 'in', 'anti', '-', 'inflammatory', 'processes', '.', 'Apelin', 'levels', 'before', 'and', 'after', 'surgery', 'correlated', 'to', 'postoperative', 'cognitive', 'disorders', 'symptom', 'measured', 'by', 'PET', '-', 'Scan', 'could', 'be', 'an', 'important', 'predictive', 'or', 'diagnostic', 'marker', 'to', 'adapt', 'therapeutic', 'strategy', 'to', 'fight', 'against', 'postoperative', 'cognitive', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT02574234,NCT02574234,Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies | No successful strategy is proposed to patients submitted to important surgery to reduce the incidence of postoperative cognitive disorders (POCD) onset. This project propose to measure plasma levels of apelin in wide population submitted to orthopedic surgery. Apelin could be involved in anti-inflammatory processes. Apelin levels before and after surgery correlated to postoperative cognitive disorders symptom measured by PET-Scan could be an important predictive or diagnostic marker to adapt therapeutic strategy to fight against postoperative cognitive disorders.,"[(30, 63, 'CONDITION', 'Postoperative Cognitive Disorders'), (70, 88, 'CONDITION', 'Orthopedic Surgery'), (209, 242, 'CONDITION', 'postoperative cognitive disorders'), (244, 248, 'CONDITION', 'POCD'), (345, 363, 'CONDITION', 'orthopedic surgery'), (475, 508, 'CONDITION', 'postoperative cognitive disorders'), (639, 672, 'CONDITION', 'postoperative cognitive disorders')]"
"['A', 'Study', 'to', 'Investigate', 'the', 'Genetic', 'Variation', 'of', 'Dopamine', 'Pathway', 'Associated', 'With', 'the', 'Observed', 'Effects', 'of', 'a', 'New', 'Treatment', 'in', 'Former', 'Studies', 'in', 'Patients', 'With', 'Chronic', 'Pain', '|', 'Patients', 'having', 'completed', 'former', 'trials', 'T1001', '-', '01', 'or', 'T1001', '-', '02', 'will', 'undergo', 'one', 'blood', 'sampling', 'for', 'genotyping', 'purposes', '.', 'In', 'addition', 'they', 'will', 'compete', 'the', 'personality', 'questionnaires', 'they', 'had', 'completed', 'in', 'the', 'former', 'trial', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02989792,NCT02989792,A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain | Patients having completed former trials T1001-01 or T1001-02 will undergo one blood sampling for genotyping purposes. In addition they will compete the personality questionnaires they had completed in the former trial.,"[(156, 168, 'CONDITION', 'Chronic Pain')]"
"['Spectral', 'Domain', 'Optical', 'Coherence', 'Tomography', 'Imaging', 'of', 'the', 'Eyes', 'of', 'Neonates', '|', 'Brief', 'Summary', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'better', 'characterize', 'the', 'retina', 'and', 'optic', 'nerve', 'in', 'newborns', 'using', 'spectral', 'domain', 'optical', 'coherence', 'tomography', '(', 's', '-', 'oct', ')', '.', 'This', 'new', 'technology', 'provides', 'a', 'very', 'detailed', 'cross', '-', 'section', 'picture', 'of', 'the', 'cellular', 'layers', 'in', 'the', 'retina', 'and', 'a', '3', '-', 'dimensional', 'picture', 'of', 'the', 'optic', 'nerve', 'head', 'and', 'the', 'fovea', '(', 'the', 'center', 'of', 'the', 'retina', 'that', 'provides', 'the', 'most', 'accurate', 'vision', ')', '.', 'These', 'images', 'have', 'been', 'used', 'by', 'doctors', 'for', 'more', 'than', '5', 'years', 'to', 'help', 'diagnose', 'and', 'treat', 'adults', 'with', 'eye', 'diseases', ',', 'such', 'as', 'macular', 'degeneration', ',', 'diabetic', 'retinopathy', ',', 'retinal', 'detachments', ',', 'and', 'melanoma', '.', 'But', ',', 'it', 'has', 'never', 'been', 'studied', 'in', 'newborns', '.', 'In', 'newborns', ',', 'it', 'would', 'potentially', 'help', 'in', 'the', 'diagnoses', 'of', 'glaucoma', ',', 'optic', 'nerve', 'hypoplasia', ',', 'foveal', 'hypoplasia', ',', 'and', 'colobomata', 'among', 'many', 'other', 'disorders', '.', 'Prior', 'to', 'diagnosing', 'disorders', ',', 'it', 'is', 'necessary', 'to', 'establish', 'normal', 'values', '.', 'It', 'is', 'the', 'purpose', 'of', 'this', 'investigation', 'to', 'study', 'the', 'retina', 'and', 'optic', 'nerves', 'in', 'neonates', 'to', 'establish', 'normal', 'values', '.', '\n\n', 'After', 'a', 'parent', 'of', 'a', 'normal', 'newborn', 'provides', 'a', 'written', 'consent', ',', 'the', 'baby', 'will', 'be', 'taken', 'to', 'the', 'Eye', 'Clinic', 'where', 'the', 'instrument', 'is', 'located', '.', 'The', 'baby', 'will', 'be', 'swaddled', 'in', 'one', 'or', 'more', 'blankets', 'as', 'needed', '.', 'The', 'infants', 'will', 'be', 'held', 'in', 'front', 'of', 'the', 'instrument', 'by', 'a', 'nurse', '.', 'The', 'technician', 'will', 'move', 'the', 'lens', 'of', 'the', 'instrument', 'to', 'about', '2', 'to', '4', 'inches', 'from', 'the', 'baby', ""'s"", 'eye', '.', 'The', 'mild', 'light', 'from', 'the', 'instrument', 'will', 'then', 'enter', 'the', 'eye', 'for', 'a', 'few', 'seconds', 'to', 'obtain', 'the', 'desired', 'image', '.', 'The', 'image', 'can', 'be', 'captured', 'through', 'an', 'immobile', 'eye', 'within', '5', 'seconds', '.', 'If', 'the', 'baby', 'is', 'fussy', ',', 'he', 'or', 'she', 'may', 'be', 'given', 'a', 'few', 'drops', 'of', 'a', 'sugar', '(', 'sucrose', ')', 'solution', 'on', 'a', 'pacifier', 'for', 'calming', '.', 'Although', 'the', 'images', 'can', 'usually', 'be', 'secured', 'through', 'a', 'normal', 'pupil', ',', 'if', 'the', 'pupil', 'is', 'found', 'to', 'be', 'too', 'small', ',', 'two', 'drops', 'of', 'Cyclomydril', 'will', 'be', 'placed', 'on', 'the', 'eye', 'for', 'dilation', '.', 'This', 'is', 'the', 'eye', 'drop', 'used', 'everyday', 'in', 'the', 'Eye', 'Clinic', 'and', 'nursery', 'to', 'dilate', 'the', 'pupils', 'of', 'babies', '.', 'The', 'dilation', 'will', 'last', 'for', 'about', '6', 'to', '10', 'hours', '.', 'After', 'the', 'test', ',', 'the', 'baby', 'will', 'return', 'to', 'the', 'nursery', 'or', 'be', 'discharged', 'home', 'as', 'intended', 'by', 'the', 'Neonatology', 'Division', '.', '\n\n', 'There', 'is', 'minimal', 'risk', 'associated', 'with', 'this', 'investigation', '.', 'The', 'instrument', 'is', 'non', '-', 'invasive', 'and', 'does', 'not', 'touch', 'the', 'eye', '.', 'The', 'babies', 'will', 'be', 'swaddled', 'and', 'held', 'by', 'a', 'nurse', 'to', 'prevent', 'any', 'contact', 'with', 'the', 'machine', '.', 'The', 'eye', 'drop', 'to', 'be', 'used', 'if', 'needed', 'for', 'dilation', 'has', 'been', 'used', 'on', 'babies', 'at', 'Harbor', 'for', 'about', '30', 'years', '.', 'It', 'has', 'been', 'found', 'to', 'very', 'safe', '.', 'The', 'fact', 'that', 'we', 'will', 'study', 'only', 'term', '(', 'not', 'premature', 'babies', ')', 'and', 'will', 'apply', 'only', 'two', 'drops', 'if', 'needed', 'should', 'minimize', 'any', 'risk', 'from', 'the', 'eye', 'drop', '.', '\n\n', 'An', 'ethical', 'issue', 'to', 'consider', 'is', 'that', 'while', 'the', 'study', 'will', 'provide', 'important', 'information', 'that', 'will', 'undoubtedly', 'help', 'babies', 'in', 'the', 'future', ',', 'it', 'will', 'probably', 'not', 'benefit', 'the', 'baby', 'being', 'studied', '.', 'However', ',', 'if', 'the', 'baby', 'has', 'an', 'undetected', 'retinal', 'or', 'optic', 'nerve', 'problem', ',', 'the', 'study', 'may', 'reveal', 'it', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01404247,NCT01404247,"Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates | Brief Summary

The purpose of this study is to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct). This new technology provides a very detailed cross-section picture of the cellular layers in the retina and a 3-dimensional picture of the optic nerve head and the fovea (the center of the retina that provides the most accurate vision). These images have been used by doctors for more than 5 years to help diagnose and treat adults with eye diseases, such as macular degeneration, diabetic retinopathy, retinal detachments, and melanoma. But, it has never been studied in newborns. In newborns, it would potentially help in the diagnoses of glaucoma, optic nerve hypoplasia, foveal hypoplasia, and colobomata among many other disorders. Prior to diagnosing disorders, it is necessary to establish normal values. It is the purpose of this investigation to study the retina and optic nerves in neonates to establish normal values.

After a parent of a normal newborn provides a written consent, the baby will be taken to the Eye Clinic where the instrument is located. The baby will be swaddled in one or more blankets as needed. The infants will be held in front of the instrument by a nurse. The technician will move the lens of the instrument to about 2 to 4 inches from the baby's eye. The mild light from the instrument will then enter the eye for a few seconds to obtain the desired image. The image can be captured through an immobile eye within 5 seconds. If the baby is fussy, he or she may be given a few drops of a sugar (sucrose) solution on a pacifier for calming. Although the images can usually be secured through a normal pupil, if the pupil is found to be too small, two drops of Cyclomydril will be placed on the eye for dilation. This is the eye drop used everyday in the Eye Clinic and nursery to dilate the pupils of babies. The dilation will last for about 6 to 10 hours. After the test, the baby will return to the nursery or be discharged home as intended by the Neonatology Division.

There is minimal risk associated with this investigation. The instrument is non-invasive and does not touch the eye. The babies will be swaddled and held by a nurse to prevent any contact with the machine. The eye drop to be used if needed for dilation has been used on babies at Harbor for about 30 years. It has been found to very safe. The fact that we will study only term (not premature babies) and will apply only two drops if needed should minimize any risk from the eye drop.

An ethical issue to consider is that while the study will provide important information that will undoubtedly help babies in the future, it will probably not benefit the baby being studied. However, if the baby has an undetected retinal or optic nerve problem, the study may reveal it.",[]
"['Augmenting', 'Language', 'Therapy', 'for', 'Aphasia', ':', 'A', 'Randomized', 'Double', '-', 'Blind', 'Placebo', '-', 'Controlled', 'Trial', 'of', 'Levodopa', 'in', 'Combination', 'With', 'Speech', '-', 'Language', 'Therapy', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'medication', 'levodopa', ',', 'in', 'combination', 'with', 'speech', '-', 'language', 'treatment', ',', 'on', 'the', 'language', 'outcome', 'of', 'study', 'subjects', 'with', 'nonfluent', 'aphasia', '(', 'i.e.', 'difficulty', 'with', 'the', 'comprehension', 'and', 'expression', 'of', 'spoken', 'and', 'written', 'language', ')', 'following', 'a', 'stroke', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01429077,NCT01429077,"Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy | The purpose of this study is to evaluate the effectiveness of the medication levodopa, in combination with speech-language treatment, on the language outcome of study subjects with nonfluent aphasia (i.e. difficulty with the comprehension and expression of spoken and written language) following a stroke.","[(11, 27, 'OTHER', 'Language Therapy'), (32, 39, 'CONDITION', 'Aphasia'), (67, 74, 'CONTROL', 'Placebo'), (95, 103, 'DRUG', 'Levodopa'), (124, 147, 'OTHER', 'Speech-Language Therapy'), (227, 235, 'DRUG', 'levodopa'), (257, 283, 'OTHER', 'speech-language treatment,'), (331, 348, 'CONDITION', 'nonfluent aphasia'), (448, 454, 'CONDITION', 'stroke')]"
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', ',', 'Pilot', 'Analgesic', 'Efficacy', 'and', 'Safety', 'Study', 'of', 'T-62', 'in', 'Subjects', 'With', 'Postherpetic', 'Neuralgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'T-62', 'in', 'subjects', 'with', 'postherpetic', 'neuralgia', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00809679,NCT00809679,"A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia | The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.","[(116, 120, 'DRUG', 'T-62'), (138, 160, 'CONDITION', 'Postherpetic Neuralgia'), (231, 235, 'DRUG', 'T-62'), (253, 275, 'CONDITION', 'postherpetic neuralgia')]"
"['Effectiveness', 'Specific', 'Manual', 'Therapy', 'in', 'a', 'Multimodal', 'Physical', 'Therapy', 'Treatment', 'in', 'Patients', 'With', 'Tinnitus', 'and', 'Temporomandibular', 'Joint', 'Disorder', '.', '|', 'Tinnitus', 'is', 'one', 'of', 'the', 'most', 'prevalent', 'symptoms', 'that', 'causes', 'more', 'disability', 'in', 'patients', 'with', 'temporomandibular', 'disorder', '(', 'TMD', ')', '.', 'The', 'present', 'study', 'postulates', 'a', 'possible', 'link', 'between', 'temporomandibular', 'joint', '(', 'TMJ', ')', 'and', 'inner', 'ear', 'based', 'on', 'their', 'anatomical', ',', 'biomechanical', 'and', 'physiological', 'relationship', ',', 'proposing', 'a', 'physiotherapy', 'treatment', 'for', 'the', 'temporomandibular', 'joint', 'to', 'improve', 'tinnitus', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'adding', 'specific', 'manual', 'therapy', 'to', 'a', 'multimodal', 'physiotherapy', 'treatment', 'in', 'patients', 'with', 'tinnitus', 'and', 'temporomandibular', 'disorder', '.']","['O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT02850055,NCT02850055,"Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder. | Tinnitus is one of the most prevalent symptoms that causes more disability in patients with temporomandibular disorder (TMD). The present study postulates a possible link between temporomandibular joint (TMJ) and inner ear based on their anatomical, biomechanical and physiological relationship, proposing a physiotherapy treatment for the temporomandibular joint to improve tinnitus. The aim of the study is to evaluate the effectiveness of adding specific manual therapy to a multimodal physiotherapy treatment in patients with tinnitus and temporomandibular disorder.","[(14, 37, 'OTHER', 'Specific Manual Therapy'), (43, 80, 'OTHER', 'Multimodal Physical Therapy Treatment'), (98, 106, 'CONDITION', 'Tinnitus'), (111, 143, 'CONDITION', 'Temporomandibular Joint Disorder'), (147, 155, 'CONDITION', 'Tinnitus'), (239, 265, 'CONDITION', 'temporomandibular disorder'), (267, 270, 'CONDITION', 'TMD'), (455, 510, 'OTHER', 'physiotherapy treatment for the temporomandibular joint'), (522, 530, 'CONDITION', 'tinnitus'), (596, 619, 'OTHER', 'specific manual therapy'), (625, 659, 'OTHER', 'multimodal physiotherapy treatment'), (677, 685, 'CONDITION', 'tinnitus'), (690, 716, 'CONDITION', 'temporomandibular disorder')]"
"['Effectiveness', 'and', 'Cost', '-', 'effectiveness', 'of', 'Ozone', 'Therapy', 'in', 'Patients', 'With', 'Pain', 'Secondary', 'to', 'Chemotherapy', '-', 'induced', 'Peripheral', 'Neuropathy', '.', 'Randomized', ',', 'Triple', '-', 'blind', 'Clinical', 'Trial', '(', 'O3NPIQ', ')', '|', 'The', 'main', 'objective', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'and', 'cost', '-', 'effectiveness', 'of', 'adding', 'ozone', 'therapy', 'to', 'the', 'clinical', 'management', 'of', 'patients', 'with', 'pain', 'secondary', 'to', 'chemotherapy', '-', 'induced', 'peripheral', 'neuropathy']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND']",NCT04299893,NCT04299893,"Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ) | The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy","[(40, 45, 'DRUG', 'Ozone'), (71, 75, 'CONDITION', 'Pain'), (89, 131, 'CONDITION', 'Chemotherapy-induced Peripheral Neuropathy'), (292, 297, 'DRUG', 'ozone'), (350, 354, 'CONDITION', 'pain'), (368, 410, 'CONDITION', 'chemotherapy-induced peripheral neuropathy')]"
"['Early', 'and', 'Late', 'Postoperative', 'Analgesia', 'and', 'Recovery', 'Effects', 'of', 'Programmed', 'Intermittent', 'Bolus', 'Infusion', 'of', 'Thoracic', 'Paravertebral', 'Block', 'for', 'Hepatectomy', ':', 'A', 'Prospective', ',', 'Randomized', ',', 'Double', '-', 'blinded', ',', 'Controlled', 'Study', '|', 'Hepatectomy', 'induces', 'moderate', 'to', 'severe', 'postoperative', 'pain', '.', 'Patient', '-', 'controlled', 'intravenous', 'analgesia', 'has', 'been', 'used', 'in', 'many', 'medical', 'centers', 'for', 'post', '-', 'hepatectomy', 'analgesia', ',', 'but', 'the', 'effects', 'are', 'limited', 'and', 'often', 'cause', 'undesirable', 'adverse', 'effects', '.', '\n\n', 'Regional', 'Block', 'has', 'been', 'used', 'for', 'postoperative', 'analgesia', 'in', 'many', 'surgeries', '.', 'Some', 'studies', 'suggest', 'that', 'regional', 'analgesia', 'has', 'an', 'opioid', '-', 'sparing', 'effect', 'and', 'can', 'reduce', 'the', 'incidence', 'of', 'chronic', 'pain', '.', 'Also', ',', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'is', 'better', 'than', 'continuous', 'infusion', ',', 'with', 'less', 'analgesic', 'consumption', 'and', 'fewer', 'adverse', 'effects', '.', '\n\n', 'Studies', 'on', 'the', 'early', 'and', 'late', 'postoperative', 'analgesia', 'and', 'recovery', 'effects', 'of', 'paravertebral', 'block', 'for', 'open', 'hepatectomy', 'are', 'scarce', '.', 'Therefore', ',', 'the', 'investigators', 'aim', 'to', 'conduct', 'a', 'prospective', ',', 'randomized', ',', 'subject', 'and', 'assessor', '-', 'blinded', ',', 'parallel', '-', 'group', ',', 'placebo', '-', 'controlled', 'study', 'to', 'test', 'the', 'hypothesis', 'that', 'the', 'programmed', 'intermittent', 'bolus', 'infusion', 'of', 'right', 'thoracic', 'paravertebral', 'block', 'reduces', 'postoperative', 'intravenous', 'analgesic', 'use', 'and', 'pain', 'scores', 'and', 'improved', 'patients', ""'"", 'satisfaction', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04304274,NCT04304274,"Early and Late Postoperative Analgesia and Recovery Effects of Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block for Hepatectomy: A Prospective, Randomized, Double-blinded, Controlled Study | Hepatectomy induces moderate to severe postoperative pain. Patient-controlled intravenous analgesia has been used in many medical centers for post-hepatectomy analgesia, but the effects are limited and often cause undesirable adverse effects.

Regional Block has been used for postoperative analgesia in many surgeries. Some studies suggest that regional analgesia has an opioid-sparing effect and can reduce the incidence of chronic pain. Also, the programmed intermittent bolus infusion is better than continuous infusion, with less analgesic consumption and fewer adverse effects.

Studies on the early and late postoperative analgesia and recovery effects of paravertebral block for open hepatectomy are scarce. Therefore, the investigators aim to conduct a prospective, randomized, subject and assessor-blinded, parallel-group, placebo-controlled study to test the hypothesis that the programmed intermittent bolus infusion of right thoracic paravertebral block reduces postoperative intravenous analgesic use and pain scores and improved patients' satisfaction.","[(63, 133, 'OTHER', 'Programmed Intermittent Bolus Infusion of Thoracic Paravertebral Block'), (138, 149, 'CONDITION', 'Hepatectomy'), (213, 224, 'CONDITION', 'Hepatectomy'), (266, 270, 'CONDITION', 'pain'), (457, 471, 'OTHER', 'Regional Block'), (639, 651, 'CONDITION', 'chronic pain'), (663, 701, 'OTHER', 'programmed intermittent bolus infusion'), (876, 895, 'OTHER', 'paravertebral block'), (905, 916, 'CONDITION', 'hepatectomy'), (1046, 1053, 'CONTROL', 'placebo'), (1103, 1179, 'OTHER', 'programmed intermittent bolus infusion of right thoracic paravertebral block'), (1232, 1236, 'CONDITION', 'pain')]"
"['A', 'Comparison', 'of', 'the', 'Incidence', 'of', 'Symptomatic', 'Urinary', 'Tract', 'Infections', 'in', 'Children', 'With', 'Spina', 'Bifida', 'Using', 'Hydrophilic', 'or', 'Non', '-', 'hydrophilic', 'Polyvinyl', 'Chloride', 'Catheters', 'for', 'Clean', 'Intermittent', 'Catheterization', ':', 'a', 'Randomized', 'Cross', 'Over', 'Trial', '|', 'The', 'primary', 'aim', 'of', 'this', 'study', 'was', 'to', 'determine', 'if', 'using', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'would', 'reduce', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', '(', 'UTI)in', 'children', 'with', 'spina', 'bifida', 'who', 'perform', 'clean', 'intermittent', 'catheterization', 'for', 'bladder', 'management', '.', 'The', 'hypothesis', 'was', 'that', 'the', 'incidence', 'of', 'symptomatic', 'urinary', 'tract', 'infections', 'would', 'be', 'significantly', 'reduced', '(', 'by', '25', '%', ')', 'in', 'users', 'of', 'the', 'SpeediCath', 'hydrophilic', 'catheter', 'when', 'compared', 'to', 'users', 'of', 'a', 'reused', 'polyvinyl', 'chloride', '(', 'PVC', ')', 'catheter', '.', 'Subjects', 'were', 'randomly', 'assigned', 'to', 'either', 'starting', 'the', 'study', 'with', 'PVC', 'catheter', 'for', '6', 'months', 'followed', 'by', 'the', 'hydrophilic', 'catheter', 'for', '6', 'months', 'or', 'visa', 'versa', '.', 'Each', 'subject', 'kept', 'a', 'weekly', 'diary', 'recording', 'urinary', 'tract', 'infections', 'symptoms', ',', 'hematuria', 'determined', 'by', 'urine', 'dipstick', ',', 'physician', 'visits', ',', 'days', 'of', 'missed', 'school', 'and', 'other', 'activities', '.', 'At', 'the', 'end', 'of', 'each', '6', 'months', 'subjects', 'completed', 'a', 'questionnaire', 'recording', 'their', 'comfort', 'and', 'satisfaction', 'in', 'using', 'the', 'PVC', 'or', 'hydrophilic', 'coated', 'catheter', '.', '70', 'subjects', 'were', 'randomized', 'and', '46', 'had', 'complete', 'data', '.', 'There', 'were', 'no', 'differences', 'in', 'febrile', 'UTI', ',', 'antibiotic', 'use', ',', 'healthcare', 'visits', 'or', 'school', 'days', 'missed', '.', 'The', 'incidence', 'of', 'self', 'reported', 'UTI', 'was', 'lower', 'in', 'the', 'PVC', 'group', 'than', 'the', 'hydrophilic', 'group', '.', '40', '%', 'of', 'subjects', 'indicated', 'that', 'the', 'hydrophilic', 'coated', 'catheter', 'was', 'slippery', 'and', 'difficult', 'to', 'handle', 'compared', 'to', '10', '%', 'for', 'the', 'PVC', 'catheter', '.', 'However', 'overall', 'satisfaction', 'was', 'no', 'different', 'between', 'products', '.', 'The', 'study', 'results', 'are', 'consistent', 'with', 'the', 'current', 'Cochrane', 'Review', 'that', 'there', 'is', 'a', 'lack', 'of', 'evidence', 'to', 'state', 'that', 'the', 'incidence', 'of', 'UTI', 'is', 'affected', 'by', 'multiuse', 'or', 'hydrophilic', 'catheter', 'use', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O']",NCT01263392,NCT01263392,"A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial | The primary aim of this study was to determine if using the SpeediCath hydrophilic catheter would reduce the incidence of symptomatic urinary tract infections (UTI)in children with spina bifida who perform clean intermittent catheterization for bladder management. The hypothesis was that the incidence of symptomatic urinary tract infections would be significantly reduced (by 25%) in users of the SpeediCath hydrophilic catheter when compared to users of a reused polyvinyl chloride (PVC) catheter. Subjects were randomly assigned to either starting the study with PVC catheter for 6 months followed by the hydrophilic catheter for 6 months or visa versa. Each subject kept a weekly diary recording urinary tract infections symptoms, hematuria determined by urine dipstick, physician visits, days of missed school and other activities. At the end of each 6 months subjects completed a questionnaire recording their comfort and satisfaction in using the PVC or hydrophilic coated catheter. 70 subjects were randomized and 46 had complete data. There were no differences in febrile UTI, antibiotic use, healthcare visits or school days missed. The incidence of self reported UTI was lower in the PVC group than the hydrophilic group. 40% of subjects indicated that the hydrophilic coated catheter was slippery and difficult to handle compared to 10% for the PVC catheter. However overall satisfaction was no different between products. The study results are consistent with the current Cochrane Review that there is a lack of evidence to state that the incidence of UTI is affected by multiuse or hydrophilic catheter use.","[(33, 69, 'CONDITION', 'Symptomatic Urinary Tract Infections'), (87, 99, 'CONDITION', 'Spina Bifida'), (106, 165, 'OTHER', 'Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters'), (170, 204, 'CONDITION', 'Clean Intermittent Catheterization'), (298, 329, 'OTHER', 'SpeediCath hydrophilic catheter'), (360, 396, 'CONDITION', 'symptomatic urinary tract infections'), (419, 431, 'CONDITION', 'spina bifida'), (544, 580, 'CONDITION', 'symptomatic urinary tract infections'), (637, 668, 'OTHER', 'SpeediCath hydrophilic catheter'), (704, 737, 'CONTROL', 'polyvinyl chloride (PVC) catheter'), (805, 817, 'CONTROL', 'PVC catheter'), (847, 867, 'OTHER', 'hydrophilic catheter'), (1193, 1227, 'OTHER', 'PVC or hydrophilic coated catheter'), (1320, 1323, 'CONDITION', 'UTI'), (1413, 1416, 'CONDITION', 'UTI'), (1507, 1534, 'OTHER', 'hydrophilic coated catheter'), (1596, 1608, 'CONTROL', 'PVC catheter'), (1804, 1807, 'CONDITION', 'UTI'), (1823, 1859, 'OTHER', 'multiuse or hydrophilic catheter use')]"
"['MIND', ':', 'An', 'RCT', 'of', 'Care', 'Coordination', 'for', 'Community', '-', 'living', 'Person', 'With', 'Dementia', '|', 'This', 'is', 'a', '24', '-', 'month', ',', 'prospective', ',', 'single-', 'blind', ',', 'randomized', 'controlled', 'trial', 'evaluating', 'the', 'MIND', 'at', 'Home', '-', 'streamlined', 'dementia', 'care', 'coordination', 'intervention', '(', 'called', 'MIND', '-', 'S', ')', 'in', 'a', 'cohort', 'of', '300', 'community', '-', 'living', 'persons', 'with', 'dementia', 'and', 'their', 'family', 'caregivers', 'in', 'the', 'Greater', 'Baltimore', 'area', '.', 'Participants', 'receiving', 'MIND', '-', 'S', 'will', 'get', '18', 'months', 'of', 'care', 'coordination', 'by', 'an', 'interdisciplinary', 'team', 'comprised', 'of', 'trained', 'memory', 'care', 'coordinators', '(', 'non', '-', 'clinical', ')', ',', 'a', 'psychiatric', 'nurse', ',', 'and', 'geriatric', 'psychiatrist', '.', 'The', 'intervention', 'involves', '4', 'key', 'components', ':', 'identification', 'of', 'needs', 'and', 'individualized', 'care', 'planning', '(', 'persons', 'with', 'dementia', '(', 'PWD', ')', 'and', 'care', 'giver', '(', 'CG', ')', 'needs', ')', ';', 'dementia', 'education', 'and', 'skill', 'building', ';', 'coordination', ',', 'referral', 'and', 'linkage', 'of', 'services', ';', 'and', 'care', 'monitoring', '.', 'Participants', 'in', 'the', 'comparison', 'group', 'will', 'receive', 'an', 'initial', 'in', '-', 'home', 'needs', 'assessment', 'and', 'will', 'be', 'given', 'the', 'written', 'results', 'along', 'with', 'any', 'recommendations', 'for', 'care', 'that', 'are', 'indicated', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02396082,NCT02396082,"MIND: An RCT of Care Coordination for Community-living Person With Dementia | This is a 24-month, prospective, single- blind, randomized controlled trial evaluating the MIND at Home-streamlined dementia care coordination intervention (called MIND-S) in a cohort of 300 community-living persons with dementia and their family caregivers in the Greater Baltimore area. Participants receiving MIND-S will get 18 months of care coordination by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (persons with dementia (PWD) and care giver (CG) needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.Participants in the comparison group will receive an initial in-home needs assessment and will be given the written results along with any recommendations for care that are indicated.","[(67, 75, 'CONDITION', 'Dementia'), (169, 233, 'BEHAVIOURAL', 'MIND at Home-streamlined dementia care coordination intervention'), (242, 248, 'BEHAVIOURAL', 'MIND-S'), (299, 307, 'CONDITION', 'dementia'), (390, 396, 'BEHAVIOURAL', 'MIND-S'), (419, 436, 'BEHAVIOURAL', 'care coordination'), (621, 677, 'OTHER', 'identification of needs and individualized care planning'), (692, 700, 'CONDITION', 'dementia'), (735, 772, 'OTHER', 'dementia education and skill building'), (774, 820, 'OTHER', 'coordination, referral and linkage of services'), (895, 927, 'CONTROL', 'initial in-home needs assessment')]"
"['An', 'Open', '-', 'Label', 'Long', 'Term', 'Effectiveness', 'and', 'Safety', 'Study', 'of', 'Oxymorphone', 'Extended', 'Release', 'Tablets', 'in', 'Patients', 'With', 'Cancer', 'or', 'Neuropathic', 'Pain', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'Oxymorphone', 'Extended', 'Release', 'is', 'effective', 'and', 'safe', 'in', 'treating', 'chronic', 'pain', 'in', 'patients', 'with', 'cancer', 'or', 'neuropathic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O']",NCT00911261,NCT00911261,An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain | The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.,"[(58, 69, 'DRUG', 'Oxymorphone'), (112, 118, 'CONDITION', 'Cancer'), (122, 138, 'CONDITION', 'Neuropathic Pain'), (186, 197, 'DRUG', 'Oxymorphone'), (249, 261, 'CONDITION', 'chronic pain'), (279, 285, 'CONDITION', 'cancer'), (289, 305, 'CONDITION', 'neuropathic pain')]"
"['Dexmedetomidine', 'Versus', 'Triamcinolone', 'Local', 'Injection', 'for', 'Pain', 'Alleviation', 'in', 'Patients', 'With', 'Carpal', 'Tunnel', 'Syndrome', ';', 'A', 'Randomized', 'Clinical', 'Trial', '.', '|', 'Carpal', 'tunnel', 'syndrome', '(', 'CTS', ')', 'is', 'a', 'common', 'mononeuropathy', 'due', 'to', 'entrapment', 'of', 'the', 'median', 'nerve', 'in', 'the', 'carpal', 'tunnel', '.', 'a', 'lot', 'of', 'modalities', 'are', 'available', 'for', 'treatment', 'of', 'mild', 'to', 'moderate', 'CTS', '.']","['B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05624866,NCT05624866,Dexmedetomidine Versus Triamcinolone Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial. | Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modalities are available for treatment of mild to moderate CTS.,"[(0, 15, 'DRUG', 'Dexmedetomidine'), (23, 36, 'DRUG', 'Triamcinolone'), (57, 61, 'CONDITION', 'Pain'), (91, 113, 'CONDITION', 'Carpal Tunnel Syndrome'), (146, 168, 'CONDITION', 'Carpal tunnel syndrome'), (170, 173, 'CONDITION', 'CTS'), (187, 201, 'CONDITION', 'mononeuropathy'), (313, 333, 'CONDITION', 'mild to moderate CTS')]"
"['An', 'Evaluation', 'of', 'the', 'Effectiveness', 'of', 'Adherence', 'Therapy', 'for', 'Schizophrenia', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'When', 'compared', 'with', 'those', 'in', 'the', 'control', '(', 'usual', 'care', ')', 'group', ',', 'participants', 'in', 'the', 'AT', 'group', 'are', 'expected', 'to', 'demonstrate', 'significant', 'improvements', 'immediately', 'and', 'at', 'three', ',', 'six', 'and', '12', 'months', 'after', 'completion', 'of', 'the', 'intervention', 'in', ':', 'level', 'of', 'medication', 'adherence', ',', 'readmission', 'rate', ',', 'mental', 'status', ',', 'insight', 'into', 'treatment', ',', 'and', 'level', 'of', 'functioning', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01780116,NCT01780116,"An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial | When compared with those in the control (usual care) group, participants in the AT group are expected to demonstrate significant improvements immediately and at three, six and 12 months after completion of the intervention in: level of medication adherence, readmission rate, mental status, insight into treatment, and level of functioning.","[(38, 55, 'BEHAVIOURAL', 'Adherence Therapy'), (60, 73, 'CONDITION', 'Schizophrenia'), (148, 158, 'CONTROL', 'usual care'), (187, 189, 'BEHAVIOURAL', 'AT')]"
"['Effect', 'of', 'EPA', 'and', 'HMB', 'on', 'Diaphragm', 'and', 'Limb', 'Muscle', 'Strength', 'in', 'Mechanically', 'Ventilated', 'Patients', '|', 'The', 'investigators', 'will', 'determine', 'if', 'administration', 'of', 'HMB', '(', 'hydroxymethylbutyrate', ')', 'or', 'EPA', '(', 'eicosapentaenoic', 'acid', ')', 'will', 'increase', 'diaphragm', 'and', 'limb', 'muscle', 'strength', 'for', 'patients', 'on', 'breathing', 'machines', 'in', 'an', 'intensive', 'care', 'unit', '.', 'The', 'investigators', 'will', 'first', 'measure', 'the', 'strength', 'of', 'the', 'diaphragm', 'and', 'a', 'limb', 'muscle', '(', 'the', 'quadriceps)using', 'magnetic', 'stimulators', 'to', 'activate', 'these', 'muscles', '.', 'Muscle', 'size', 'will', 'be', 'measured', 'by', 'using', 'an', 'ultrasound', 'to', 'measure', 'diaphragm', 'thickness', 'and', 'quadriceps', 'thickness', '.', 'The', 'investigators', 'will', 'also', 'perform', 'a', 'vastus', 'lateralis', 'muscle', 'biopsy', '.', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'placebo', '(', 'saline', '30', 'ml', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ',', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', ',', 'or', 'the', 'combination', 'of', 'EPA', '(', '1000', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', 'and', 'HMB', '(', '1500', 'mg', 'given', 'every', '12', 'hours', 'via', 'the', 'GI', 'tract', ')', '.', 'Drugs', 'will', 'be', 'given', 'for', '10', 'days', ';', 'at', 'the', 'end', 'of', 'this', 'time', '(', 'on', 'day', '11', ')', ',', 'strength', 'measurements', ',', 'ultrasound', 'muscle', 'size', 'measurements', ',', 'and', 'the', 'vastus', 'lateralis', 'biopsy', 'will', 'be', 'repeated', '.', 'On', 'day', '21', 'an', 'additional', 'followup', 'set', 'of', 'diaphragm', 'and', 'quadriceps', 'strength', 'and', 'size', 'measurements', 'will', 'be', 'made', '(', 'the', 'biopsy', 'will', 'not', 'be', 'repeated', 'for', 'this', 'last', 'set', 'of', 'measurements', ')', '.', 'Patients', 'will', 'be', 'followed', 'clinically', 'and', 'patient', 'outcomes', '(', 'mortality', ',', 'duration', 'of', 'mechanical', 'ventilation', 'after', 'study', 'entry', ')', 'will', 'be', 'recorded', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01270516,NCT01270516,"Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients | The investigators will determine if administration of HMB (hydroxymethylbutyrate) or EPA (eicosapentaenoic acid) will increase diaphragm and limb muscle strength for patients on breathing machines in an intensive care unit. The investigators will first measure the strength of the diaphragm and a limb muscle (the quadriceps)using magnetic stimulators to activate these muscles. Muscle size will be measured by using an ultrasound to measure diaphragm thickness and quadriceps thickness. The investigators will also perform a vastus lateralis muscle biopsy. Patients will then be randomized to receive either placebo (saline 30 ml every 12 hours via the GI tract, EPA (1000 mg given every 12 hours via the GI tract), HMB (1500 mg given every 12 hours via the GI tract), or the combination of EPA (1000 mg given every 12 hours via the GI tract) and HMB (1500 mg given every 12 hours via the GI tract). Drugs will be given for 10 days; at the end of this time (on day 11), strength measurements, ultrasound muscle size measurements, and the vastus lateralis biopsy will be repeated. On day 21 an additional followup set of diaphragm and quadriceps strength and size measurements will be made (the biopsy will not be repeated for this last set of measurements). Patients will be followed clinically and patient outcomes (mortality, duration of mechanical ventilation after study entry) will be recorded.","[(10, 13, 'DRUG', 'EPA'), (18, 21, 'DRUG', 'HMB'), (63, 86, 'CONDITION', 'Mechanically Ventilated'), (152, 155, 'DRUG', 'HMB'), (157, 178, 'DRUG', 'hydroxymethylbutyrate'), (183, 186, 'DRUG', 'EPA'), (188, 209, 'DRUG', 'eicosapentaenoic acid'), (276, 294, 'CONDITION', 'breathing machines'), (716, 722, 'DRUG', 'saline'), (762, 765, 'DRUG', 'EPA'), (815, 818, 'DRUG', 'HMB'), (890, 893, 'DRUG', 'EPA'), (946, 949, 'DRUG', 'HMB')]"
"['Combined', 'Constraint', 'Therapy', 'and', 'Bimanual', 'Therapy', 'for', 'Children', 'With', 'Unilateral', 'Brain', 'Injury', '|', 'To', 'examine', 'efficacy', 'of', 'combined', 'unimanual', 'and', 'bimanual', 'intensive', 'therapy', 'in', 'children', 'with', 'unilateral', 'brain', 'injury', '.', 'A', 'key', 'question', 'in', 'hemiplegia', 'therapy', 'is', 'whether', 'the', 'affected', 'hand', 'should', 'be', 'trained', 'alone', 'or', 'in', 'tandem', 'with', 'the', 'other', 'hand', '.', 'In', 'constraint', '-', 'induced', 'movement', 'therapy', '(', 'CIMT', ')', ',', 'a', 'participant', ""'s"", 'less', '-', 'affected', 'upper', 'extremity', 'is', 'restricted', 'with', 'a', 'sling', ',', 'cast', ',', 'or', 'mitt', ',', 'while', 'the', 'participant', 'actively', 'uses', 'the', 'affected', 'arm', 'and', 'hand', 'in', 'skill', '-', 'based', 'therapeutic', 'activities', '.', 'Bimanual', 'therapy', ',', 'in', 'contrast', ',', 'engages', 'both', 'hands', 'in', 'therapeutic', 'movement', '.', 'Since', 'constraint', 'and', 'bimanual', 'therapy', 'target', 'different', 'aspects', 'of', 'hand', 'use', ',', 'they', 'could', 'have', 'synergistic', 'effects', 'on', 'hand', 'function', 'when', 'given', 'in', 'combination', '.']","['O', 'B-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02840643,NCT02840643,"Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury | To examine efficacy of combined unimanual and bimanual intensive therapy in children with unilateral brain injury. A key question in hemiplegia therapy is whether the affected hand should be trained alone or in tandem with the other hand. In constraint-induced movement therapy (CIMT), a participant's less-affected upper extremity is restricted with a sling, cast, or mitt, while the participant actively uses the affected arm and hand in skill-based therapeutic activities. Bimanual therapy, in contrast, engages both hands in therapeutic movement. Since constraint and bimanual therapy target different aspects of hand use, they could have synergistic effects on hand function when given in combination.","[(9, 27, 'PHYSICAL', 'Constraint Therapy'), (32, 48, 'PHYSICAL', 'Bimanual Therapy'), (67, 90, 'CONDITION', 'Unilateral Brain Injury'), (116, 165, 'PHYSICAL', 'combined unimanual and bimanual intensive therapy'), (183, 206, 'CONDITION', 'unilateral brain injury'), (226, 236, 'CONDITION', 'hemiplegia'), (335, 370, 'PHYSICAL', 'constraint-induced movement therapy'), (372, 376, 'PHYSICAL', 'CIMT'), (569, 585, 'PHYSICAL', 'Bimanual therapy'), (650, 681, 'PHYSICAL', 'constraint and bimanual therapy')]"
